










The handle http://hdl.handle.net/1887/20128  holds various files of this Leiden University 
dissertation. 
 
Author:  Blad, Clara Catelijne 
Title: A quest for connections : ligands for the HCA2, adenosine A3 and GPR88 
receptors 
Date:  2012-11-15 
A QUEST FOR CONNECTIONS
 


























































A quest for connections
ligands for the HCA2, 
adenosine A3 and GPR88 receptors
Clara C. Blad

A quest for connections
ligands for the HCA2, 
adenosine A3 and GPR88 receptors
Proefschrift
ter verkrijging van 
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof. mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties







Promotor:  Prof. Dr. Adriaan P. IJzerman
 
Overige leden: Prof. Dr. Theo J. van Berkel
   Prof. Dr. Meindert Danhof
   Prof. Dr. Johan Kuiper
   Prof. Dr. Stefan Offermanns
   
The research described in this thesis was performed at the Division of Medicinal Chemistry of the 
Leiden/Amsterdam Center for Drug Research, Leiden University, Leiden, the Netherlands and at 
the Institut de Biologie Moléculaire et Cellulaire, Illkirch, France. The research performed in the 
Netherlands has been financially supported by TI Pharma (project number D1-105).
This thesis was printed by Wöhrmann Print Service (Zutphen, The Netherlands)
Table of contents
1. General introduction        9
2. Biological and pharmacological roles of hydroxy-
carboxylic acid (HCA) receptors
          35
       
3. Effects of pyrazole partial agonists on HCA2-mediated 
flushing and VLDL-triglyceride levels in mice  
          63
4. Structure-activity relationships of trans-substituted-
propenoic acid derivatives on the nicotinic acid receptor 
HCA2 (GPR109A)
          77
5. Novel 3,6,7-substituted pyrazolopyrimidines as positive 
allosteric modulators for the hydroxy-carboxylic acid 
receptor 2 (GPR109A)
       85
6. Putative role of the adenosine A3 receptor in the 
antiproliferative action of N6-(2-isopentenyl)adenosine
         101
7. Compound screen on orphan G protein-coupled receptor 
GPR88
         119
8. General discussion, future perspectives and conclusion  135
 
 Summary       147
 Samenvatting       151
 Samenvatting voor algemeen publiek    155
 Nawoord       159
 Curriculum vitae      161







G protein-coupled receptors in health and disease
G protein-coupled receptors (GPCRs), alternatively called 7-TM receptors (for 7 
transmembrane domains), comprise a large family of eukaryotic membrane proteins. 
When a GPCR is activated, for example by a hormone or a neurotransmitter, it transfers 
the message to intracellular signaling cascades. The most well-known of these cascades 
involve G protein activation, but recently it has become clear that other possible signaling 
mechanisms exist. In the end, these GPCR signals mediate vital functions of the human 
body, such as perception of the world around us, communication between the brain and 
other parts of the body, energy storage or mobilization, movement and fertility. 
Table 1. Examples of drugs acting on GPCRs. Adapted from [5].
GPCR Drug Indication
β2 adrenergic albuterol asthma
angiotensin AT1 losartan hypertension
calcitonin calcitonin osteoporosis
dopamine D2 haloperidol schizophrenia
gonadotropin-releasing factor goserelin cancer
histamine H2 ranitidine ulcer
serotonin 1D sumatriptan migraine
leukotriene pranlukast allergy, asthma
µ opioid morphine pain
Figure 1. Common secondary structure of GPCRs. A: Schematic representation of a GPCR, indicating transmembrane 
domains 1-7 (TM1-7), the α-helical domain termed helix 8 (H8), a palmitoylation site next to it (zigzag line) and two 
potential glycosylation sites in the N-terminal tail (Y shapes). From [6]. B. High-resolution crystal structure of the 
β2 adrenoceptor bound to carazolol (blue) together with the stabilizing T4 lysozyme protein (green) in place of the 
third intracellular loop. The helices that are shown next to each other in A form a barrel-like arrangement here, 
which is probably the form of the protein in vivo. The helices are indicated in roman numerals, including helix VIII 
in the C-terminal region. A small helix in extracellular loop 2 (ECL2), which may be typical for this receptor subtype, 


















A total of 799 verified human GPCRs are known, thus representing about 3% of all genes 
in our genome [1]. These receptors bind to a large variety of ligands including small 
organic compounds, lipids, peptides, proteins and even photons. Approximately 50% of 
the GPCR repertoire is dedicated to olfaction.
From a pharmacological point of view, GPCRs are interesting drug targets because they 
are implicated in many different pathophysiological processes. Furthermore, it is relatively 
straightforward to design molecules that interact with GPCRs and this type of drugs are 
successfully used in the clinic [2]. An estimated 30 to 40% of all available drugs target 
GPCRs, with annual sales of over 65 billion dollars [3]. Some examples are given in table 
1. The variety of indications, for which these drugs are used, illustrates the omnipresence 
of GPCRs in the human body.
On a molecular level, all GPCRs have a common secondary structure. Their most striking 
features are the seven hydrophobic membrane-spanning alpha-helices (TM1-7) [4]. 
Extracellular and intracellular loops (EL and IL) connect the helices, and an extracellular 
N-terminal domain and intracellular C-terminus complete the protein (see figure 1A). The 
TM helices have been shown to form a barrel-like tertiary structure in the membrane, with 
TM1 and TM7 in close proximity (figure 1B). 
GPCR classification
Several classifications have been proposed for the GPCR superfamily on the basis of 
primary structure, endogenous ligand specificity and species source. In a classical system 
by Kolakowski, the GPCRs are segregated into seven families or classes (A-F and O) [8]. 
A modern version of this system is used in the GPCRDB database www.gpcr.org [9], 
distinguishing the following classes: A: rhodopsin-like, B: secretin-like, C: metabotropic 
glutamate-like, D: pheromone receptors, E: cAMP receptors and F: frizzled/smoothened. 
After the human genome sequence became available, a slightly different system called 
GRAFS was proposed [10-12]. In this system, the classes are named Glutamate, Rhodopsin, 
Adhesion, Frizzled and Secretin, plus a recent addition, Taste2. Thus, class B from the 
A-F system is divided in the Adhesion and Secretin classes, which reflects the inherent 
differences between these receptor clusters. Classes A (Rhodopsin), B (Secretin&Adhesion) 
and C (Glutamate) are most important in mammalian physiology. Of these, class A is by 
far the largest and most diverse. It contains 672 receptors, which includes 388 olfactory 
receptors [13]. The GPCRs that will be discussed in this thesis all belong to the class A, 
rhodopsin-like, GPCR family.
Properties of Rhodopsin-like GPCRs
Although the class A receptors are highly diverse in sequence and ligand binding 
properties, certain residues in the TM regions are conserved (see figure 2). Most striking 
are the microdomains D/ERY (TM3), CWxP (TM6) and NPxxY (TM7). Furthermore, two 
conserved cysteine residues are present in the extracellular domain, at the end of TM3 and 
in extracellular loop 2. They are thought to form a disulfide bridge in most class A GPCRs, 
which may be crucial to structural integrity and receptor function (see for example [14]).
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The position of the ligand binding site varies among class A receptors. Small ligands (such 
as biogenic amines, nucleosides, eicosanoids, lysophosphatidic acid and sphingosine-1-
phosphate) bind in a so-called TM cavity, formed by the seven TM alpha helices ([15] 
and references therein). The ligands for the hydroxy-carboxylic acid receptors and the 
adenosine receptors, which are described in the present work, fall in this category. Larger 
ligands, such as peptides and glycoprotein hormones, interact with the N-terminus 
and/or the extracellular loops, and in some cases also with the outer portions of the 
transmembrane helices. Examples are oxytocin, vasopressin, opioids, thyroid-stimulating 









































































Figure 2. Conserved features and structural motifs within the Class A, rhodopsin-like, GPCRs. The lower part of 
the figure shows the conserved residues from eight diverse class A GPCRs. Conserved residues are shown as circles 
colour-coded for amino acid properties. In the blue boxes conserved class A motifs are indicated with uppercase 
letters for completely conserved positions, lowercase letters for well-conserved positions (>50%) and x for variable 
positions. Conserved cysteine residues are shown in yellow and the disulphide bridge between EL1 and EL2, 
which is conserved in most GPCRs, is indicated as two lines. Dashed black lines show hydrogen bonds within 
bovine rhodopsin whereas dashed blue lines (from DRY to 247 and 251) show the postulated ionic lock, which is 
thought to keep the receptor in the inactive state. Dashed red lines display Van der Waals interactions within the 
β2-adrenoceptor model. In the upper part of the figure different N-termini of class A GPCRs are shown. The scissors 




Recently, some of the most important advances in the field have been made using 
X-ray crystallography. Structural analysis of GPCR molecules is very challenging and 
until recently, only the structure of rhodopsin was known [17-19]. In the last four years 
crystallization efforts finally paid off with the elucidation of high resolution crystal 
structures of squid rhodopsin, the β2 adrenergic receptor (β2AR), the β1AR, the A2A 
adenosine receptor (for a review see [20], see also figure 1), and most recently, the CXCR4 
receptor [21], the dopamine D3 receptor [22] and the histamine H1 receptor [23]. These 
receptors were all stabilized in the inactive state, since this facilitates crystallization. For 
(rhod)opsin, the active apoprotein was also crystallized [24-25]. In 2011, active, transmitter-
bound GPCRs have finally been crystallized, namely rhodopsin [26-27], the human β2AR 
[28] and the adenosine A2A receptor [29-30]. The newest structure of activated β2AR is even 
complexed with a Gs protein [31]. This new (relative) wealth of structural information 
has increased our understanding of the structure of the specific GPCRs, the position 
of the ligand binding pockets and the orientation of the ligands in those pockets. The 
structures of the different receptors are remarkably similar, confirming that the secondary 
and tertiary structure of GPCRs is highly conserved, although there are, of course, subtle 
differences. For example, the binding pocket of the antagonist ZM241385 in the A2A 
receptor was not as was anticipated on the basis of the β2 adrenergic crystal structure 
with its antagonist carazolol. Therefore, care should be taken when homology models are 
used to predict the structure of a receptor that has not been crystallized yet. Comparison 
of active and inactive structures suggests that binding of an agonist results in conserved 
rearrangements near the binding site, which then propagate through the transmembrane 
domains to yield an active state. Binding of a G protein or substitute seems necessary to 
stabilize a fully active state [32].
Receptor activation leads to G protein signaling
GPCRs form an important connection between the outside and the inside of the mammalian 
cell. When an endogenous agonist like a hormone or a neurotransmitter binds to a GPCR, 
a conformational change occurs in the receptor protein, which commonly leads to the 
activation of a G protein (guanine nucleotide-binding protein) [33]. The G protein α subunit 
will release GDP from its GTPase catalytic site and bind GTP. This causes the G protein to 
dissociate from the GPCR, and divide into the α subunit and the βγ complex. Both parts of 
the G protein can activate downstream effectors. The main Gα families are Gαs, Gαi/0 and 
Gαq. Gαs stimulates adenylate cyclase, thus stimulating cAMP production, whereas Gαi/0 
has the opposite effect, inhibiting adenylyl cyclase. Gαq can stimulate phospholipase C, 
which causes an increase in cytoplasmic calcium concentrations. Gβγ dimers can activate 
phosphoinositide 3-kinases, which in turn activate other proteins, including MAP-kinases. 
Interestingly, these mitogen-activated protein kinases can also be activated by GPCRs via 
other, G protein-independent pathways [34]. When activated, they can influence gene 
expression. Other effects can also occur; the skin flushing side effect of drugs acting on 
the hydroxy-carboxylic acid receptor 2 (HCA2) is possibly mediated by this pathway (see 
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chapter 2 and 3). The Gα subunit is deactivated when it converts GTP into GDP in its 
intrinsic GTPase domain. Gβγ dimers are deactivated when they bind a Gα subunit again.
The next step: internalization and arrestins
After a receptor has been activated, it is in many cases removed from the cell membrane. 
This internalization process is often (but not always) mediated by arrestins, which act as 
scaffold proteins that assemble a protein complex at the intracellular face of the receptor. 
Once inside the cell, the receptor protein can be broken down or recycled to the membrane 
after removal of the bound agonist [35-36]. Recruitment of arrestins to a receptor protein 
can also result in arrestin-mediated signaling, leading for example to the MAP-kinase 
activation mentioned above [37-38]. 
Different ligands have different effects
Next to agonists, GPCR ligands exist that de-activate the receptor (inverse agonists), as 
well as ligands that block the binding site but do not change the receptor activation state 
(neutral antagonists) (figure 3). We can also distinguish full agonists, which fully activate 
the receptor, and partial agonists, which cannot cause full activation even at concentrations 
that fully occupy the receptor. This last type of ligands for the HCA2 receptor is investigated 
in chapter 3. The existence of partial agonists suggests that GPCRs are not simply on-off 
switches. Rather, the receptor protein is now thought to exist in a range of conformational 
states. A bound ligand stabilizes a particular subset of states, and this determines which 
of all possible signaling pathways will be influenced, and also with which efficacy. In this 
more complex view of the receptor protein, a ligand is not simply an agonist, antagonist 
or inverse agonist, but can be, for example, an inverse agonist for the Gs pathway, and at 
the same time an agonist for the arrestin pathway [38-39]. In fact, this extreme example 
of ‘biased signaling’ has been demonstrated for the β2-adrenoceptor, where propranolol 
functioned as an inverse agonist on the Gs protein and its downstream pathways, but 
as a partial agonist on (most likely arrestin-mediated) activation of extracellular signal-
regulated kinase (ERK)1/2 [40]. Thus, one ligand binding to one receptor can have a whole 
spectrum of effects. A slightly different ligand may prompt the downstream cascades of 
Figure 3. Dose-response curves of ligands with different efficacy. Many GPCRs also display some basal activity in 






















the same receptor in a different manner. These phenomena, termed ligand texture and 
ligand-directed signaling, have only recently been recognized [39]. Ligand bias on the 
HCA2 receptor is discussed in chapters 2 and 3 of this thesis.
Manipulating downstream signaling
Understanding of the intracellular signaling cascades and how GPCRs stimulate them 
made it possible to bend these pathways to suit research purposes. For example, in 
immortalized cell lines expressing high levels of the chimeric G protein Gqi5 , all GPCRs that 
normally interact with Gi proteins are forced to signal through the Gq pathway, leading to 
an easily detectable increase in intracellular calcium concentration [41-42]. Gqi5 is identical 
to the Gq protein, except for five C-terminal residues which are exchanged for their Gi 
counterparts. These five amino acids determine the interaction with the receptor. Many 
variations of this strategy exist and are employed in the search for new GPCR ligands, 
often in a high-throughput screening setup where thousands of compounds can be tested 
per day. One example of such a screen is reported in chapter 7 of this work. 
Allosteric modulators
A special class of GPCR ligands is formed by allosteric modulators. These compounds 
bind to the receptor at a site distinct from the so-called orthosteric binding site, where the 
endogenous ligand binds. Binding of the modulator can influence the conformation of 
the receptor and modify the affinity and/or efficacy of orthosteric ligands. Some allosteric 
modulators also have intrinsic efficacy themselves and can activate the receptor without 
binding of an orthosteric agonist. Allosteric modulators can be promising drug candidates 
since they may be more specific and have less side effects. Allosteric binding sites of 
synthetic ligands are, in principle, not evolutionarily conserved, which makes it less 
likely for an allosteric modulator to have affinity for related GPCRs [43]. Furthermore, an 
allosteric enhancer that makes the endogenous agonist more potent could boost the natural 
signal without constantly activating the receptor. This can be an important therapeutic 
advantage because it improves the timing and localization of receptor activation. Two 
allosteric GPCR modulators are currently on the market: the calcimimetic cinacalcet, 
which is a positive allosteric enhancer of Ca2+-sensing receptors, and the anti-HIV drug 
maraviroc, an allosteric inhibitor of chemokine receptor CCR5 [44]. In chapter 5 of this 
thesis a number of new allosteric modulators for the HCA2 receptor are presented.
Orphan receptors and the quest for ligands
As mentioned above, a total of 799 human GPCRs have been identified, of which 369 are 
presumably non-sensory GPCRs (not involved in taste, vision or smell). Approximately 
100 to 140 of these potential drug targets are still ‘orphans’, with no known endogenous 
ligand and in most cases no known function [1, 45].
Classic and reverse pharmacology
The first GPCRs that were purified and cloned in the 1980s, were receptors for known 
signaling molecules (adrenalin and noradrenalin) that had been studied for decades (for 
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a review see [46]). This approach, where receptors are identified to match the known 
signaling molecules, has later been termed the classic pharmacology approach (see figure 
4, left scheme). After the first expression cloning of the β2-adrenoceptor in 1986 [47], and 
the finding that this receptor probably shared the 7 transmembrane domain topology of 
rhodopsin, pioneers of GPCR research soon suspected that this feature was common to 
many receptors signaling through G proteins. The rapid homology cloning of many other 
GPCRs, including those for acetylcholine, serotonin and the neuropeptide substance K, 
confirmed their hypothesis [48-49]. Some of the receptors that were cloned did not have 
a known ligand, but in many cases they were readily paired to one of the many ‘orphan’ 
signaling molecules. However, in the 1990s the number of cloned receptors had vastly 
increased due to the advent of PCR techniques, and the number of known signaling 
molecules that were not yet coupled to a receptor was dwindling. This imbalance reversed 
the roles of transmitter and receptor in research: known orphan receptors were used to 
fish for novel signaling molecules, instead of the other way around. The term reverse 
pharmacology is used for this approach. In this thesis, it was applied on the orphan 
receptor GPR88 (chapter 7).
The differences between the classical approach and the reverse pharmacology approach 
are illustrated in figure 4. In reverse pharmacology, an orphan GPCR is first identified 
Figure 4. Flow charts of the classical pharmacology approach and the reverse pharmacology approach that arose in 



























by homology cloning using molecular biology techniques, or, since the sequence of 
the human genome is known, in silico. The GPCR of interest is then expressed in a 
heterologous cell system, followed by screening against a compound collection or purified 
tissue extracts for receptor activation. The use of tissue extracts increases the chances of 
finding the endogenous ligand. However, important technical difficulties are associated 
with the latter strategy, including low signal-to-noise ratio and failure to isolate the ligand 
from an active extract. Therefore, synthetic compound collections are often used instead. 
The first receptors that were deorphanized by reverse pharmacology were the 5-HT1A 
serotonin receptor and the dopamine D2 receptor [51-52]. In total, the application of the 
reverse pharmacology approach led to the ‘deorphanization’ of more than 150 GPCRs, 
coupling them to approximately 75 endogenous ligands. Many of these ligands were novel 
Table 2. GPCRs listed as orphan receptors by IUPHAR with (putative) ligands identified from the literature.
Name Pseudonyms Ligand(s) References
CCRL2 CRAM CCL5 (RANTES), CCL19, chemerin [53-56]
CMKRL1 ChemR23 chemerin, resolvin E1 (RvE1), SIV/HIV-1 coreceptor [57-60]
CMKOR1 CXCR7, RDC1 CXCL12/SDF-1α [61-62]
GPR1 chemerin; glucose/sucrose (S. cerevisiae), HIV/SIV coreceptor [63-65]
GPR3 sphingosine 1-phosphate (S1P) [66]
GPR4 protons, lysolipids (?) [67-69]
GPR6 S1P (?) [66, 70]
GPR12 tyrosol, S1P, sphingosylphosphorylcholine (SPC) [66, 71-72]
GPR17 nucleotides, cysteinyl leukotriene (CysLT) [73]
GPR18 N-arachidonoylglycine, Δ(9)-tetrahydrocannabinol [70, 74-75]
GPR23 P2Y9, LPA4 lysophosphatidic acid (LPA) [76]
GPR32 resolvin D1 (RvD1) [77]
GPR34 lysophosphatidyl-L-serine [78]
GPR35 kynurenic acid, 2-acyl lysophosphatidic acids [79-80]
GPR37 PAEL neuropeptide head activator [81]
GPR39 Zn2+ [82-83]
GPR55 lysophosphatidylinositol, cannabinoids [84-85]
GPR63 S1P (?), dioleoylphosphatidic acid [70, 86]
GPR65 TDAG8 protons, psychosine (?) [87-88]
GPR68 OGR1 protons, sphingosylphosphorylcholine (?) [68, 89-90]
GPR75 CCL5 (RANTES) [91]
GPR84 medium-chain free fatty acids (FFA) [92]
GPR92 GPR93, LPA5 LPA, farnesyl pyrophosphate, geranyl geranyl diphosphate [93-96]
GPR119
oleoyl-lysophosphatidylcholine (OLPC), oleoylethanolamide
(OEA), N-oleoyldopamine (OLDA) [97-99]
GPR120 FFA [100]
GPR132 G2A protons, lysolipids (?), oxydized FFA (9-HODE, 11-HETE) [101-103]
MAS1 Mas Angiotensin 1-7, neuropeptide FF [104-105]
MRGPRD β-alanine [106]
MrgprX1 MrgX1, SNSR4 BAM8-22, BAM22 (1-22) and related peptides [107]
MrgprX2 MrgX2 corticostatin-14 [108]
OPN5 GPR99 photoreceptor (birds) [109]
OXGR1 GPR99 α-ketoglutarate (2-oxoglutarate) [110]
SUCNR1 GPR91 succinate [110]
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and unexpected signaling molecules, including calcium ions, trace amines, bile acids, 
kynurenic acid, protons, oleoylethanolamide, lysophosphatidylinositol, lysophosphatidic 
acid and a plethora of new neuropeptides. 
Ligands recently proposed for class A orphans
In the receptor database of the International Union of Basic and Clinical Pharmacology 
(IUPHAR-db), 97 rhodopsin-like (class A) orphans are listed. However, a search of the 
recent literature yielded putative endogenous ligands for 33 of these receptors (see table 
2). In some cases further studies may be needed, but we can assume that many of these 
receptors are now truly deorphanized. This shows that the deorphanization efforts 
still yield results. All but four of the new receptor-ligand pairs belong in 6 subgroups: 
proton/lysolipid (GPR4, GPR65, GPR68, G2A), chemokine (CCRL2, CMKRL1, CMKOR1, 
GPR1, GPR75), lipid mediators (GPR3, GPR6, GPR12, GPR23, GPR32, GPR34, GPR63, 
GPR92, GPR119), cannabinoid (GPR18, GPR55), Mas related (Mas, MRGPRD, MrgprX1, 
MrgprX2), and metabolic intermediates (GPR84, OXGR1, SUCNR1, GPR120). A number 
of these receptors seem to have more than one endogenous ligand. One could state that 
these receptors were not truly deorphanized when only one of the ligands was identified. 
Of course, it is impossible to prove that no additional ligands remain to be discovered for 
any given receptor. In chapter 6 of the current work, a new, possibly endogenous, ligand 
for the adenosine A3 receptor is reported.
Deorphanized receptors and the regulation of food intake
Clearly, deorphanization of GPCRs has had a profound influence on our understanding of 
mammalian physiology. For example, particularly large advances have been made in our 
understanding of the regulation of food intake. Several novel neuropeptides have been 
discovered as ligands for orphan GPCRs, including leptin, ghrelin and orexin [for a review 
see 45]. Furthermore, several GPCRs have been shown to react to nutrients and metabolic 
intermediates. These receptors seem to function as sensors for food and metabolic status, 
which is an unexpected new role for GPCRs. Nutrient sensing receptors include the calcium 
sensing receptor, GPRC6A and the dimeric taste receptor complex T1R1/T1R3, which are 
promiscuous receptors for several L-α-amino acids and divalent cations, as well as the 
T1R2/T1R3 dimer, which responds to sugars and D-amino acids [111]. These receptors are 
expressed in taste tissue, the gastrointestinal tract, endocrine glands, adipose tissue, and/
or kidney, where they regulate the release of hormones important for metabolism and the 
regulation of food intake. They can also influence gene expression, for example yielding 
an increase in the expression of nutrient transporters. Next to these class C receptors, 
several class A receptors are also involved in nutrient sensing. GPR92/93 expressed in the 
small intestine is activated by proteolytic degradation products and by lysophosphatidic 
acid [93-96]. Medium- and long-chain free fatty acids, from the hydrolysis of ingested fat 
and oil, activate the free fatty acid receptor 1 (FFA1) as well as GPR84 and GPR120 [92, 
100, 112-114]. FFA1 is expressed in the islets of Langerhans in the pancreas and the gut, 
whereas GPR120 is expressed in the gut, in adipose tissue and in the lung. FFA1 activation 
stimulates the release of the hormone GLP-1 from the gut, a role which may be shared 
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by GPR120. Activated FFA1 also potentiates glucose-stimulated insulin release from the 
pancreas, and it might be involved in the toxic effect of chronic high circulating free fatty 
acid levels on pancreatic β cells [115]. GPR84 is expressed in immune cells and its role 
in physiology has not yet been elucidated. Short-chain free fatty acids, which are mainly 
fermentation products of carbohydrate fibers, are ligands of the FFA2 and FFA3 receptors 
[116-117]. FFA2 is primarily expressed in immune cells, and has been shown to play an 
important role in neutrophil recruitment during intestinal inflammation [118], and it 
is thought to be involved in leukocyte chemotaxis by sensing the presence of bacterial 
fermentation products. Additionally, it appears to be involved in energy homeostasis and 
appetite regulation [119], including the mediation of the anti-lipolytic effect of acetate 
and proprionate [120]. FFA3 is more widely expressed than FFA2, with the highest 
expression in adipose tissue, and more moderate levels in immune cells and tissues. It has 
been suggested that FFA3 mediates the effect of proprionate on leptin release [121]. Next 
to nutrients, intermediates in (energy) metabolism have also been identified as GPCR 
ligands, some of which were mentioned above (see table 2). More specifically, succinate 
and α-ketoglutarate (2-oxoglutarate), two intermediates from the citric acid cycle, are 
the endogenous ligands of GPR91 and GPR99, respectively, and the receptors are now 
named SUCNR1 and OXGR1 [110]. These receptors are predominantly expressed in the 
kidney. Succinate stimulates renin release via GPR91, which causes an increase in blood 
pressure. Intermediates of the β-oxidation process, which is upstream of the citric acid 
cycle, activate HCA3 (GPR109B) [122]. The main ligand seems to be 3-hydroxy-octanoic 
acid. The same receptor has also been reported as a receptor for aromatic D-amino acids 
[123]. Two related receptors, HCA2 (GPR109A) and HCA1 (GPR81), are activated by the 
ketone body 3-hydroxybutyrate and by lactate, respectively [124-126]. Butyrate, a short-
chain free fatty acid, may be an additional ligand for HCA2 in the gut [127]. All three 
hydroxy-carboxylic acid receptors have an anti-lipolytic effect when activated. HCA2 and 
HCA3 are part of a negative feedback loop which keeps the release of fat stores in check 
under starvation conditions, whereas HCA1 plays a role in the antilipolytic effect of insulin 
[review 128]. This family of hydroxy-carboxylic acid receptors is discussed in detail in 
chapter 2, and HCA2 is the focus of chapters 3, 4 and 5.
Current challenges in deorphanization
After a peak in 2003 the deorphanization rate seems to be declining (see figure 5) [129]. 
This may be partly due to a shift in focus in the pharmaceutical industry. Many companies 
are currently faced with expiring patents of major blockbusters and increasing rules and 
regulations regarding safety, resulting in increased numbers of leads that fail to reach 
the market. The cost of compound screens for deorphanization is high and success not 
assured. Even if a ligand can be linked to an orphan receptor many years of additional 
R&D are needed to put a drug on the market. Less costly R&D programs could target the 
approximately 175 non-orphan GPCRs that are not currently targeted by drugs. Novel 
ligands, including allosteric modulators, or optimized versions of known ligands, can also 
be developed for the ~50 current GPCR drug targets. In the present climate pharmaceutical 
companies may more likely choose these R&D strategies.
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Furthermore, a number of challenges complicate the identification of ligands for the 
remaining orphan GPCRs. Many of the remaining orphan GPCRs do not show high 
sequence homology to a cluster of GPCRs with similar ligands. When orphans are 
phylogenetically localized between two receptor subfamilies it may mean they bind 
ligands that share properties of both ligand families. Some other orphans, such as GPR88, 
do not show any significant homology to a known receptor subfamily. Purification of a 
known ligand type from tissue extracts is already a highly challenging task, and if the 
ligand properties are totally unknown another degree of complexity is added.
Why did traditional screening methods fail to bring to light the ligands for the remaining 
orphan GPCRs? It is possible that some of these orphans display non-traditional signaling, 
for example through G protein-independent signaling cascades. Traditional assays are 
not equipped to identify this activation. The orphans may also need unknown interacting 
partners in order to function, for example another GPCR to form a functional heterodimer. 
In heterologous cell systems correct expression of functional GPCRs cannot always be 
obtained due to the absence of necessary protein partners. 
Finally, some of the orphans may be ‘real’ orphans with no physiological ligand at all, 
GPCR
Orphan 7TM
protein Effect on function 
GABAB1 GABAB2 Export to the cell surface and G protein coupling
DOR22a DOR83b Export and improvement of functionality
DOR43a DOR83b Export and improvement of functionality
T1R1 T1R3 Effect on receptor functionality and pharmacology
T1R2 T1R3 Effect on receptor functionality and pharmacology
MrgD MrgE Decrease of internalization; increase of ERK phosphorylation 
and intracellular [Ca2+]
MT1 GPR50 Loss of ligand binding and function
ORF74 Constitutive activity responsible for oncogenic action of Herpesvirus 8
UL33 Constitutive activity responsible for HCMV-related pathologies
EBI2 Constitutive activity in Epstein-Barr virus-infected cells
Table 3. Ligand-independent functions of orphan GPCRs. Adapted from [130].
DOR: Drosophila odorant receptors; EBI2: Epstein-Barr virus-induced receptor 2; ERK: extracellular signal-regulated 
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Figure 5. Declining rate of deorphanization since 2004. Adapted from [129].
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Table 4. Remaining class A orphan GPCRs from IUPHAR-db excluding the putatively liganded GPCRs shown in 
table 2. The receptors are classified according to a phylogenetic analysis by Joost and Methner [143]. The receptors 
at the bottom of the table were not included in this analysis.
Group Orphan Pseudonyms Remarks
A03 GPR15 GPRF
GPR25





























GPR61 constitutive activity [145]
GPR62





GPR20 constitutive activity [147]
GPR26 constitutive activity [146]
GPR33 pseudogene in most individuals [148]
GPR37L1





















TAAR3 probable pseudogene in primates [150]







that exert their function(s) through ligand-independent mechanisms. Some examples of 
orphan GPCRs with known ligand-independent activity are summarized in table 3 [130]. 
The top four ‘orphan 7TM proteins’ (indeed, they may not be receptors, nor G protein-
coupled) in the table interact with the listed non-orphan GPCR to help it reach the cell 
surface (GABA, DOR) [131-133], change its functionality and/or signalling (DOR, T1R, 
Mrg) [131-132, 134-137], or inhibit its function (MT1/GPR50) [138]. The bottom three 
orphans, all virus-encoded, do not need a ligand to function because they are active in the 
absence of a ligand [139-142]. Evolutionary analysis showing the presence or absence of 
evolutionary pressure on the protein as a whole, or on the predicted binding site, can be 
used to determine whether the protein is likely to be functional and whether it is likely to 
interact with a ligand in order to function.
Inventarisation of Class A orphan GPCRs
In table 4, all remaining class A (Rhodopsin-like) orphan receptors are shown, taken from 
the IUPHAR-db but not including the receptors listed in table 2. Some of the receptors 
display constitutive activity, which may indicate that these proteins do not need ligands 
to function. Others are likely to be pseudogenes in some or all individuals. Phylogenetic 
analysis showing sequence similarities between orphan and liganded receptors can give 
valuable clues where to start the quest for a ligand. In table 4 the orphan GPCRs are 
classified according to an analysis by Joost and Methner [143]. Another useful method 
to classify orphan receptors is using phylogenetic analysis of the residues predicted to 
line the ligand binding cavity, as was done by Surgand and colleagues [15]. This method 
yielded surprising results in the case of GPR88, which belongs to the Rhodopsin-like 
receptors on the basis of its full sequence, but was classified with the Glutamate-like 
receptors (class C) in this analysis.
Deorphanization of the 65 orphan GPCRs in table 4, and/or elucidation of their biological 
functions, could have a great impact on our understanding of mammalian physiology. 
Furthermore, keeping in mind that drugs on the market today target only ~50 GPCRs, 
understanding of these orphans may give rise to a whole range of new medicines. 
Objectives and overview of this thesis
In the current work deorphanization and receptor-ligand pairing are a leading theme. I 
will describe studies on three GPCRs: the hydroxy-carboxylic acid receptor 2 (HCA2) , the 
orphan receptor GPR88 and the adenosine A3 receptor (A3R). 
HCA2 is a recently deorphanized GPCR that is of great interest as a drug target. In fact, one 
of its ligands, nicotinic acid, has been used as an anti-dyslipidemia drug for over 50 years. 
As described above, the endogenous ligand of HCA2 is 3-hydroxybutyrate, which acts as 
a negative feedback signal to preserve fat tissue during times of starvation. The biological 
and pharmacological roles of the HCA2 receptor and its two close family members HCA1 
and HCA3 are reviewed in chapter 2. In my research, I explored the signaling cascades 
that are influenced upon HCA2 activation by synthetic and endogenous agonists (chapter 
3). In the same chapter I describe the in vivo effects of two partial agonists for HCA2. 
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Furthermore, I investigated the binding of synthetic compounds to HCA2 both in an 
orthosteric and in an allosteric manner (chapter 4 and 5). 
As I have mentioned above, a receptor does not necessarily have only one unique ligand. 
For the adenosine A3 receptor, there are indications that it binds an additional ligand next 
to its canonical agonist adenosine. This ligand could be involved in the resistance of muscle 
tissue to tumor metastases. I attempted to identify this elusive ligand, and identified the 
antiproliferative compound N6-isopentenyl adenosine as an A3R ligand that may or may 
not be endogenous (chapter 6). 
GPR88 is an orphan GPCR expressed predominantly in two brain regions: the striatum 
and the central extended amygdala. GPR88 could be of major interest therapeutically, and 
I set out to identify a synthetic, if not endogenous, agonist for this receptor, screening a 
large number of compounds in a functional assay (chapter 7).
In this thesis, a recently discovered and deorphanized receptor is further investigated, 
expanding the ligand repertoire for two binding sites on the receptor; a new ligand is 
proposed for a GPCR long since paired to its ligand; and a ligand screen on an orphan 
GPCR is described, clearly identifying the challenges of such an operation. This research 
into the ‘simple’ interaction between small molecules and membrane proteins gives 
insights into human physiology and the mechanism of action of (future) drugs, and opens 
new horizons for pharmacotherapy.
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Chapter 2
Biological and pharmacological roles of 
hydroxy-carboxylic acid receptors





The hydroxy-carboxylic acid (HCA) receptors HCA1, HCA2 and HCA3 were previously 
known as GPR81, GPR109A and GPR109B, respectively, or as the nicotinic acid receptor 
family. They form a cluster of G protein-coupled receptors with high sequence homology. 
Recently, intermediates of energy metabolism, all hydroxyl-carboxylic acids, have 
been reported as endogenous ligands for each of these receptors. The HCA receptors 
are predominantly expressed on adipocytes and mediate the inhibition of lipolysis by 
coupling to Gi–type proteins. HCA1 is activated by lactate, HCA2 by the ketone body 
3-hydroxy-butyrate and HCA3 by hydroxylated β-oxidation intermediates, especially 
3-hydroxy-ocatanoic acid. Both HCA2 and HCA3 are part of a negative feedback loop 
which keeps the release of fat stores in check under starvation conditions, whereas HCA1 
plays a role in the antilipolytic (fat conserving) effect of insulin.
HCA2 was first discovered as the molecular target of the anti-dyslipidemic drug nicotinic 
acid (or niacin). Many synthetic agonists have since been designed for HCA2 and HCA3, but 
the development of a new, improved HCA-targeted drug has not been successful so far, 
despite a number of clinical studies. Recently, it has been shown that the major side-effect 
of nicotinic acid, skin flushing, is mediated by HCA2 receptors on keratinocytes, as well 
as on Langerhans cells in the skin. In this chapter, we summarize the latest developments 
in the field of HCA receptor research, with emphasis on (patho)physiology, receptor 
pharmacology, major ligand classes and the therapeutic potential of HCA ligands. 
List of non-standard abbreviations
5-HpETE, 5-hydroperoxy-eicosatetraenoic acid; 5-oxo-ETE, 5-oxo-6,8,11,14-eicosatetraenoic acid; BAC, bacterial 
artificial chromosome; CETP, cholesterol ester transfer protein; COX-1, cyclooxygenase 1; COX-2, cyclooxygenase 
2; CysLT2, cysteinyl-leukotriene 2; DP1, prostaglandin D2 receptor 1; EC50, half-maximal effective concentration; EL, 
extracellular loop; ER, extended release; ERK, extracellular signal-related kinase; GTPγS, guanosine 5'-O-[gamma-
thio]triphosphate; HCA, hydroxy-carboxylic acid; HDL, high density lipoprotein; IFN-γ, interferon-γ; IL, 
intracellular loop; LDL, low density lipoprotein; LTD4, leukotriene D4; MEF, monoethyl ester of fumaric acid; 
MMF, monomethyl ester of fumaric acid; PGD2; prostaglandin D2; PGE2, prostaglandin E2; PLA2, phospholipase 
A2; PPARγ; peroxisome proliferator-activated receptor γ; PUMA-G, protein up-regulated in macrophages by INF-γ 
(murine HCA2); TM, transmembrane domain; VLDL, very low density lipoprotein.
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I. Introduction
In the past twenty years it has become clear that GPCR ligands include not only traditional 
hormones and neurotransmitters, but also ions and other endogenous molecules. In 
this chapter, we focus on a recently discovered GPCR family with affinity for several 
intermediates of energy metabolism. These metabolite ligands are all hydroxy-carboxylic 
acids, hence the novel nomenclature for this receptor family: hydroxy-carboxylic acid 
receptors [1]. HCA1 (GPR81) is endogenously activated by lactate, HCA2 (GPR109A) by 
3-hydroxy-butyrate and HCA3 (GPR109B) by 3-hydroxylated β-oxidation intermediates, 
especially 3-hydroxy-octanoic acid [2-5]. All three receptors are predominantly expressed 
in adipose tissue, where they couple to Gi proteins [1]. Activation of the receptors has 
an antilipolytic effect. Discovery of the endogenous HCA ligands has increased our 
understanding of the (patho)physiological roles of their receptors, and opens new avenues 
for research and drug discovery.
Of the HCA family, HCA2 is most extensively studied since it is the target of the anti-
dyslipidemic drug nicotinic acid (or niacin) [6-8]. Nicotinic acid has been used since the 
1950’s [9] and is still the most efficacious drug approved to raise HDL cholesterol plasma 
levels [10]. In HCA2 knockout mice, the antilipolytic and triglyceride lowering effects of 
nicotinic acid are abolished [8]. Skin flushing, the major nicotinic acid side-effect, was 
also shown to be receptor dependent [11]. Separating this side-effect from the therapeutic 
effects of HCA2 ligands is one of the major challenges in this field. In addition, it will 
be important to analyze the potential of HCA1 and HCA3 as therapeutic targets. This 
review will summarize current knowledge on the pharmacology and physiology of HCA 
receptors as well as the recent development of new synthetic ligands of this receptor class.
II. Identification and characterization of HCA receptors
A. Cloning of HCA receptors
The HCA3 receptor (GPR109B) was first cloned from a human monocyte cDNA library 
and identified as an orphan G protein-coupled receptor, HM74 [12]. 
Lee et al. [13] discovered the HCA1 receptor (GPR81) as another orphan GPCR by BLAST 
analysis. The cDNA of the HCA1 receptor was then cloned from a bacterial artificial 
chromosome (BAC) clone carrying a region of human chromosome 12. The HCA1 receptor 
cDNA showed high homology [11] to the HCA3 receptor (GPR109B/HM74), and the genes 
encoding HCA1 and HCA3 receptors were localized in close proximity on the same BAC 
clone. The HCA2 receptor (GPR109A) was originally identified in murine macrophages 
upon stimulation of cells with interferon-γ (INF-γ) and called “protein up-regulated in 
macrophages by INF-γ” (PUMA-G) [14]. In 2003, the human and rat HCA2 receptors were 
cloned and shown to be highly homologous to the murine orthologue PUMA-G [6, 7].
B. Sequence alignment and phylogenetic tree
The HCA2 and the HCA3 receptor are highly homologous as they share 95% sequence 
identity on the protein level. In fact, HCA3 differs from HCA2 in only 16 amino acids of 
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which 12 are non-conservative changes which are clustered around extracellular loops 
1 and 2. In addition, the HCA3 receptor has an extended C-terminus of 24 amino acids. 
The HCA1 receptor has almost 50% sequence homology with both HCA2 and HCA3. Most 
notably, HCA1, HCA2 and HCA3 receptors share a conserved arginine residue in the third 
transmembrane helix which is supposed to be critically involved in ligand binding (see 
Section VI). While HCA1 and HCA2 receptors are present in the genome of numerous 
mammalian species including humans and rodents, the HCA3 receptor is exclusively 
found in humans and higher primates like chimpanzee. The HCA3 receptor obviously 
evolved through a relatively recent gene duplication, as indicated by its tandem location 
with HCA2 on human chromosome 12 and its high level of sequence identity to HCA2.
Several single nucleotide polymorphisms in the coding regions of genes encoding HCA2 
and HCA3 receptors have been described [15]. The effects of these mutations on the 
physiological or pharmacological functions of the respective receptors are unknown.




In two recent studies it was shown that lactate was able to activate the HCA1 receptor 
with half-maximal effective concentrations of 1.3 and 4.8 mM, respectively [5]. Lactate 
was a specific agonist of HCA1 as it did not activate the closely related receptors HCA2 
and HCA3. Various other hydroxy-carboxylic acids structurally related to lactate had a 
strongly reduced potency or were inactive towards HCA1. For instance, 2- and 4-hydroxy-
butyrate were weak agonists with an EC50 value of 8.5 and 15 mM, respectively, whereas 
3-hydroxy-butyrate was completely inactive. Interestingly, the physiologically relevant 
stereoisomer (S)-lactate was much more potent and efficacious than (R)-lactate. Given the 
fact that plasma levels of (S)-lactate can reach concentrations sufficient to activate HCA1, 





In 2005, the ketone body 3-hydroxy-butyrate was described as an endogenous ligand of 
HCA2, the receptor of the anti-dyslipidemic drug nicotinic acid [3]. Racemic 3-hydroxy-
butyrate activated human and mouse HCA2 receptor with an EC50 value of 0.7 and 0.8 
mM, respectively. 3-hydroxy-buty rate was a specific agonist of HCA2 as it was inactive on 
the closely related receptor HCA3. Other ketone bodies like acetoacetate or acetone had 
no activity on HCA2. Short and medium chain fatty acids like butyrate, hexanoate and 
octanoate were also weak agonists on mouse and human HCA2 with EC50 values ranging 
from 0.13 to 1.6 mM. While under physiological conditions plasma concentrations of short 
chain fatty acids would be too low to activate HCA2, plasma levels of ketone bodies like 





Despite the high homology of the HCA3 receptor to the nicotinic acid and ketone body 
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receptor HCA2, HCA3 is not activated by nicotinic acid or 3-hydroxy-butyrate. Recently, 2- 
and 3-hydroxylated medium-chain fatty acids have been identified as endogenous ligands 
of the orphan HCA3 receptor [4]. 2- and 3-hydroxy-octanoate were specific agonists of 
HCA3 with EC50 values of 4 and 8 µM, respectively. Under certain conditions, which go 
along with increased fatty acid β-oxidation rates, plasma concentrations of 3-hydroxy-
octanoate reach levels sufficient to activate the HCA3 receptor [4, 16, 17]. 
Moreover, aromatic D-amino acids like D-phenylalanine or D-tryptophan were shown to 
specifically activate the HCA3 receptor [18]. Given the extreme rare occurrence of D-amino 
acids, it is unclear whether the ability of aromatic D-amino acids to activate HCA3 is of 
physiological or pathophysiological significance.
D. Novel nomenclature of HCA receptors
In the past, various names were given to the receptors HCA1 (GPR81), HCA2 (GPR109A/
HM74A/NIACR1) and HCA3 (GPR109B/HM74/NIACR2) (see table 1). After the 
identification of HCA2 (GPR109A) as the receptor of the anti-dyslipidemic drug nicotinic 
acid, HCA1 (GPR81), HCA2 (GPR109A) and HCA3 (GPR109B) were often called the 
“nicotinic acid receptor family” or “niacin recep tor family”. This was, however, for two 
reasons misleading: firstly, nico tinic acid is unlikely to be the physiologically relevant 
ligand because its concentrations are too low to activate HCA2 (GPR109A), and secondly, 
the two closely related receptors HCA1 (GPR81) and HCA3 (GPR109B) do not respond to 
nicotinic acid at reasonable concentrations and therefore are no nicotinic acid receptors. 
With the identification of hydroxy-carboxylic acids as the endogenous ligands of HCA1, 
HCA2 and HCA3, the physiological and pathophysiological functions of these receptors 
could be clarified (see section IV). Based on sequence homology, ligand similarity and 
Receptor Aliases Naturally occurring ligands
HCA1 GPR81, GPR104, TA-GPCR, 
LACR, FKSG80
2-OH-propanoate (lactate)
GPR109A, PUMA-G, HM74A, 
HM746, NIACR1
3-OH-butyrate

















their physiological role, HCA1, HCA2 and HCA3 are now regarded as members of a novel 
subfamily of G protein-coupled receptors, the hydroxy-carboxylic acid (HCA) receptor 
family.
The orphan receptor GPR31 and the 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) 
receptor OXER1 are the receptors most closely related to HCA1, HCA2 and HCA3 [19-
21]. Interestingly, the arginine residue in transmembrane helix 3, which is conserved 
among HCA1, HCA2 and HCA3 and which has been suggested to serve as a molecular 
anchor of the carboxylic group of HCA1 receptor ligands, is also present in GPR31 and the 
5-oxo-ETE receptor. OXER1 binds 5-oxo-ETE as well as, with lesser affinity, 5-hydroxy-
eicosatetraenoic acid and 5-hydroperoxy-eicosatetraenoic acid (5-HpETE). Thus, OXER1, a 
receptor for polyunsaturated fatty acids with an oxo, hydroxy or hydroperoxy substitution 
in the 5-position may well be regarded as another member of the hydroxy-carboxylic acid 
receptor family.
III. Gene structure and tissue distribution
A.	 Gene structure
The genes encoding HCA1, HCA2 and HCA3 receptors are tandemly located on human 
chromosome 12q24.31 and have likely evolved from gene duplication (see figure 1). In 
humans and other mammals which express HCA receptors the genes for HCA1, HCA2 and 





The HCA1 receptor was originally reported to be expressed in human pituitary [13]. 
However, this has never been confirmed. Several studies have independently shown that 
HCA1 is primarily expressed in white and brown adipose tissue of both humans and rodents 
[5, 7, 22-24]. Only minor amounts of mRNA of HCA1 were detected in kidney, skeletal 
muscle or liver. In addition, expression of HCA1 was increased during differentiation of 
3T3-L1 preadipocytes [5, 22, 23]. In mouse and human adipocyte cell lines transcription 
of the HCA1 gene was induced upon treatment with peroxisome proliferator-activated 







Figure 1. Gene structure of the HCA receptors. Schematic representation of the genomic organization of the genes 
encoding hydroxy carboxylic acid (HCA) receptors.





Similar to the HCA1 receptor, HCA2 is highly expressed in human and murine white and 
brown adipose tissue [6-8]. Expression of HCA2 was increased during differentiation of 
3T3-L1 preadipocytes, as well as upon treatment with PPARγ agonists [23]. Moreover, the 
HCA2 receptor is expressed in various immune cells including monocytes, neutrophils, 
macrophages, dendritic cells and epidermal Langerhans cells [14, 25-27]. In macrophages 
expression of HCA2 was inducible by treatment with IFN-γ. A recent study demonstrated 
expression of the HCA2 receptor in keratinocytes by utilizing advanced BAC-transgenic 
reporter mice for HCA2 [28]. Similar to macro phages, expression of the HCA2 receptor 
in keratinocytes and keratinocyte cell lines was in duced by IFN-γ [29]. In addition, 
expression of GPR109A has also been reported in retinal pigment epithelium as well as in 




Expression of the HCA3 receptor appears to be very similar to the expression pattern of 
the HCA2 receptor and can be found to be highly expressed in white adipose tissue [6-8]. 
In addition, the HCA3 receptor is expressed in various human immune cells including 
neutrophils, monocytes and macrophages [4, 12, 18, 32]. Evidence has also been provided 
for the expression of the HCA3 receptor in epi thelial cells of the colon [30].





The HCA1 receptor mediates the inhibitory regulation of adipocyte lipolysis by lactate 
[2, 5, 24].  Since plasma lactate levels are strongly increased under conditions of intensive 
physical exercise, it would be conceivable that lactate inhibits and thereby restricts the 
supply of fatty acids under anaerobic conditions. However, Ahmed et al. [24] studied 
wild-type and HCA1 receptor-deficient mice which were trained to exercise at an intensity 
 resulting in plasma lactate levels sufficient to activate the HCA1 receptor and found 
that plasma concentrations of free fatty acids were not different between wild-type and 
HCA1 receptor-deficient mice. Thus, there is so far no evidence for a role of lactate and its 
receptor in the regulation of lipolysis during intensive exercise.
Interestingly, the adipose tissue can convert more than 50% of the metabolized glucose to 
lactate, a process stimulated by insulin and glucose uptake [33]. Lactate is then released 
from adipocytes and taken up by the liver to serve as a substrate for gluconeogenesis and 
glycogen synthesis. Insulin-induced glucose uptake results in a several-fold increase in 
lactate levels in the adipose tissue [24, 34, 35]. In HCA1 receptor-deficient mice as well as 
in HCA1-deficient adipocytes, insulin-induced inhibition of lipolysis and insulin-induced 
decrease in adi pocyte cAMP were strongly reduced [24]. This suggests that lactate acting 
through HCA1 functions in an autocrine and paracrine fashion to mediate insulin-induced 
antilipolytic effects and thereby regulates lipolysis postprandially (figure 2A). When on a 
high fat diet, mice lacking HCA1 showed a reduced weight gain (Ahmed et al., 2010). This 
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indicates that the lactate/HCA1-mediated antilipolytic effects contribute to the increase in 




The ketone body 3-hydroxy-butyrate which activates the HCA2 receptor with an EC50 of 
0.7 mM has been described as the endogenous ligand of HCA2 [3]. In fact, 3-hydroxy-buty-
rate plasma levels increase to 1-2 mM after an overnight fast and reach 6-8 mM during 
prolonged fasting [36]. It is very likely that the HCA2 receptor activated by 3-hydroxy-
butyrate at millimolar concentrations during starvation mediates a negative feedback 
regulation that controls the lipolytic rate [37] (figure 2B). This regulatory mechanism 
would help to avoid excessive triglyceride degradation and thereby save energy during 
food shortage.
The antidyslipidemic drug nicotinic acid activates HCA2 receptors expressed on 
adipocytes resulting in a rapid decrease in the release of free fatty acids from fat cells. This 
in turn reduces the supply of free fatty acids to the liver, leading to a reduced synthesis of 
triglycerides and very low density lipoprotein (VLDL) as well as to a subsequent decrease 
of low density lipoprotein (LDL)-cholesterol levels [38]. It is less clear how nicotinic 
acid increases levels of high density lipoprotein (HDL)-cholesterol. It is possible that 
the decrease in triglyceride content of apolipoprotein B (ApoB) containing lipoproteins 
results in a decreased exchange of triglycerides for cholesteryl esters from HDL-particles 
mediated by the cholesterol ester transfer protein (CETP) eventually leading to increased 
HDL-cholesterol levels [39-41]. Consistent with this hypothesis, HDL-cholesterol elevation 
in response to nicotinic acid has been shown to depend on the presence of CETP [42, 43]. 
Whether the HCA2 receptor mediates the increase in HDL-cholesterol levels in response 
to nicotinic acid is, however, currently not clear [44, 45]. It is also unknown whether the 
activation of HCA2 receptors expressed by cells outside the adipose tissue plays a role 
during starvation. It is possible that elevated 3-hydroxy-butyrate levels during starvation 
activate HCA2 receptors expressed on immune cells and thereby induce anti-inflammatory 
effects which could be advantageous under conditions of starvation. 
Besides its antilipolytic effect, nicotinic acid has been shown to influence the function of 
the adipose tissue as an endocrine organ. Both in vitro and in vivo data indicate that 
nicotinic acid increases the release of adiponectin from adipocytes through HCA2 [46, 47]. 
The anti-inflammatory and antidiabetic consequences of increased adiponectin plasma 
levels [48] may contribute to the beneficial effects of nicotinic acid.
Recently, studies in mice have shown that the anti-atherosclerotic effect of nicotinic acid 
is not only due to nicotinic acid-induced changes in lipid metabolism but also results 
from direct effects of nicotinic acid on HCA2 expressed by immune cells. In contrast to 
atherosclerosis-prone LDL-receptor-deficient mice carrying the wild-type receptor, mice 
lacking HCA2 or mice transplanted with HCA2-deficient bone marrow showed strongly 
reduced anti-atherosclerotic effects in response to nicotinic acid. The nicotinic acid receptor 
HCA2 is expressed by monocytes and macrophages including plaque macrophages, 
and nicotinic acid inhibits the recruitment of macrophages to atherosclerotic lesions in 
HCA2-dependent manner. In addition, HCA2 mediates a stimulatory effect of nicotinic 
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acid on the cholesterol efflux from macrophages. Thus, nicotinic acid appears to reduce 
the progression of atherosclerosis also through direct anti-inflammatory effects and 
stimulatory effects on the reverse cholesterol transport [49, in press].
Evidence has been provided that HCA2 receptors expressed by epidermal Langerhans cells 
and keratinocytes mediate the major unwanted effects of nicotinic acid, the flush reaction. 
The symptoms of flushing consist of a cutaneous vasodilation as well as sensations of 
tingling and burning which impair patients’ compliance [11, 25, 27, 50, 51]. Nicotinic acid 
or the antipsoriatic drug monomethyl fumarate induce a biphasic increase in dermal 
blood flow which is mediated by HCA2 [28]. While the first phase is due to activation of 
HCA2 on Langerhans cells, the second phase of the flush depends on HCA2 expressed 
by keratinocytes. The Langerhans cell-mediated flushing involves cyclooxygenase-1 
(COX-1), prostaglandin D2 (PGD2) and prostaglandin E2 (PGE2). In contrast, keratinocyte-
mediated flushing at later phases of the reaction involves cyclooxygenase-2 (COX-2) and 
PGE2 [27, 28, 52, 53]. 
There is evidence indicating that the HCA2 receptor expressed in intestinal epithelial cells 
responds to butyrate which is present in millimolar concentrations in the gut lumen, and 
that HCA2 thereby functions as a tumor suppressor and anti-inflammatory receptor [30]. 
Furthermore, comparison of the HCA2  potencies [3] and reported fecal concentrations of 
the short-and medium-chain fatty acids [54] suggests that pentanoate and hexanoate may 




Similar to HCA2, the primary physiological role of the HCA3 receptor appears to be the 
















































Figure 2. Biological roles of the HCA receptors. Functions of the recently deorphanized receptors HCA1, HCA2 and 
HCA3. The lactate receptor HCA1 mediates the acute anabolic effects of insulin on adipocytes and thereby helps to 
store energy after feeding (A). In contrast, HCA2 and HCA3 receptors are involved in the long-term regulation of 
lipolytic activity being receptors for the ketone body 3-hydroxy-butyrate (HCA2) and the β-oxidation intermediate 
3-hydroxy-octanoate (HCA3). In situations of increased β-oxidation rates (e. g. during starvation) 3-hydroxy-
butyrate and 3-hydroxy-octanoate plasma levels are increased and result in the inhibitory regulation of lipolysis via 
HCA2 and HCA3 receptors, respectively, in form of a negative feedback loop (B). Thereby HCA2 and HCA3 receptors 
help preserve energy stores during starvation. AC, adenylyl cyclase; TG, triglycerides; HSL, hormone-sensitive 
lipase; ATGL, adipocyte triglyceride lipase; FFA, free fatty acids; PKA, cAMP-regulated protein kinase.
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octanoate, which activates HCA3 receptors at micromolar concentrations, are elevated 
under conditions of increased fatty acid oxidation such as starvation, diabetic ketoacidosis, 
various mitochondrial fatty acid β-oxidation disorders and under a ketogenic diet [4, 
16, 17]. Under such conditions the HCA3 receptor mediates a negative feedback loop to 
counterregulate pro-lipolytic stimuli in order to prevent excessive lipolysis which would 
result in the futile release and circulation of free fatty acids [1] (figure 2B). The fact that 
the HCA3 receptor is only found in humans and chimpanzee suggests that a negative 
feedback loop of lipolysis mediated through 3-hydroxy-octanoate/HCA3 has evolved in 
higher primates to economize the use of fatty acids during periods of starvation. Whether 
HCA3 has potential physiological roles in immune cells or other organs is currently not 
known.
V. Receptor classification with pharmacological tools
Although nicotinic acid was introduced in man in the 1950s [9], structure-activity 
relationships for its target(s) were developed much later. Only in the 1980s Aktories and 
colleagues [55, 56] proposed the existence of a specific receptor for nicotinic acid and a 
related compound, acipimox. Progress being slow, members of the same laboratory 
explored a few more compounds related to nicotinic acid in a number of receptor assays, 
using membranes from rat adipocytes and rat spleen [57]. A few years later, the human 
HCA2 receptor was cloned [7]. In that paper a number of nicotinic acid-like compounds 
were also tested. As most medicinal chemistry efforts have been directed towards the 
HCA2 receptor we will discuss the synthetic ligands for this receptor first, followed by the 
more restricted information on the HCA3 receptor. To our knowledge synthetic ligands 
for the HCA1 receptor have only been reported in the patent literature, which is beyond 
the scope of this review. Last but not least, antagonists have not been disclosed for any of 
the HCA receptors, which is currently hampering a full pharmacological characterization 
of these receptors. A few years ago we published a review on the then available ligands, 
largely nicotinic acid-like compounds (Soudijn et al., 2007). The current review does not 
reiterate that but starts from there, and is organized according to chemical classes. We 
report representative structures of these classes in Figure 3.
A. Structure-activity relationships for the HCA
2
 receptor
1. Nicotinic acid-like compounds
Lorenzen and colleagues [57] observed that nicotinic acid (1 in figure 3) displaces [3H]
nicotinic acid from and increases [35S]GTPγS binding to rat epididymal adipocyte and 
spleen membranes with (sub)micromolar potency. The same two assays were used by 
Wise et al. [7] with similar results, now on the cloned human HCA2 receptor. Apparently 
there are no huge species differences between rat and man for nicotinic acid itself. Two 
other marketed products, acifran (2 in figure 3) and acipimox (3 in figure 3), were also 
tested but showed lower potencies. Nicotinamide (4 in figure 3) was inactive, indicating 
that the carboxylic acid group is essential for activity. Gharbaoui et al. [58] evaluated other 
heterocyclic scaffolds, confirming that changing this moiety invariably led to compounds 
with lower potency than nicotinic acid, if at all.
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2. Pyrazoles
Pyrazole-3-carboxylic acid acted as a high-efficacy partial agonist in a rat tissue [35S]GTPγS 
binding assay [57]. This finding was taken as the starting point for a synthetic program, 
both in academia and industry. Partial agonists may display tissue selectivity, thought 

































































6 (biphenyl anthranilic acid derivative)
3 (acipimox)
7 (MK-6892) 8 (fumaric acid esters)
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9 (pyridopyrimidinones)








might be separated from the desired action in dyslipidemia. Van Herk et al. [59] prepared 
two series of alkyl- and benzyl-substituted pyrazole-3-carboxylic acid derivatives; 
they were all partial agonists, and some compounds had micromolar affinity. This was 
particularly true for the butyl-substituted derivative. Gharbaoui et al. [58] and Skinner et 
al. [60] reported on a more extended series of pyrazoles largely corroborating the findings 
of Van Herk et al. [59]. In the latter publication it was shown that the carboxylic acid 
could not easily be replaced by a tetrazole bioisostere. Later, Semple and colleagues [61] 
reported on one particular exception, in which the carboxylic acid/tetrazole switch yielded 
a partial agonist. In mice this compound (MK-0354, 5 in figure 3) was as active as nicotinic 
acid in reducing the amount of plasma free fatty acids in vivo and had quite favorable 
pharmacokinetic properties, whilst not causing vasodilation in the mouse ear, a surrogate 
marker for flushing (see also section VIII). Imbriglio et al. [62] synthesized further MK-
0354 analogues by introducing fluorinated phenyl substituents, the 2,3,5-trifluoro variant 
of which was 2-3 fold more potent than nicotinic acid in vitro. Similar derivatives, now 
with a carboxylic acid function were reported by Schmidt et al. [63] and Imbroglio et al. 
[64]. A further derivatization of MK-0354 with a cyclopropane extension was reported by 
Boatman et al. [65].
3. Acifran analogues
Acifran (5 in figure 3) was developed in the early 1980s as a lipid lowering agent. Only in 
2006 Mahboubi and coworkers [66] synthesized and evaluated a small number of acifran 
analogs. The introduction of a para-fluoro substituent on the phenyl ring preserved 
activity in the in vivo animal model, while other modifications were not allowed. There 
was little selectivity with respect to the HCA3 receptor. A further, more extensive, study 
was performed by Arena Pharmaceuticals [67]. Other substituents on the phenyl ring (e.g., 
3-chloro) or replacement by thiophene yielded some compounds that showed slightly 
higher potency than acifran, but without a significant degree of selectivity towards the 
HCA3 receptor. Some of the analogs were resolved into their individual stereoisomers, 
showing that invariably the (+)-isomer was the biologically active principle.
4. Anthranilic acid derivatives
High-throughput screening (HTS) campaigns at a number of companies, in particular 
Merck, led to the discovery of anthranilic acid derivatives as HCA2 ligands, first reported 
by Shen et al. [68]. Such compounds [63] appear prone to have high plasma protein binding 
with a strong negative impact on the in vivo activity of the molecules, e.g. the biphenyl 
compound 6 in figure 3. Other anthranilic acid derivatives were reported by Shen et al. 
[69]. Partial hydrogenation of the anthranilic acid phenyl ring yielded compounds that 
retained activity on the HCA2 receptor, elaborately explored by Raghavan et al. [70]. 
The authors concluded that the tetrahydro variants of anthranilic acid derivatives show 
improved oral bioavailability and better cytochrome P450 profiles. A recent publication 
[71] describes the discovery of (pre)clinical candidate MK-6892 (7 in figure 3). It was also 
found (Ding et al., 2010; Schmidt et al., 2010) that the cyclohexene ring system in such 
compounds can be further substituted.
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5. Fumaric and other acids and their esters
A mixture of fumaric acid esters is on the market in Germany for the treatment of psoriasis. 
Interestingly, the monomethyl (MMF) and monoethyl (MEF) ester of fumaric acid (8 in 
figure 3), but not fumaric acid itself, have micromolar affinity for the HCA2 receptor [29] 
(see also section VIII). A number of ‘simple’ acids rather than esters were tested by Ren 
et al. [72]. The two most potent compounds were trans-cinnamic acid and para-coumaric 
acid, although substantially less active than nicotinic acid. On the HCA3 receptor trans-
cinnamic acid was also active, while para-coumaric acid was not. Oral administration of 
trans-cinnamic acid to wild-type mice led to a significant reduction in plasma free fatty 
acid levels, whereas the compound was without effect in HCA2 receptor KO animals. 
Further SAR on the HCA2 receptor for this ligand class was recently reported by us. A 
rather restricted binding pocket on the receptor was delineated with trans-cinnamic acid 
itself being the largest planar ligand with appreciable affinity for the receptor [73 in press].
6. Pyridopyrimidinones
Peters et al. [74] reported on a very different scaffold from which HCA2 receptor agonists 
were derived. The pyridopyrimidinones (e.g., 9 in figure 3) can be regarded as derivatives 
of nicotinamide, but that compound is inactive at HCA2 receptors. Nevertheless 
submicromolar affinity and potency were observed in this series, although the compounds 
behaved poorly in pharmacokinetic studies.
7. Pyrazolopyrimidines as allosteric agonists
Shen and coworkers [75] described another series of agonists for the HCA2 receptor 
with intriguing pharmacological activity, in particular 7 in figure 3. When tested alone it 
behaved as a partial agonist with 8-fold higher potency than nicotinic acid. Interestingly, 
the presence of 10 shifted the concentration-effect curve of nicotinic acid significantly to 
the left, suggestive of an allosteric mechanism of action. In a radioligand binding assay 
the pyrazolopyrimidine dose-dependently increased rather than displaced specific [3H]
nicotinic acid binding, yet another token of its nature as an allosteric enhancer.
8. Patent literature
Many companies have published patents on ligands for the HCA2 receptor. As these 
publications are not peer-reviewed we refrain from discussing them here. However, the 
most remarkable developments in this area have been published in four recent reviews, to 
which we refer the interested reader [76-79].
B. Structure-activity relationships for the HCA
3
 receptor
Despite the high (>95%) homology between HCA2 and HCA3 receptors, nicotinic acid 
is very selective for the HCA2 receptor, whereas acifran is not (see e.g. [66, 72, 80]. The 
most extensive structure-activity study with acifran analogs [67] showed that an ethyl 
rather than a methyl substituent at the chiral center in acifran provided some selectivity 
for the HCA3 receptor, whereas all other compounds were slightly selective for the HCA2 
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receptor. Ren et al. identified ortho-coumaric acid as approx. 20-fold selective for the 
HCA3 receptor, while the isomer para-coumaric acid was inactive at the HCA3 receptor 
but not at the HCA2 receptor (see paragraph A.5. in this section).
New HCA3 receptor ligands were reported by Semple and coworkers [81]. In a screening 
campaign the authors discovered a benzotriazole compound (11 in figure 3) with 
nanomolar activity. Further exploration, e.g. by replacing the isopropyl group by 2-butyl, 
led to even more potent compounds, but without effect on the HCA2 receptor. 
Some 4-amino-3-nitrobenzoic acids, used as intermediates in the synthesis of the 
benzotriazoles, also displayed significant activity at HCA3 receptors and selectivity over 
HCA2 receptors [82]. Further substitution of the 4-amino group led to compounds with 
potencies in the higher nanomolar range. In the same publication the nitro-aryl moiety 
was substituted by a pyridine ring like in nicotinic acid, yielding HCA3 receptor-selective 
full agonists.
Recently, the synthetic efforts were extended to the pyrazole carboxylic acids as a template 
for the HCA3 receptor [83]. A similar substituted amino group as mentioned above was 
introduced to the pyrazole ring system. A typical representative (12 in figure 3) displayed 
high potency with an EC50 value of 3 nM, and over 1000-fold selectivity with respect to the 
HCA2 receptor.
An intriguing conclusion from this research is that ‘on average’ ligands for the HCA3 
receptors have higher affinity than ever met for the HCA2 receptor, despite intensive 
efforts on the latter receptor.




Prior to the deorphanization of HCA1, Ge and coworkers [22] constructed a chimeric 
cysteinyl-leukotriene 2 (CysLT2) receptor where the intracellular domains (all ILs and 
the C-terminus) were replaced by the HCA1 sequence. The endogenous CysLT2 ligand, 
leukotriene D4 (LTD4), activated the receptor and this resulted in stimulation of Gi. Wild-
type CysLT2 predominantly couples to Gq, so these findings suggested that HCA1 is a Gi 
coupled receptor. A first clue regarding the biological function of HCA1 was obtained 
when LTD4 was shown to inhibit lipolysis in primary mouse adipocytes expressing the 
chimera. After lactate was identified as the endogenous HCA1 ligand, a homology model 
was constructed of the binding pocket [5]. Four conserved residues predicted to interact 
with lactate were mutated to alanine in separate mutant receptors: Arg99Ala (TM3), 
Tyr233Ala (TM6), Arg240Ala (TM6) and Thr267Ala (TM7). Stimulation of [35S]GTPγS 
binding by lactate was absent in all four mutants, suggesting that these residues are all 






The HCA2 and HCA3 receptors have different ligand repertoires and SAR, although 
there is some cross-selectivity (see section V). For example, nicotinic acid binds almost 
exclusively to HCA2, whereas acifran [84] stimulates both HCA2 (EC50 = 1.9 µM) and HCA3 
(EC50 = 90 µM). This is surprising since these receptors have > 95 % amino acid sequence 
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identity. To investigate which amino acids are involved in ligand selectivity, Tunaru and 
coworkers [85] constructed HCA2/HCA3 chimeras and introduced point mutations in 
both native receptors. For the chimeras, the receptors were cut at the interface of IL2 and 
TM4, and then the fragments were joined together at this point (see figure 4A). On the 
chimera with the HCA2 receptor C-terminally, acifran had HCA2-like potency (EC50 = 2 
µM). At the same time, this receptor was insensitive to nicotinic acid. It was also HCA3-
like in its response to 2-oxo-octanoic acid, which is a close analogue of the endogenous 
HCA3 ligand [4]. The HCA3 N-terminal part seemed indeed responsible for the affinity 
of 2-oxo-octanoic acid, since the ‘reverse’ chimera with the HCA2 sequence N-terminally 
did not respond to this compound. Using the site-directed mutagenesis approach, a HCA2 
mutant containing HCA3 residues on three positions was constructed. The mutations 
Asn86Tyr, Trp91Ser (interface of TM2 and IL1) and Ser178Ile (EL2) prevented HCA2 
from responding to nicotinic acid and lowered the potency of acifran to HCA3-like levels 
(see figure 4B). As a next step, the positively charged arginine residues in HCA2 were 
investigated as likely counterparts for the negatively charged carboxylate function in 
nicotinic acid and acifran. All four arginine residues in the sequence were mutated to 
alanine, and only the Arg111Ala (TM3) mutant was rendered insensitive to nicotinic 
acid. The HCA3 single mutant Arg111Ala, which was later constructed, also showed a 
deficient binding of the ligand 2-hydroxy-octanoic acid, which is another analogue of the 
endogenous HCA3 ligand [4] (see figure 4C). This suggests that the acidic moiety of the 
ligands is anchored at the same position in both HCA2 and HCA3. Interestingly, the HCA 
Arg111 corresponds to the conserved Asp residue important for agonist binding in the 
biogenic amine receptors. In HCA2, three more residues seem implicated in nicotinic acid 
binding: Phe180 (EL2), Phe276 and Tyr284 (both TM7) [85]. In a later paper, the roles of 
HCA2 residues Asn86, Met103 and Leu107 were investigated further [4]. Mutations into 
corresponding HCA3 residues (respectively Tyr, Val and Phe) conferred a full HCA3-like 


























Figure 4. HCA2/HCA3 chimeras and residues involved in ligand binding. A. Schematic representation of HCA2/
HCA3 chimeras discussed in Tunaru et al. [85] and Ahmed et al. [4]. The arrow indicates the juncture point. B. 
Schematic representation of HCA2 indicating the positions of residues important for ligand binding (black dots). 
C. Schematic representation of HCA3 indicating the position of residues important for ligand binding (black dots).
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Trp91Ser, Met103Val showed no response to this ligand. In the paper describing the 
HCA2/HCA3 chimeras, a receptor homology model for HCA2 was also presented [85]. The 
model was based on the rhodopsin crystal structure [86], although the binding mode of 
the large ligand retinal did not give many clues on how to dock the small HCA receptor 
ligands. It was proposed that Trp91, Phe276 and Tyr284 interact with the pyridine ring of 
nicotinic acid, whereas a hydrogen bond may be present between Ser178 and the nitrogen. 
An independently constructed HCA2 homology model, also based on the rhodopsin 
structure, was used to dock an anthranilic acid derivative [87]. The proposed binding 
pocket was lined by residues mainly from TM3, TM5, TM6 and EL2, which could bind the 
ligand in an extended conformation. Three residues important for nicotinic acid binding, 
Arg111 (TM3), Ser178 (EL2) and Phe276 (TM7), were also implicated here. Recently the 
repertoire of available GPCR crystal structures has grown considerably [88-91]. These new 
templates have not been exploited yet for HCA receptor homology modeling, but may 
yield better models in the near future.
VII. Signal transduction and receptor desensitization
A. G protein coupling
It was previously shown that nicotinic acid-induced effects are sensitive to treatment with 
pertussis toxin which specifically inactivates α-subunits of Gi-type G proteins [56]. During 
the last decade numerous studies have shown that HCA1, HCA2 and HCA3 receptor-
mediated effects are sensitive to pertussis toxin [2, 4-8, 18, 22]. Thus, HCA1, HCA2 and 
HCA3 receptors couple to Gi/Go -type G proteins.
B. Downstream signaling pathways
Agonists of HCA1, HCA2 and HCA3 receptors have been shown to inhibit adenylyl cyclase 
activity and thereby to decrease cAMP levels in various cells after heterologous expression 
of the receptors as well as in primary adipocytes [4-8, 24, 92]. Since cAMP is the major 
intracellular regulator of lipolysis by stimulating cAMP-dependent kinase to activate 
lipolytic enzymes, a decrease in cAMP results in an antilipolytic effect in adipocytes [93]. 
Activation of Gi-type G proteins in immune cells results in stimulation of phospholipase 
C β-iso forms most likely through the release of βγ-subunits of G proteins [94], and 
activation of HCA2 and HCA3 receptors in neutrophils, macrophages or other immune 
cells has been shown to result in increases in free intracellular Ca2+ concentrations [4, 
11, 18, 26, 95]. An increase in the intracellular Ca2+ concentration induced by nicotinic 
acid via HCA2 receptors may lead to the activation of Ca2+-sensitive phospholipase A2 
(PLA2) and subsequent formation of prostanoids [11, 27, 95]. PLA2 can also be activated 
by phosphorylation through extracellular signal-regulated kinase (ERK) which can be 
activated via HCA receptors as well [4, 5, 8, 92, 96]. 
C. Receptor desensitization
Some of the effects mediated by the HCA2 receptor are subject to de sensitization [97]. For instance, 
nicotinic acid-induced flushing and nicotinic acid-induced increases in intracellular 
Ca2+ con centrations via the HCA2 receptor desensitize within minutes [26, 27]. Whether 
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these desensitization phenomena are due to effects on the receptor itself or at the level of 
downstream signaling processes is unclear. There is some evidence that heterologously 
expressed HCA1 and HCA2 receptors internalize in response to full agonists [5, 92, 98]. 
In contrast, a partial agonist, which did not induce ERK phosphorylation, did not induce 
receptor internalization [92]. Ligand-dependent internalization of HCA2 appears to 
involve G protein-coupled receptor kinase 2 (GRK2) and arrestin 3  [98].
D. Receptor oligomerization
It is generally accepted that some G protein-coupled receptors can form dimers or 
oligomers. In a recent study it was shown by bioluminescence resonance energy transfer 
that HCA2 and HCA3 receptor constructs can interact when heterologously expressed in 
human embryonic kidney cells [80]. However, the existence of homo-/heterodimers of 
HCA2 and HCA3 in native tissues and the implications of oligomerization for receptor 
function remain unknown.
VIII. Therapeutic potential of HCA receptor ligands
Although all members of the HCA receptor family are potentially interesting drug targets, 
only HCA2 is currently exploited as such. Therefore, this section will focus on this receptor 
alone.
A. Nicotinic acid alone
The use of high-dose nicotinic acid in the clinic has a long history starting in the 1950’s 
[9]. A number of clinical studies demonstrated the usefulness of this compound as a lipid-
modulating drug, although patient comfort and compliance are compromised by the 
common skin flushing side-effect [for reviews see: 10, 99; see also section IV]. Nowadays 
anti-flushing formulations of nicotinic acid are usually chosen over the crystalline form 
of the drug.
B. Nicotinic acid with anti-flushing strategies
Flushing is a widely occurring side effect of high-dose nicotinic acid. It seems to decrease 
with continued nicotinic acid treatment, but still up to one in five patients stops the 
treatment due to this side effect [100].  Administration of nicotinic acid with a meal seems 
to attenuate the flushing, probably due to a slower absorption rate. Acetylsalicylic acid, 
which is an inhibitor of prostaglandin synthesis, is also effective against flushing [101]. 
The more elegant versions of these strategies are extended-release nicotinic acid [102] and 
a combined formulation of nicotinic acid with laropiprant [52]. Modern extended-release 
(ER) nicotinic acid has been proven efficacious and has overcome the initial hepatotoxicity 
problems by decreasing the half-life compared to earlier sustained-release preparations 
[103]. In all of the clinical trials discussed below, ER nicotinic acid was used instead of 
an immediate-release formulation. Laropiprant is a prostaglandin D2 receptor 1 (DP1) 
antagonist. Like aspirin, it can reduce the cutaneous vasodilatation which is at the core 
of the flushing syndrome (see sections IV and VII). Nicotinic acid with laropiprant and 
 Chapter 2
52
nicotinic acid alone (4 weeks 1 g/day followed by 20 weeks 2 g/day) were shown to have 
comparable lipid-modifying effects and safety profiles except for flushing, which was less 
severe with laropiprant [104].  In a separate study, severity of flushing in the first 16 weeks 
of nicotinic acid treatment was evaluated in patients with dyslipidemia [105]. Despite 
higher nicotinic acid doses, patients receiving the combination treatment experienced 
significantly less flushing. Furthermore, a lower number of patients from the combination 
group discontinued the trial due to flushing (7.4% vs 12.4%). The data from these and 
all other trials evaluating nicotinic acid/laropiprant have recently been compiled by 
McKenney and coworkers [106]. A fixed-dose formulation (1000 mg nicotinic acid/20 mg 
laropriprant) is on the market in Europe since 2008, but the FDA has requested further 
studies before introduction in the USA.
C. Nicotinic acid in combination with other lipid-altering drugs
HMG-CoA reductase inhibitors (‘statins’) are the first choice for lowering cholesterol 
plasma levels. Therefore, it was a logical step to investigate if combination of statins 
with nicotinic acid had any added benefit. An early example of such a trial showed 
that combination treatment with simvastatin and nicotinic acid for 3 years significantly 
improved the lipid profile in patients with coronary heart disease and low HDL cholesterol 
[107]. Furthermore, the frequency of a first cardiovascular event was only 3% in the 
treatment group versus 24% in the placebo group. Overall, the therapeutic efficacy of the 
combination was much better than simvastatin alone [see for example: 108]. 
An important surrogate endpoint in the evaluation of lipid-modifying therapy is the 
effect on the size of atherosclerotic lesions, usually measured by carotid intima-media 
thickness (CIMT) [99]. Statin monotherapy does not greatly influence atherosclerotic 
plaque formation, whereas statin/nicotinic acid combination treatment has been shown to 
reduce lesion development in several clinical trials. In the ARBITER 2 study, patients on 
statins received supplementary nicotinic acid or placebo therapy during one year [109]. 
CIMT was significantly increased in the placebo group, whereas it was unchanged in the 
group receiving nicotinic acid treatment, although the difference between the groups 
did not reach significance. In the more recent ARBITER6-HALTS study the effects of ER 
nicotinic acid or ezetimibe as add-on therapy with statin treatment were assessed [110]. 
Ezetimibe inhibits cholesterol absorption from the gut. After 14 months of treatment, a 
significant reduction in mean and maximal CIMT was observed in the nicotinic acid/
statin group; HDL cholesterol was significantly increased, whereas it was decreased in the 
ezetimibe/statin group. Although the majority of the patients completed the study, it was 
halted prematurely because of an unexpected increase in atherosclerosis in the ezetimibe/
statin group [see also: 111, 112]. In another very recent clinical study, participants 
received ezetimibe/statin combination treatment with or without additional nicotinic 
acid [113]. This triple therapy significantly improved lipid levels including HDL, LDL 
and apolipoprotein AI, and was well tolerated overall. Small and transient side-effects on 
fasting glucose were seen with nicotinic acid use. 
The nicotinic acid/statin combination therapy is currently being evaluated further in 
two large trials. The endpoints are progression of cardiovascular disease, incidence of 
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major cardiovascular events and cardiovascular disease-associated mortality. The AIM-
HIGH study compares ER nicotinic acid/simvastatin with simvastatin monotherapy 
and enrolled 3300 patients suffering from cardiovascular disease, low HDL cholesterol 
and high triglyceride levels (see at http://clinicaltrials.gov/ct2/show/NCT00120289). The 
HPS2-THRIVE compares ER nicotinic acid/simvastatin/laropiprant with simvastatin 
alone in patients with coronary heart disease (N>20,000) (see at http://clinicaltrials.gov/
ct2/show/NCT00461630). The results of these trials are expected between 2011 and 2013. If 
a significant benefit of nicotinic acid is shown, a much more widespread use of the drug 
can be expected. 
D. Fumaric acid derivatives
Fumaric acid esters, which have now been identified as HCA2 agonists [29], have been 
used for the treatment of psoriasis as early as the 1950’s [114]. Although their mechanism 
of action is still poorly understood, good and prolonged clinical efficacy and an acceptable 
safety profile have been reported for the oral administration of a mixture of monoethyl- 
and dimethylfumarate [115, 116]. For a recent retrospective analysis of almost 1000 
patients see Reich et al. [117]. Dimethylfumarate (DMF) is quickly metabolized in vivo to 
monomethylfumarate (MMF), which has a higher potency at HCA2 [29; see also section 
V]. DMF was also evaluated in a phase II trial including 240 patients for the treatment 
of relapsing-remitting multiple sclerosis [118]. Administration of 3 times 240 mg/day 
reduced the mean number of new brain lesions emerging between the 12th and 24th week 
of treatment by 70%, compared to placebo. It has not been conclusively demonstrated 
that activation of HCA2 is at the basis of the therapeutic effects of fumaric acid esters, 
but the receptor is a plausible mediator as it is definitely expressed in immune cells. 
Nicotinic acid itself has also been suggested for the treatment of multiple sclerosis [119]. 
If HCA2 agonists can indeed act as anti-inflammatory or immunosuppressive drugs, the 
treatment of several auto-immune diseases could be improved with these relatively safe 
and inexpensive compounds.
E. Clinical candidates
An HCA2 agonists, MK-0354, was selected on the basis of low or negligible ERK1/2 activation 
in vitro and greatly reduced flushing in animal studies [61]. In a phase II study, 2.5 g of 
MK-0354 lowered free fatty acid levels in dyslipidemic patients consistently, comparable to 
1 g of ER nicotinic acid. Little flushing was observed with MK-0354; however, no clinically 
meaningful lipid modification occurred either [120]. The recently completed trial with 
another HCA2 agonist, MK-1903 (structure not disclosed), seems to have yielded similar 
results (see at http://www.clinicaltrial.gov/ct2/show/NCT00847197). Merck announced 
that the HDL cholesterol elevation was not large enough to meet the objectives for efficacy, 
and no safety problems were mentioned (see at http://drugdiscovery.pharmaceutical-
business-review.com/news/merck_to_discontinue_development_of_mk1903_091224/). 
It seems that clinical efficacy of HCA2 agonists cannot (yet) be accurately predicted at 
the preclinical stage. A better understanding of the mechanism of action of nicotinic acid 




The first steps towards understanding the physiological relevance of the HCA receptor 
family have only recently been taken. These receptors seem to have evolved to recognize 
hydroxylated intermediates of energy metabolism with a relatively low affinity, in order 
to regulate lipolysis. HCA1 seems to contribute to insulin-induced anti-lipolysis, and also 
to the weight gain induced by a hypercaloric diet. HCA2 is important for the conservation 
of adipose tissue under starvation conditions, next to its pharmacological role as the high-
affinity nicotinic acid receptor. HCA3 seems to be part of the same negative feedback loop 
to limit lipolysis during starvation. HCA2 and HCA3 may have additional roles in the 
immune system, but further studies are needed in that area. 
Despite rather spectacular effects on lipid levels and also on atherosclerosis progression, 
and the introduction of reduced-flushing formulations, the use of the antidyslipidemic 
drug nicotinic acid is still stunted by its side-effects. Other HCA2 ligands, including partial 
agonists and biased agonists, may be better tolerated. However, despite extensive efforts 
of the pharmaceutical industry, no new HCA2 ligands have been successful as clinical 
candidates so far. More research is needed to enable the identification of genuinely 
promising molecules. Possibly the most important enigma is how nicotinic acid induces 
HDL elevation. Recent animal experiments suggest that nicotinic acid reduces the 
progression of atherosclerosis also via lipid-independent anti-inflammatory effects and 
by increasing cholesterol efflux from plaque macrophages. Lipid-independent beneficial 
effects of nicotinic acid, in particular anti-inflammatory effects, deserve further analysis in 
the future. HCA1 also has potential as a drug target for antilipolysis, and it is very unlikely 
that agonists for this receptor cause flushing because no skin expression has been detected. 
HCA1 antagonists may reduce weight gain, but no antagonists are known to date for any 
of the HCA receptors. Thus, studies in animals have revealed unexpected physiological 
and pharmacological roles of HCA receptors. Much more work on the generation of new 
agonistic and antagonistic ligands of HCA receptors and their analysis in in vitro and 
in vivo models is required to explore all options to harness HCA receptors as targets 
to prevent and treat a variety of diseases like dyslipidemia, adipositas, cardiovascular 
diseases or chronic inflammatory and immune diseases.
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Effects of pyrazole partial agonists on HCA
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-mediated 
flushing and VLDL-triglyceride levels in mice
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Background and purpose: Niacin can effectively treat dyslipidemic disorders. However, 
its clinical use is limited due to the cutaneous flushing mediated by the nicotinic acid 
receptor HCA2. In the current study, we evaluated two partial agonists for HCA2, LUF6281 
and LUF6283, with respect to their anti-dyslipidemic potential and cutaneous flushing 
effect.
Experimental approach: In vitro potency and efficacy studies with niacin and the two 
HCA2 partial agonists were performed using HEK293T cells stably expressing human 
HCA2. Normolipidemic C57BL/6 mice received either niacin or HCA2 partial agonists (400 
mg/kg/day) once a day for 4 weeks for evaluation of their effects in vivo.
Key results: Radioligand competitive binding assay showed Ki values for LUF6281 and 
LUF6283 of 3 μM and 0.55 μM. [35S]-GTPγS binding determined niacin > LUF6283 > 
LUF6281 as rank order of their potency. All three compounds similarly reduced plasma 
VLDL-triglyceride concentrations, while LUF6281 and LUF6283 - in contrast to niacin - 
did not also exhibit the unwanted flushing side effect in C57BL/6 mice. Niacin lowered 
the adipose tissue expression of lipolytic genes HSL and ATGL by 50% (P<0.05). LUF6281 
and LUF6283 unexpectedly did not. In contrast, the decrease in the VLDL-triglyceride 
concentration upon LUF6281 and 6283 treatment was associated with a parallel >40% 
decrease (P<0.05) in the expression level of APOB within the liver.
Conclusions and Implications: The current study identifies LUF6281 and LUF6283, two 
HCA2 partial agonists of the pyrazole class, as promising drug candidates to achieve 
optimal lipid-lowering while successfully avoiding the unwanted flushing side effect.
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Introduction
Niacin, also known as nicotinic acid, is the most effective agent currently available to treat 
dyslipidemic disorders [1]. It lowers plasma levels of pro-atherogenic lipids, including 
chylomicrons, very-low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and 
triglycerides (TG) in normolipidemic as well as hypercholesterolemic subjects [2]. Several 
clinical trials have shown that nicotinic acid reduces cardiovascular disease and myocardial 
infarction incidence, providing a solid rationale for the use of niacin in the treatment of 
atherosclerosis [3-4]. The G protein-coupled receptor GPR109A, also known as PUMA-G 
in mouse and HM74A in humans, has been identified as a high-affinity receptor for niacin 
[5-6]. We now know that the endogenous ligand for GPR109A is 3-hydroxybutyrate, and 
this receptor has recently been renamed as hydroxy-carboxylic acid receptor 2 (HCA2) [7].
Despite its established cardiovascular benefits, the clinical use of niacin has been limited 
due to the cutaneous flushing, a well-recognized adverse skin effect from niacin therapy. 
Flushing has been cited as the major reason for the discontinuation of this therapy [8]. The 
nicotinic acid receptor HCA2 expressed in the skin is a critical mediator of niacin-induced 
flushing [9]. Niacin stimulates HCA2 in epidermal Langerhans cells and keratinocytes, 
causing the cells to produce vasodilatory prostaglandin D2 (PGD2) and prostaglandin E2 
(PGE2), which leads to cutaneous vasodilation [10-13].
For the past decade, the pharmacology of HCA2 has been studied and full or partial 
agonists for HCA2 have been developed in an attempt to achieve the beneficial effects 
of niacin while avoiding the unwanted flushing side effect [14]. Based on the structure-
activity relationship of niacin-related molecules, several potent agonists for HCA2 have 
been identified, including acipimox, acifran, 3-pyridine-acetic acid, 5-methylnicotinic 
acid, pyridazine-4-carboxylic acid, and pyrazine-2-carboxylic acid [15-16]. However, 
the challenge remains that HCA2 partial agonists failed to mimic the beneficial effects 
of niacin on LDL-cholesterol, triglycerides or HDL-cholesterol despite the absence of 
flushing events in clinical studies [17]. Further understanding of the medicinal chemistry 
of HCA2 is needed to pharmacologically dissociate the anti-lipolytic and vasodilatory 
effects of niacin by acting on HCA2.
In the current study, we assessed the properties of two HCA2 partial agonists, LUF6281 
and LUF6283, of the pyrazole class, which were developed in our laboratory [18]. We 
first characterized these two compounds in vitro, using a radioligand binding assay, 
[35S]-GTPγS assay and ERK phosphorylation assay. The ERK phosphorylation assay was 
included because it has been suggested that ERK1/2 phosphorylation downstream from 
HCA2 correlates positively with skin flushing [19]. Subsequently, we determined the 
cutaneous flushing effect and the lipid-lowering potential of these two partial agonists in 
normolipidemic C57BL/6 mice which represent a good mouse model to study the VLDL-
triglyceride lowering effect of niacin [20].
Methods
Materials
[3H]-nicotinic acid (60 Ci/mmol) was obtained from BioTrend (Köln, Germany). [35S]-
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GTPγS (1250 Ci/mmol) was obtained from Perkin Elmer (Waltham, MA).
Cell culture and membrane preparation
Human embryonic kidney (HEK) 293T cells stably expressing human HCA2 were cultured 
in DMEM supplemented with 10% newborn bovine serum, 0.4 mg/mL G418, 50 IU/mL 
penicillin and 50 μg/mL streptomycin. The cells were harvested by scraping in cold PBS, 
centrifuged at 1000 x g for 10 minutes and resuspended in cold 50 mM Tris-HCl buffer, 
pH 7.4. Then a DIAX 900 electrical homogenizer (Heidolph, Schwabach, Germany) was 
used for 15 seconds to obtain cell lysis. The suspension was centrifuged at 225000 x g for 
20 minutes at 4 °C and the supernatant was discarded. The pellet was resuspended in Tris-
HCl, and the homogenization and centrifugation steps were repeated. The membranes 
were resuspended in cold assay buffer (50 mM Tris HCl, 1 mM MgCl2, pH 7.4) and the 
protein content was determined using BCA assay (Thermo Scientific, Waltham, USA). 
During membrane preparation the suspension was kept on ice at all times. Membrane 
aliquots were stored at -80°C until the day of use.
[3H]-nicotinic acid displacement assay
Membranes of our stable HEK293T-HCA2 cell line (50 μg protein per tube) were incubated 
for 1 hour at 25°C with 20 nM [3H]-nicotinic acid and with increasing concentrations of the 
test compounds in assay buffer (50 mM Tris HCl, 1 mM MgCl2, pH 7.4). The total assay 
volume was 100 μL. To assess the total binding, a control without test compound was 
included. The non-specific binding was determined in the presence of 10 μM unlabeled 
nicotinic acid. Final DMSO concentration in all samples was ≤0.25%. The incubation 
was terminated by filtering over GF/B filters using a 24-sample harvester (Brandel, 
Gaithersburg, USA). The filters were washed 3 times with 2 mL cold buffer (50 mM Tris 
HCl, pH 7.4). Filters were transferred to counting vials and counted in a Perkin Elmer 
LSA Tri-Carb 2900TR counter after 2 hours of extraction in 3.5 mL Emulsifier Safe liquid 
scintillation cocktail (Perkin Elmer, Waltham, USA). 
[35S]-GTPS binding assay
This assay was performed in 96-well format in 50 mM Tris-HCl, 1 mM EDTA, 5 mM MgCl2, 
150 mM NaCl, pH 7.4 at 25°C with 1 mM DTT, 0.5% BSA and 50 μg/mL saponin freshly 
added. HEK-HCA2 membranes (5 μg protein per well in 25 μL) were pre-incubated with 
25 μL of 40 μM GDP and 25 μL of increasing concentrations of the test compounds, for 
30 minutes at room temperature. Then, 25 μL [35S]-GTPγS was added (final concentration 
0.3 nM) and the mixture was incubated for 90 minutes at 25°C with constant shaking. The 
incubation was terminated by filtration over GF/B filterplates on a FilterMate harvester 
(PerkinElmer). The filters were dried and 25 μL Microscint 20 (PerkinElmer) was added 
to each filter. After ≥3 hours of extraction the bound radioactivity was determined in a 
Wallac Microbeta Trilux 1450 counter (PerkinElmer, MA, USA).
ERK1/2 phosphorylation assay
The assay was performed using the AlphaScreen SureFire Phospho-ERK1/2 kit 
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(PerkinElmer, MA, USA), following the kit protocol. Briefly, a 96-well cell culture plate 
was coated with poly-D-lysine and HEK cells stably expressing human HCA2 were seeded 
at 50,000 cells/well in 200 μL DMEM supplemented with 10% newborn bovine serum, 0.4 
mg/mL G418, 50 IU/mL penicillin and 50 μg/mL streptomycin. After overnight incubation 
the cells were serum starved for 4 h in the same medium lacking the serum, and then 
the medium was replaced by 90 μL prewarmed PBS and incubated for an additional 30 
minutes. Increasing concentrations of the test compounds were diluted in prewarmed PBS 
and 10 μL was added per well for stimulation. After 5 minutes the stimulation solution 
was removed from the plates, the wells were washed once in ice-cold PBS and 100 μL 
lysis buffer was added per well. After 15 minutes of incubation and shaking at room 
temperature, the lysates were mixed by pipetting and 4 μL was transferred to a 384-well 
OptiPlate (PerkinElmer, MA, USA). The reaction mix was prepared according to the kit 
protocol (60 μL reaction buffer and 10 μL activation buffer with 1 μL of the donor and 
acceptor beads each) and 7 μL mix was added to each proxyplate well. After 2 h the plate 
was read on an EnVision multilabel plate reader (PerkinElmer, MA, USA).
Animals
Twelve week old female C57BL/6 mice were fed a regular cholesterol-free chow diet 
containing 4.3% (w/w) fat (RM3, Special Diet Services, Witham, UK). Mice received niacin, 
or HCA2 partial agonists LUF6281 and LUF6283 (400 mg/kg/day in 50% (v/v) DMSO in 
PBS) once a day for 4 weeks via oral gavage. After euthanization, mice were bled via orbital 
exsanguination and perfused in situ through the left cardiac ventricle with ice-cold PBS 
(pH 7.4) for 20 minutes. Liver and fat were dissected and snap-frozen in liquid nitrogen. 
Animal care and procedures were performed in accordance with the national guidelines 
for animal experimentation. All protocols were approved by the Ethics Committee for 
Animal Experiments of Leiden University.
Measurement of skin flushing
Cutaneous flushing in C57BL/6 mice was assessed by monitoring the change of the skin 
temperature at the mouse paw location. Temperature measurements were recorded using 
a non contact infrared thermometer (Pro Exotics PE-1 Infrared Temp Gun, Littleton, 
USA). The probe was held at a distance of 1 to 2 mm from the metacarpal pad of the 
mouse paw, and temperature readings were taken from a circular area approximately 3 
mm in diameter. Animals were habituated to handling and to the infrared probe before 
use. Skin temperature was initially recorded from the abdominal area, tail, ear, and paw, 
after which it was determined that mouse paw skin temperature yielded the most reliable 
and consistent results. During the experiment, the animals were dosed with niacin or 
partial agonists LUF6281 and LUF6283 (400 mg/kg/day) via oral gavage (10:00-11:00 AM), 
and the paw temperature was measured every 10 minutes for a period of 60 minutes 
in total. Three readings from the center area of mouse paw were recorded routinely for 
each time point. Baseline paw temperature was recorded right before animals were dosed. 
All the administration was performed in conscious mice to avoid the interference of the 




The distribution of cholesterol over different lipoproteins in plasma was determined 
by fast protein liquid chromatography (FPLC) through a Superose 6 column (3.2 x 30 
mm; Smart-System, Pharmacia, Uppsala, Sweden). Cholesterol content of the lipoprotein 
fractions was measured using the enzymatic colorimetric assay (Roche Diagnostics, 
Mannheim, Germany).
Quantitative real-time PCR
Total RNA was isolated using acid guanidinium thiocyanate (GTC)-phenol-chloroform 
extraction. Briefly, 500 μL of GTC solution (4 M guanidine isothiocyanate, 25 mM 
sodium citrate, 0.5% N-lauroylsarcosine) was added to each sample, followed by 
acid phenol:chloroform extraction. RNA in the aqueous phase was precipitated with 
isopropanol. The quantity and purity of isolated RNA were examined using an ND-1000 
Spectrophotometer (Nanodrop, Wilmington, DE, USA). One microgram of RNA from each 
sample was converted into cDNA by reverse transcription with RevertAid™ M-MuLV 
Reverse Transcriptase (Promega, Madison, WI, USA). Negative controls without addition 
of reverse transcriptase were prepared for each sample. Quantitative real-time PCR 
was carried out using ABI Prism 7700 Sequence Detection system (Applied Biosystems, 
Foster City, CA, USA) according to the manufacturer’s instructions. 36B4, beta-actin, and 
GAPDH were used as internal housekeeping genes. The gene-specific primer sequences 
used are listed in Table 1. Amplification curves were analyzed using 7500 Fast System SDS 
software V1.4 (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
Analysis of the in vitro studies was performed using Prism 5.0 software (GraphPad 
Software Inc., La Jolla, USA). Nonlinear regression was used to determine IC50 values from 
competition binding curves. The Cheng-Prusoff equation was then applied to calculate 
Ki values [21]. [35S]-GTPγS and pERK curves were analysed by nonlinear regression to 
obtain EC50 values. For the in vivo studies, data were analyzed by T-test or one way 
ANOVA with Student-Newman-Keuls post test (Instat GraphPad software, San Diego, 
USA) were appropriate. Statistical significance was defined as p<0.05. Data are expressed 
as means+SEM.









Table 1. Primers used for quantitative real-time PCR analysis
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Results
The chemical structures of niacin and the HCA2 partial agonists LUF6281 and LUF6283 
are shown in Figure 1. The affinity of the compounds for HCA2 was determined by a 
competitive binding assay using radiolabeled nicotinic acid and a HEK293T cell line stably 
expressing the human HCA2 nicotinic acid receptor (Figure 2). The Ki values determined 
for LUF6281 and LUF6283 were 3.1 μM and 0.55 μM, respectively (Table 2).
As functional readout the potencies and intrinsic efficacies of niacin, LUF6281, and 
LUF6283 were measured by their ability to stimulate [35S]-GTPγS binding. The results 
show that LUF6281 and LUF6283 are partial agonists compared to niacin (100%), with 
intrinsic efficacies of 55±4% and 76±3%, respectively (N=3). The rank order of their potency 
was niacin > LUF6283 > LUF6281, with EC50 values of 0.41, 3.1 and 8.6 μM, respectively 
(Figure 3; Table 2).
The second functional assay monitored ERK1/2 phosphorylation upon HCA2 activation 
by the different compounds. All compounds appeared to be high efficacy full agonists 












Figure 1. Chemical structures of niacin, LUF6281, and LUF6283.




























Figure 2. Competitive radioligand binding 
assay using 20 nM [3H]-nicotinic acid revealing 
the relative affinities of niacin, LUF6281 and 
LUF6283. The assay was performed on HEK293T-
HCA2 membranes (50 μg/tube). A representative 








Niacin 0.04 ± 0.02 0.41 ± 0.11 0.02 ± 0.004 21
LUF6281 3.1 ± 0.5 8.60 ± 1.00 1.37 ± 0.31 6
LUF6283 0.55 ± 0.01 3.10 ± 0.13 0.32 ± 0.06 10




LUF6281 and 0.32 μM for LUF6283. Thus, all compounds seemed to be more potent in the 
pERK1/2 assay than in the [35S]-GTPγS assay. Importantly, this difference was much more 
pronounced for niacin (21-fold) than for LUF6283 (10-fold) and LUF6281 (6-fold) (Table 2).
To examine the vasodilatory effects of these compounds in vivo, we used normolipidemic 
C57BL/6 mice to assess the cutaneous flushing. Normal paw skin temperature of C57BL/6 
mice is approximately 26.4°C (n=30). Flushing was measured as absolute increase in 
mouse paw skin temperature. As anticipated, niacin treatment induced a strong increase 
in skin temperature (+3°C; P<0.001). However, neither of the partial agonists displayed a 
significant temperature rise. At 20 minutes after compound administration, LUF6281 and 
LUF6283 induced a temperature increase of maximally 0.6°C (n = 10 per group), which 
was significantly lower than the temperature rise observed in the niacin group (P<0.001; 
Figure 5) and not different from the temperature rise induced by mouse handling alone. 
Both of the HCA2 partial agonists thus avoided the unwanted flushing side effect seen 
upon niacin exposure in mice.
To evaluate the lipid lowering potential of the LUF compounds, we tested their effect on 
plasma lipid levels. Although treatment with niacin or the LUF compounds for 4 weeks 
did not alter the plasma total cholesterol or triglyceride concentrations (data not shown), 
separation of plasma lipoproteins by FPLC in combination with analysis of the lipid 
content across the FPLC fractions showed that both niacin and the two partial agonists 



































Figure 4. Concentration-response curves of 
niacin, LUF6281 and LUF6283 in an ERK1/2 
phosphorylation assay, showing the relative 
potencies and intrinsic efficacies. All ligands 
are full agonists in this assay. The assay was 
performed on attached HEK293T-HCA2 cells. A 
representative experiment is shown (of N=3-5).





















Figure 3. Concentration-response curves of 
niacin, LUF6281 and LUF6283 in a [35S]-GTPγS 
binding assay, showing the relative potencies 
and intrinsic efficacies. Niacin is a full agonist, 
whereas LUF6281 and LUF6283 are partial 
agonists in this assay. The assay was performed 
on HEK293T-HCA2 membranes (5 μg/tube). A 
representative experiment is shown (of N=3).
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greatly reduced plasma VLDL-triglyceride concentrations in C57BL/6 mice (Figure 6).
It is well established that niacin lowers plasma triglycerides through its anti-lipolytic 
action in adipocytes. In accordance, in white adipose tissue of niacin-treated mice 
we detected a marked decrease in the relative mRNA expression level of key lipolytic 
enzymes adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL; Figure 
7). Strikingly, no effect of the partial agonists on adipose tissue ATGL/HSL expression was 
noted. In contrast, in liver, LUF6281 and LUF6283 significantly reduced (-50%; P<0.05) 
the expression of apolipoprotein B (APOB), the essential protein moiety of triglyceride-
rich VLDL/LDL particles, while niacin did not (Figure 8). None of the treatments 
significantly changed the expression level of microsomal triacylglycerol transfer protein 
(MTP) in livers of C57BL/6 mice, suggesting that the loading of APOB with lipids was not 
affected. Combined, these findings suggest that the partial agonists lower plasma VLDL-
triglycerides levels by interfering with hepatic VLDL production rather than inhibiting 
adipocyte lipolysis.
Discussion and conclusions
Although niacin can effectively lower lipid levels through inhibition of adipocyte 
lipolysis, its clinical use has been restricted by its off target cutaneous flushing effect 
that is mediated by HCA2 located in skin Langerhans cells and keratinocytes [12, 22]. To 
overcome this problem, a variety of niacin derivates have been developed in the past that 
act as partial or biased agonists for HCA2 [18-19, 23]. To date, the most promising lead 
compound has been the pyrazole MK-0354 which was shown to stimulate the G protein 
pathway associated with anti-lipolysis in adipocytes without inducing parallel ERK1/2 
phosphorylation, an in vitro measure for flushing [23]. Also in pre-clinical mouse studies 
MK-0354 showed promising results as no vasodilatation (flushing) was observed while 
the anti-lipolytic activity was retained. Unfortunately, in clinical trials this compound 
eventually failed since it did not provide the beneficial effect of niacin on plasma lipid 
levels [17]. Although the clinical failure of MK-0354 argues against a high potential for 
this class of compounds in general, our current studies indicate that there is still hope for 
pyrazoles. More specifically, here we present data on the potential of two novel partial 





























Figure 5. Mouse flushing after administration of niacin, LUF6281, 
and LUF6283. The cutaneous vasodilation was determined by 
change in paw skin temperature in C57BL/6 mice. Mice received 
niacin, LUF6281, or LUF6283 (400 mg/kg/day) via oral gavage. 
Data are expressed as the change of skin temperature at 20 min 
after compound administration (n=10 per group). ***P<0.001 vs 
untreated mice; ### P<0.001 vs niacin-treated mice.
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causing the off target flushing response.
Our in vitro studies suggest that niacin, LUF6281, and LUF6283 may all have a certain 
bias, since these compounds all show a higher potency for ERK1/2 phosphorylation than 
for G protein activation. Furthermore, LUF6281 and LUF6283 were both partial agonists 
in the [35S]-GTPγS assay but high efficacy full agonists in the ERK1/2 phosphorylation 
assay. The fold difference in potency was dependent on the compound; niacin was 21-fold 
more potent for ERK phosphorylation, while LUF6283 and LUF6281 were respectively 
10-fold and only 6-fold more potent. The high potency of niacin for activation of the MAP 
kinase pathway may explain why this compound causes flushing so effectively. Previous 
findings of Walters et al. have suggested an important role for an additional pathway, 
i.e. beta-arrestin dependent signaling, in ERK phosphorylation and the flushing response 
associated with niacin treatment [24]. Since we do not possess data on the effect of our 
compounds on beta-arrestin membrane recruitment, we cannot draw a firm conclusion 
























Figure 6. Effect of niacin, LUF6281, and LUF6283 on the plasma VLDL-
triglyceride concentration in C57BL/6 mice. Mice were fed a regular chow 
diet and received either niacin or HCA2 partial agonists LUF6281 and 
LUF6283 (400 mg/kg/day) once a day for 4 weeks. Plasma lipoproteins were 
separated by FPLC and the triglyceride level was measured in each fraction. 
Fractions 2 to 7 represented VLDL. Values are means+SEM (n=3/4 per group). 






























































































Figure 7. Effect of niacin, LUF6281, and LUF6283 on relative 
gene expression levels of adipose triglyceride lipase (ATGL) 
and hormone-sensitive lipase (HSL) in white adipose tissue of 
C57BL/6 mice. Data are presented as percent change relative to 
the untreated group. Values are means+SEM (n=5/6 per group). 
*P<0.05 ** P<0.01 vs untreated mice; # P<0.05 vs niacin-treated 
mice.
Figure 8. Effect of niacin, LUF6281, and LUF6283 on hepatic 
relative gene expression levels of apolipoprotein B (APOB) and 
microsomal triacylglycerol transfer protein (MTP) in C57BL/6 
mice. Data are presented as percent change relative to the 
untreated group. Values are means+SEM (n=5/6 per group). 
*P<0.05 ** P<0.01 vs untreated mice; # P<0.05 vs niacin-treated 
mice. 
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in the current study are more potent in the ERK-phosphorylation assay (lower EC50 
values), we do not anticipate that biased agonism is the reason for their negligible flushing 
effect. Although, unlike MK-0354, our pyrazole compounds are still active in the ERK1/2 
assay, we hypothesized that their relatively low ratio of GTPγS over ERK1/2 might still 
attenuate the flushing response. Indeed, our in vivo findings in C57BL/6 mice confirm that 
the pyrazoles do not provoke a similar flushing response as niacin.
Both pyrazoles however induced a similar level of VLDL-triglyceride lowering as observed 
with niacin treatment, suggesting that they do also exhibit the anti-lipolytic activity of 
niacin. Strikingly, niacin treatment decreased the relative expression level of the lipolytic 
genes ATGL and HSL in adipose tissue, while the two LUF compounds did not. From 
these combined findings it seems that the novel partial agonists – in contrast to niacin – 
actually do not execute their VLDL-triglyceride lowering action by modulating adipocyte 
lipolysis. Our further gene expression analysis suggests that the compounds rather lower 
plasma triglyceride levels by inhibiting VLDL production, since they decrease the hepatic 
relative expression level of APOB. The assembly and secretion pathway of VLDL in the 
liver involves the transfer of lipid by MTP to APOB during translation and then the fusion 
of APOB-containing precursor particles with triglyceride droplets to generate mature 
VLDL particles [25-26]. APOB is thus essential for proper assembly and secretion of APOB-
containing lipoproteins [27] and several novel lipid lowering therapies are therefore based 
on decreasing APOB transcription and mRNA stability by antisense oligonucleotides 
[28-29]. As our new HCA2 partial agonists target another metabolic pathway, i.e. hepatic 
VLDL production, as compared to both niacin and MK-0354 (inhibition of adipocyte 
lipolysis), we anticipate that they may still also effectively achieve lipid lowering in the 
human situation. However, their efficacy in the clinical setting remains to be validated.
In conclusion, the current study identifies the two HCA2 partial agonists LUF6281 and 
LUF6283 as promising drug candidates to achieve the beneficial lipid lowering effect of 
niacin without producing the unwanted flushing side effect.
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Nicotinic acid (niacin) has been used for decades as an antidyslipidemic drug in man. 
Its main target is the Hydroxy-Carboxylic Acid receptor HCA2 (GPR109A), a G protein-
coupled receptor. Other acids and esters such as methyl fumarate also interact with 
the receptor, which constituted the basis for the current study. We synthesized a novel 
series of substituted propenoic acids, such as fumaric acid esters, fumaric acid amides 
and cinnamic acid derivatives, and determined their affinities for the HCA2 receptor. We 
observed a rather restricted binding pocket on the receptor with trans-cinnamic acid being 
the largest planar ligand in our series with appreciable affinity for the receptor. Molecular 
modeling and analysis of the structure-activity relationships in the series suggest a planar 
trans-propenoic acid pharmacophore with a maximum length of 8 Å and out-of-plane 
orientation of the larger substituents. 
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Since the 1950’s nicotinic acid (niacin) has been used as an antidyslipidemic drug in 
man. Even today nicotinic acid is the most efficacious drug to raise the levels of HDL, the 
“good” cholesterol [1]. In 2003 different groups identified that the lipid-lowering actions 
of nicotinic acid are mediated by the G protein-coupled receptor HCA2. HCA2 is also 
known as GPR109A, HM74A, NIACR1 or, in mice, as PUMA-G. It is a member of a G 
protein-coupled receptor subfamily involved in metabolism, with HCA3 (GPR109B) and 
HCA1 (GPR81) as closely related members [2-5]. The HCA2 receptor is primarily expressed 
in adipocytes, spleen tissue, retinal pigment epithelium [6], intestinal epithelium [7] and 
various immune cells such as monocytes and macrophages [8]. Unfortunately, the HCA2 
expression in a type of epidermal macrophages known as Langerhans cells is the cause of 
flushing of the skin, a harmless but unpleasant side effect which undermines treatment 
compliance [3, 9].
Due to the discovery of the HCA2 receptor, industrial and academic groups have 
now started or intensified synthetic research lines to improve on the poor safety and 
pharmacokinetic properties of nicotinic acid. The majority of promising novel agonists, 
such as derivatives of acifran, anthranilic acids, anthranilic acid bioisosteres, xanthines, 
barbituric acid and pyrazole-3-carboxylic acids, was published and/or patented by GSK, 
Merck, Arena, Schering-Plough, Roche, Incyte, and our group [10]. Recently, ‘simple’ 
acids such as trans-cinnamic acid and 4-hydroxy-cinnamic acid have been described as 
modestly active HCA2 receptor agonists with potencies in the higher micromolar range. 
Cinnamic acid derivatives had been described before as anti-inflammatory compounds 
and as suppressors of elevated blood lipid levels in atherosclerosis [11-13]. 
Some other simple acid derivatives, i.e. methyl fumarate and ethyl fumarate, were also 
reported as potent agonists for the HCA2 receptor [14]. These fumarates have long been 
known as anti-psoriasis compounds [15]. They are micromolar affinity agonists for the 
HCA2 receptor, but have not been extensively explored in a synthetic structure-activity 
approach. Therefore, we decided to investigate the medicinal chemistry of such fumaric 
and cinnamic acid derivatives in more detail. These constrained propenoic acid derivatives 
appeared also useful in a pharmacophore analysis, which we also performed.
The fumaric acid esters 2 and 3 (Table 1) were commercially available. Compounds 4-24 
(Table 1 and Supplementary information) were synthesized according to two methods; 
A) starting from fumaric acid (1), the appropriate alcohol and EDC dissolved in DMF.[16] 
B) starting from a mixture of fumaric acid (1) and the suitable alcohol dissolved in DMF 
under microwave conditions [17]. Method A resulted in a mixture of both trans (4, 9-11, 
13) and cis isomers of the desired esters, even if the reaction was carried out at 0 °C. Due 
to the difficult separation of the two isomers this method was eventually not preferred. 
According to method B, described by Averyanov [17], an equimolar mixture of 1 and the 
appropriate alcohol in DMF was heated in a sealed tube in the microwave at 180 °C. This 
method resulted solely in the desired trans substituted fumarates (5-8, 12, 14-24). With 
both methods also a substantial amount of the disubstituted fumarates was formed.
The propenoic acids with aromatic rings (49, 52-54, 57 and 58) that were not commercially 
available were prepared in a 32-74% yield (Table 2 and Supplementary information), 
catalyzed by piperidine via the Knoevenagel condensation of the commercially available 
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aromatic aldehydes and malonic acid (47) [18].
All compounds listed in Tables 1 and 2 were tested at 10 µM in radioligand binding assays 
for displacement of [3H]-nicotinic acid (20 nM) from the human HCA2 receptor stably 
expressed in HEK293 cells. Homologous displacement with unlabeled nicotinic acid 
yielded a Ki value of 64 nM for nicotinic acid (data not shown).  Both the methyl and ethyl 
fumarates (2 and 3) also displayed submicromolar affinities for the HCA2 receptor (Table 
1), comparable to data reported by Tang [14]. In comparison with the reference agonist 
nicotinic acid, only a 3- (methyl derivative) or 7-fold (ethyl derivative) lower affinity was 
obtained. The unsubstituted fumaric acid (1) did not display any appreciable affinity 
towards the receptor, suggesting that the intact ester is crucial for receptor activity. In a 
series of aliphatic fumarate esters, increasing size did not substantially affect the receptor 
affinity. The propyl, butyl and pentyl substituents (4, 6 and 7) showed affinities between 0.7 
and 1.0 µM, which is in the same range as the ethyl derivative. The larger hexyl substituent 
(8) resulted in a slightly poorer Ki value of 2.5 µM. Branched aliphatic compounds were 
also less tolerated e.g. derivatives 5 and 9.. A phenyl substituent (10) was not well tolerated 
either, but introduction of a spacer between the fumarate moiety and the aromatic system 
resulted in a gain of affinity. The methylene spacer, as in 11 (Ki = 3.5 µM), appeared to be 
optimal since α-methylbenzyl (12), phenylethyl (13) and phenylpropyl (14) substituents 
Compound R Ki (µM) or % disp.a
1 H 10% 
2 Me 0.18 ± 0.03
3 Et 0.41 ± 0.02
4 Pr 1.0 ± 0.1 
5 iPr 4.2  ± 0.9
6 Bu 0.76 ± 0.19
7 Pe 0.70 ± 0.05
8 Hex 2.5 ± 0.03
9 cHex 17% 
10 Phenyl 10% 
11 Benzyl 3.5 ± 0.2
12 Benzyl-α-methyl rac. 5.7 ± 0.1
13 Phenyl ethyl 10 ± 1
14 Phenyl propyl 26% 
15 2-Br Benzyl 0%
16 2-OMe Benzyl 5%
17 3-Br Benzyl 9.8 ± 0.6
18 3-Cl Benzyl 8.9 ± 1.5
19 3-F Benzyl 2.4 ± 0.6 
20 3-OMe Benzyl 4%
21 4-Br Benzyl 21% 
22 4-Cl Benzyl 14% 
23 4-Me Benzyl 30% 






Table 1. Affinities of substituted fumaric acid esters 1-24 in radioligand binding assays of the human HCA2 receptor.
a Ki ± SEM (n = 3), % Displacement at 10 µM (average of n = 2, with less than 10% difference between the two values). 
Ki values were determined in full displacement studies on membranes from HEK293T cells stably expressing HCA2 
(GPR109A), using [3H]-nicotinic acid as the radioligand. Single point displacement assays were carried out using 10 
µM of the test compound and 20 nM [3H]-nicotinic acid
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resulted in Ki values of 5.7 µM and 10 µM, and 26% of radioligand displacement at 10 µM, 
respectively. Subsequently, various additional substitutions of the benzylic ring system 
were explored. The binding pocket of the HCA2 receptor was not able to accommodate the 
ortho substituted compounds 15 and 16 at a concentration of 10 µM. Meta substitution, on 
the other hand, was better tolerated (17-20). The 3-bromo- and 3-chloro-benzyl derivatives 
(17 and 18) showed a slight decrease in affinity and the smaller 3-fluoro-benzyl compound 
(19) a slight increase in affinity with respect to the unsubstituted benzyl fumarate. On 
the contrary the 3-methoxy-benzyl derivative 20 showed no affinity for the receptor. 
Furthermore, introduction of para substituents such as halogen, methyl or methoxy (21-
24) resulted in a reduced affinity. 
Since the ester moiety in methyl and ethyl fumarate can be hydrolysed in vivo[19], we 
investigated  the non-hydrolysable amide linker as an alternative. However, these trans 
amide isosteres of compounds 2, 3, 10 and 11 were not able to bind to the receptor at 10 
µM (data not shown).
To further explore the SAR, a number of cis anologs of the active trans fumaric acid 
derivatives were synthesized and tested, namely the maleic acid esters and maleic acid 
amides. Nevertheless none of these cis compounds interacted with the receptor (data not 
shown). 
Next, a series of trans substituted propenoic acids (25-46, 48-58) were tested for their 
Compound R R1 Ki (µM) or % disp.a
25 Me H 6%
26 Et H 19%
27 Me Me 0% 
28 Phenyl H 4.9 ± 1.8
29 2-OH Phenyl H 4% 
30 2-Me Phenyl H 0% 
31 3-OH Phenyl H 0% 
32 3-Me Phenyl H 0% 
33 3-Cl Phenyl H 6% 
34 3-NO2 Phenyl H 0% 
35 4-OH Phenyl H 14 ± 2
36 4-Me Phenyl H 2% 
37 4-Cl Phenyl H 17%
38 4-OMe Phenyl H 0% 
39 4-NH2 Phenyl H 2% 
40 4-N(CH3)2 Phenyl H 0%
41 3,4-di-OH Phenyl H 4% 
42 3-OMe, 4-OH Phenyl H 0% 
43 3,4-OCH2O- Phenyl H 7% 
44 Phenyl Me 1% 
45 Phenyl Phenyl 0% 
46 Phenyl NHCOMe 0% 
48 Pyridin-3-yl H 3% 
49 Pyrrol-2-yl H 7% 
50 Furan-3-yl H 14 ± 2.5
51 Furan-2-yl H 8.1 ± 0.8
52 5-Br-furan-2-yl H 9%
53 5-Me-furan-2-yl H 7% 
54 5-Et-furan-2-yl H 14% 
55 5-(4-Cl-Ph)-furan-2-yl H 0%
56 Thiophen-2-yl H 5.5 ± 0.3
57 3-Br-thiophen-2-yl H 6% 





Table 2. Affinities of trans-substituted-propenoic acids 25-58 in radioligand binding assays on the human HCA2 
receptor.
a See footnote Table 1
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affinities (Table 2). The small aliphatic compounds 25-27 were without effect, while the 
phenyl derivative 28 (cinnamic acid) showed micromolar affinity. In our assay, compound 
28 showed a higher affinity (Ki = 4.9 µM) compared to the Ki value of 36 µM reported by 
Ren and colleagues.[20] To explore this lead, commercially available aromatic substituted 
trans propenoic acids were tested for their affinities (29-43). Only the 4-hydroxy derivative 
35 was able to bind with an affinity of 14 µM.  Related substituents such as 4-methoxy 
(38) and 4-amino (39) decreased the affinity dramatically. In general, except for the 
4-hydroxy, aromatic substitution is not tolerated on the ortho, meta or para position. Also 
substituents at the β-position of cinnamic acid (44-46) resulted in a dramatic decrease in 
binding. Replacement of the phenyl moiety in cinnamic acid by aromatic isosteres such as 
3-pyridinyl (48) and 2-pyrrole (49) resulted in a significant loss of affinity. On the contrary, 
2-furanyl (51) and 2-thiophenyl (56) were accommodated like the phenyl compound. 
3-Furanyl substitution (50) resulted in a 2 fold decrease compared to the 2-furanyl 
derivative 51.  As in the cinnamic acid series, the 5-substituted 2-furanyl derivatives (52-
55) and both the 3-bromo and 4-bromo-substituted 2-thiophenyl derivatives (57, 58) were 
devoid of affinity for the receptor.
To visualize the SAR, a pharmacophore model was generated by manually superimposing 
the minimized structures of: nicotinic acid, cinnamic acid 28, fumaric acid esters 6 and 
11, and the inactive phenylfumaric acid ester 10 (Figure 1). The alignment of the two sp2 
carbons of the propenoic fragment, which all the compounds have in common, resulted 
in a planar and constrained pharmacophore. The carbonyl oxygen of the ester function of 
compounds 6, 10 and 11 and the nitrogen of nicotinic acid overlay smoothly as a hydrogen 
acceptor region. This might explain the improved binding characteristics of the fumaric 
acid esters compared to cinnamic acid and also why the trans configuration is superior 
over the cis substituted propenoic acids. Molecular modeling and analysis of the structure-
activity relationships in the series suggest a planar trans-propenoic acid pharmacophore 
with a maximum length of 8 Å, because this is the size of the largest planar ligand (28) in 
our series with appreciable affinity for the receptor. Larger compounds need an out-of-
8 Å
7.3 Å
Figure 1. Aligned pharmacophore model (left- nicotinic acid in plane, right – nicotinic acid 90 degrees rotated) 
constructed of the active compounds nicotinic acid (red), butyl fumarate 6 (blue), benzyl fumarate 11 (yellow) and 
cinnamic acid 28 (green) and the inactive compound phenyl fumarate 10 (grey).
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plane orientation as in the case of the fumaric acid ester series (2-24). 
Molecular modeling studies of the Merck Research group based on anthranilic acid 
derivatives confirmed the importance of the planar orientation of the carboxylic acid 
function and the nearby α,β sp2 carbon atoms [21][22]. Full saturation of the phenyl ring 
in anthranilic acid resulted in inactive compounds. If the double bond in the α,β position 
was maintained, as in tetrahydro-anthranilic acids, the planar orientation and also the 
affinity was regained however [22]. 
In conclusion, methyl fumarate, ethyl fumarate and cinnamic acid have been published 
as agonists for the HCA2 receptor [14, 20]. Our synthetic program confirmed the affinity 
of these compounds for the HCA2 receptor and further explored the structure-activity 
relationships for a series of derivatives. Molecular modeling studies and the analysis of 
the structure-activity relationships in the series suggest a planar trans-propenoic acid 
pharmacophore with a maximum length of 8 Å and out-of-plane orientation of the larger 
substituents.       
Acknowledgments 
This study was performed within the framework of Top Institute Pharma, project number 
D1-105.
References
1. Mack, W.J., et al., One-year reduction and longitudinal analysis of carotid intima-media 
thickness associated with colestipol/niacin therapy. Stroke, 1993. 24(12): p. 1779-83.
2. Soga, T., et al., Molecular identification of nicotinic acid receptor. Biochem Biophys 
Res Commun, 2003. 303(1): p. 364-9.
3. Tunaru, S., et al., PUMA-G and HM74 are receptors for nicotinic acid and mediate its 
anti-lipolytic effect. Nature Medicine, 2003. 9(3): p. 352-355.
4. Wise, A., et al., Molecular identification of high and low affinity receptors for nicotinic 
acid. J Biol Chem, 2003. 278(11): p. 9869-74.
5. Offermanns, S., et al., Nomenclature and classification of hydroxy-carboxylic acid 
(HCA) receptors (GPR81, GPR109A and GPR109B). Pharmacolog Rev, in press.
6. Martin, P.M., et al., Expression and localization of GPR109A (PUMA-G/HM74A) 
mRNA and protein in mammalian retinal pigment epithelium. Molecular Vision, 2009. 
15(37): p. 362-372.
7. Thangaraju, M., et al., GPR109A Is a G-protein-Coupled Receptor for the Bacterial 
Fermentation Product Butyrate and Functions as a Tumor Suppressor in Colon. Cancer 
Research, 2009. 69(7): p. 2826-2832.
8. Gille, A., et al., Nicotinic acid: Pharmacological effects and mechanisms of action. 
Annual Review of Pharmacology and Toxicology, 2008. 48: p. 79-106.
9. Benyo, Z., et al., Nicotinic acid-induced flushing is mediated by activation of epidermal 
langerhans cells. Molecular Pharmacology, 2006. 70(6): p. 1844-1849.
10. Shen, H.C. and S.L. Colletti, Novel patent publications on high-affinity nicotinic acid 
receptor agonists. Expert Opinion on Therapeutic Patents, 2009. 19(7): p. 957-967.
11. Simonyan, A.V., Activity of cinnamic acid derivatives and new methods for their 
 Chapter 4
84
synthesis (review). Pharmaceutical Chemistry Journal, 1993. 27(2): p. 92-100.
12. Watanabe, T., et al., Studies of hypolipidemic agents. 1. Synthesis and hypolipidemic 
activities of alkoxycinnamic acid derivatives. J Med Chem, 1980. 23(1): p. 50-9.
13. Lee, M.K., et al., Hypocholesterolemic and antioxidant properties of 3-(4-hydroxyl)
propanoic acid derivatives in high-cholesterol fed rats. Chem Biol Interact, 2007. 
170(1): p. 9-19.
14. Tang, H., et al., The psoriasis drug monomethylfumarate is a potent nicotinic acid 
receptor agonist. Biochemical and Biophysical Research Communications, 2008. 
375(4): p. 562-565.
15. Schweckendiek, W., Treatment of psoriasis vulgaris. Medizinische Monatsschrift, 
1959. 13(2): p. 103 -104.
16. Ekici, Ö.D., et al., Aza-Peptide Michael Acceptors:  A New Class of Inhibitors Specific 
for Caspases and Other Clan CD Cysteine Proteases. Journal of Medicinal Chemistry, 
2004. 47(8): p. 1889-1892.
17. Aver'yanov, D.M., et al., Esterification of dicarboxylic acids with benzyl alcohol under 
the action of the microwave radiation. Russian Journal of General Chemistry, 2008. 
78(10): p. 1920-1923.
18. Shiotani, S. and H. Morita, Furopyridines. I. Synthesis of furo[2,3-c]pyridine. Journal 
of Heterocyclic Chemistry, 1982. 19(5): p. 1207-1209.
19. Litjens, N., et al., In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC 
Pharmacology, 2004. 4(1): p. 22.
20. Ren, N., et al., Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic 
acid receptor GPR109A (HM74a/PUMA-G). J Lipid Res, 2009. 50(5): p. 908-14.
21. Deng, Q.L., et al., Molecular modeling aided design of nicotinic acid receptor GPR109A 
agonists. Bioorganic & Medicinal Chemistry Letters, 2008. 18(18): p. 4963-4967.
22. Raghavan, S., et al., Tetrahydro anthranilic acid as a surrogate for anthranilic acid: 
Application to the discovery of potent niacin receptor agonists. Bioorganic & Medicinal 
Chemistry Letters, 2008. 18(11): p. 3163-3167.
Chapter 5
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A number of pyrazolopyrimidines were synthesized and tested for their positive allosteric 
modulation of the HCA2 receptor (GPR109A). Compound 24, an efficacious and potent 
agonist and allosteric enhancer of nicotinic acid’s action, was the basis for most other 
compounds. Interestingly, some of the compounds were found to increase the efficacy of 
the endogenous ligand 3-hydroxybutyrate and enhance its potency almost 10-fold. This 
suggests that the pyrazolopyrimidines may have therapeutic value when given alone.
Abbreviations
NA, nicotinic acid; 3-OHB, 3-hydroxybutyrate; [35S]-GTPγS, 35S-labeled guanosine 5'-O-[gamma-thio]triphosphate; 
BSA, bovine serum albumin; DMEM, Dulbecco’s Modified Eagle Medium; DTT, dithiothreitol; GDP, guanosine 
5’-diphosphate; GPCR, G protein-coupled receptor; HCA, hydroxy-carboxylic acid receptor; HEK, human 
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Introduction
Hydroxy-Carboxylic Acid Receptor 2 (HCA2) [1] or GPR109A is a G protein-coupled 
receptor (GPCR) that was first identified in 2001 [2]. Two years later its involvement in 
the anti-lipolytic action of nicotinic acid (NA) was reported [3-5] and 3-hydroxybutyrate 
was identified as its endogenous ligand in 2005 [6] (for a review [1, 7]). A broad range of 
synthetic ligands (agonists only) for this receptor has been developed [7-9]. An intriguing 
class among those are substituted pyrazolopyrimidines, as recently reported by Shen and 
colleagues [10]. These compounds act as agonists, some with potencies comparable to 
nicotinic acid, but were also suggested to bind allosterically to HCA2. One compound in 
particular (25 in the present study) was shown to behave as a positive allosteric modulator 
(PAM) as well, by significantly enhancing the potency of nicotinic acid at HCA2 (~100-fold 
at 1 µM). We decided to further investigate the pyrazolopyrimidines by synthesizing a 
new series of derivatives and evaluating their activity on HCA2 in several [3H]-nicotinic 












































  7   4-iPrPh    Me
14  Br              Me
13  H               Me
12   4-iPrPh    Pr
11   4-iPrPh    Et
10   4-iPrPh    H
  9   4-iPrPh    Cl
  8   4-iPrPh    OH
19   Br             Me
18   4-iPrPh    Pr
17   4-iPrPh    Et
16   4-iPrPh    H
15   4-iPrPh    Me





20-30   R1 = 4-iPrPh, Table 1
31  R1 = Br
Scheme 1. Synthetic route to the substituted pyrazolo[1,5-a]pyrimidine-carboxamides 20-43a
aReagents and conditions: (a) EtOH, reflux, 3 h; (b) POCl3, N,N-
dimethylaniline, reflux, 3 h; (c) NaOAc, 5% Pd/C, H2 2.5 bar, RT, 1 h; (d) NBS, 
DCM, 0 °C, 1.5 h, RT, 16 h; (e) LiOH, H2O/MeOH/THF, RT, 16 h; (f) R3-NH2, 
EDC*HCl, DCM, RT, 4 h; (g) R1-B(OH)2, 31, Pd(Ph3P)4, Na2CO3, toluene/H2O, 
MW 150 °C, 2 h.
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The synthetic route used to obtain the pyrazolo[1,5-a]pyrimidine-6-carboxamides 20-30 
and 32-43 is depicted in Scheme 1. The 1H-pyrazol-5-amine 1 [10] or the commercially 
available compound 2 were ring closed with the respective ethyl 2-(ethoxymethylene)-
3-oxoate [11] (3, 5 or 6) or the available diester 4 in EtOH at reflux temperature, resulting 
in the ethyl-pyrazolo[1,5-a]pyrimidine-6-carboxylates (7, 8 and 11-13) [10, 12-13] in good 
yields. The 7-hydroxypyrazolopyrimidine 8 was converted into the 7-chloro analogue (9) in 
the presence of POCl3 [13] followed by palladium-catalyzed reductive dechlorination [13] 
4-OMe
4-tBu




EC50 shift NAb %Emax  NA
 (SEM)c
20 4-iPr Me 3 (1) 0.60 129 (9)
21 4-iPr Me 23 (1) 0.32 135 (5)
22d 4-iPr Me 22 (8) 0.36 134 (7)
23 4-iPr Me 1 (2) 1.07 128 (4)
24d 4-iPr Me 71 (17) 0.04 109 (6)
25d 4-iPr Me 5 (2) 0.53 115 (9)
26d 4-iPr Me 22 (0.4) 0.22 100 (1)
27 4-iPr Me 41 (6) 0.15 139 (10)
28 4-iPr H 10 (3) 0.62 106 (7)
29 4-iPr Et 69 (7) 0.08 151 (6)
30 4-iPr Pr 58 (20) 0.17 151 (9)
32 4-Me Me 52 (4) 0.13 113 (7)
33 3-Me Me 17 (2) 0.25 119 (5)
34 2-Me Me 3 (1) 0.58 91 (6)
35 4-Et Me 64 (9) 0.13 153 (15)
36 Me 80 (5) 0.09 141 (4)
37 Me 20 (3) 0.24 129 (3)
38 4-OiPr Me 50 (3) 0.09 139 (2)
39 4-Ph Me 41 (4) 0.16 139 (6)
40 4-Cl Me 42 (9) 0.16 141 (14)
41 3-Cl Me 16 (6) 0.37 126 (13)
42 3,4 diCl Me 31 (5) 0.19 139 (12)



































































































Table 1. Different measures for HCA2 receptor activation in [35S]-GTPγS binding assays
a) Percentage of [35S]-GTPγS binding in the presence of 10 µM of the test compound alone (100% is 
the Emax at 100 µM nicotinic acid); b) the shift in EC50 of nicotinic acid (NA) in the presence of 10 µM 
of the test compound  (1 is without test compound and values less than unity indicate increased 
affinity of nicotinic acid,  e.g. 0.1 means a 10-fold shift); c) the Emax reached at 100 µM nicotinic 
acid (NA) in the presence of 10 µM of the test compound (100% is without test compound); d) 
also reported by Shen et al [10] (26, racemate only). Values are means (± SEM) of 3 independent 
experiments performed in duplicate.
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to give the pyrazolo[1,5-a]pyrimidine 10. The 3-position of the pyrazolo[1,5-a]pyrimidine 
compound 13 [14] was functionalized using NBS [15] to the versatile 3-bromo analogue 14. 
Subsequently, hydrolysis of the ethyl esters 7, 10-12 and 14 with LiOH resulted smoothly 
in the corresponding acids (15-19). The final pyrazolo[1,5-a]pyrimidine carboxamides 20-
30 and the 3-bromo building block 31 were synthesized from the corresponding acids (15-
19) and a range of amines by use of coupling reagent EDC*HCl. Finally a Suzuki reaction 
with building block 31 and various arylboronic acids, under microwave conditions, 
yielded the 3-aryl compounds 32-43 [16]. 
Biological evaluation and discussion
To evaluate the compounds we performed [3H]-nicotinic acid binding assays (see 
Supporting Information, Table S1) and [35S]-GTPγS binding assays (Table 1) on HEK-
HCA2 membranes. In Table 1 the following results are reported: a) the percentage of [35S]-
GTPγS binding in the presence of 10 µM of the test compound alone; b) the shift in EC50 
value of nicotinic acid in the presence of 10 µM of the test compound; c) the Emax reached 
at 100 µM nicotinic acid in the presence of 10 µM of the test compound (100% is without 
test compound).
Structure-activity relationships
Compounds 20-23 show that linker lengths of 2 or 3 carbons between the carboxamide 
and the phenyl group are preferred for agonism and potentiation of nicotinic acid’s 
effects. However, linker length does not appear to influence the Emax of nicotinic acid, 
which was approximately 130% for all four compounds. Introduction of an ether function 
in the linker (24) resulted in a higher activity in the [35S]-GTPγS binding assay. So, the 
compound acted as an agonist in its own right, while the EC50 value of nicotinic acid was 
increased approximately 25-fold without a change in its Emax value. This compound also 
considerably slowed the dissociation of [3H]-nicotinic acid from the receptor and increased 
the equilibrium specific binding of the radioligand to an extent that was not surpassed 
by any of the other test compounds (Supporting Information, Table S1). Introduction of 
a methyl substituent on the linker (25) was not beneficial in our hands, as opposed to 
the findings of Shen et al [10]. Removal of the phenyl group yielded 26, which enhanced 
nicotinic acid’s activity somewhat better. Replacing the ether of 24 by a secondary amine 
to obtain aniline 27 rendered the compound more active than 25 in all respects. 
Next, a small series was synthesized with varying substituents on the 7-position (R2, 
Table 1). Absence of the methyl substituent (28) severely reduced the activity compared 
to 24. The ethyl and propyl substituted compounds (29 and 30) behaved highly similar to 
each other, and also to the parent derivative 24 except for the enhancement of nicotinic 
acid’s Emax value by 29 and 30 but not 24. Finally, a series of derivatives of 24 with varying 
substituents on the 3-phenyl ring was then tested (R1, Table 1, compounds 32-43). A 
methyl substituent on the para position (32) resulted in more agonism and potentiation 
of nicotinic acid compared to methyl substituents on the meta (33) or ortho (34) positions. 
Compounds with ethyl (35) and tert-butyl (36) substituents had activities highly similar 
to the isopropyl-substituted compound 24, except that 35 and 36 significantly increased 
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the Emax value of nicotinic acid, which was not affected by 24. Compounds substituted 
with methoxy (37) or isopropoxy (38) were also highly active. These compounds, like 
methyl derivatives 32 and 33, seemed to have a more modest agonistic activity compared 
to their activity as enhancers of nicotinic acid potency. A phenyl derivative (39) retained 
activity in the [35S]-GTPγS binding assay. Meta-substitution (41) and, to a lesser extent, 
para-substitution (40) with chlorine deminished activity. The 3,4-dichloro-substituted 
compound (42) behaved very similarly to the 4-chloro derivative (40). A trifluoromethyl 
group (43) conferred good enhancement of nicotinic acid potency and efficacy, paired with 
a moderate agonistic activity. To investigate any correlation between the agonistic and 
modulating effects of the pyrazolopyrimidines, the [35S]-GTPγS binding activation and the 
potency shift of nicotinic acid, both at 10 µM, were plotted against each other (Supporting 
Information Figure S2), yielding a nonlinear correlation. The plot suggests that the ability 
of the pyrazolopyrimidine agonists to stabilize active receptor conformations contributes 
to, or even determines, the modulator strength of the compounds.
Modulation of nicotinic acid-mediated receptor activation
We next examined the effects at 1, 3 and 10 µM of five selected enhancers on the 
concentration-effect curves for nicotinic acid in [35S]-GTPγS binding assays. Figure 1 
shows the results of a representative experiment, and the average values obtained from 
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Figure 1. Dose-response 
curves of nicotinic acid in the 
presence of 0, 1, 3 and 10 µM 
pyrazolopyrimidines. The 
data are from [35S]-GTPγS 
binding assays performed 
on HEK-HCA2 membranes. 
Representative graphs from 
one experiment performed in 
duplicate.
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activation at 10 µM without any nicotinic acid present, and nicotinic acid further increased 
activation to 109±6%, with a 24-fold increased potency compared to control.
At concentrations of 3 µM and 1 µM, 24 increased [35S]-GTPγS binding to 51±14% and 
30±5% respectively, and caused shifts in the EC50 value of nicotinic acid of approximately 
5-fold for both concentrations. Compound 27 caused modest increases in both the potency 
(2-fold at 1 µM, 5-fold at 3 µM and 7-fold at 10 µM) and the Emax values (120±3% at 1 µM, 
129±3% at 3 µM and 139±10% at 10 µM) of nicotinic acid, which seemed to follow the 
increase in [35S]-GTPγS binding due to agonist activity alone (13±2% at 1 µM, 31±2% at 3 
µM and 41±6% at 10 µM). Compound 29 was highly efficacious in all aspects: an agonist 
in its own right (28±3, 53±5 and 69±7% receptor activation at 1, 3 and 10 µM, respectively) 
and a positive allosteric modulator of nicotinic acid’s EC50 (5, 9 and 13-fold shifts) and Emax 
(122±7, 129±6 and 151±6% of control) values. Both 38 and 42 were in every respect less 
potent and efficacious than 29. As an agonist, 38 was more potent and efficacious than 
42, causing more receptor activation at 1 µM (15±6 vs 5±3%), 3 µM (27±2 vs 16±3%) and 
10 µM (50±3 vs 31±5%). The modulation of the EC50 value of nicotinic acid was similar 
at 1 µM (both 2-fold) and 3 µM (5-fold vs 4-fold) but at 10 µM 38 was the more active 
compound again (11-fold vs 5-fold shift). Both compounds increased the Emax of nicotinic 
acid similarly (139±12; 139±6% at 10 µM). However, compound 42 showed a relatively low 
potency compared to 38 since no effect was seen at 1 µM (compared to 111±4% for 38) and 
only a small effect at 3 µM (114±3% for 42 compared to 123±5% for 38). For EC50 values and 
Emax values of 24, 29, 30, 32, 35, 36 and 38, tested again in the absence of nicotinic acid, see 
Table S2 in Supporting Information. Some further observations are discussed on page S7 
of Supporting Information.
Positive allosteric modulation of 3-hydroxybutyrate potency and 
efficacy
Allosteric modulators that enhance the potency of nicotinic acid on the HCA2 receptor 
are of interest clinically since they could greatly reduce the daily dose of nicotinic acid 
when used in combination therapy. Clearly, the pyrazolopyrimidines fit this picture, but 
























Figure 2. Concentration-response 
curves of 3-hydroxybutyrate in 
the presence and absence of 10 
µM pyrazolopyrimidine in the 
presence and absence of 10 µM 
pyrazolopyrimidine. The data 
are from [35S]-GTPγS binding 
assays performed on HEK-HCA2 
membranes. Representative graphs 
from one experiment performed in 
duplicate (see also Table S3 in SI).
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ligand 3-hydroxybutyrate (3-OHB) may also be enhanced by the pyrazolopyrimidines, 
but this cannot be assumed a priori since allosteric enhancement is probe dependent [17]. 
Therefore, 3-OHB dose-response curves were recorded in the presence of five compounds, 
and four of these increased the potency of 3-hydroxybutyrate approximately 8-fold 
(Figure 2 and Supporting Information Table S3). The modulators caused an increase in 
the intrinsic efficacy of the endogenous ligand as well. It should be noted that in a [35S]-
GTPγS binding assay 3-OHB was previously reported as a high-efficacy partial agonist for 
HCA2 [18], whereas it behaved as a low-efficacy partial agonist with approx. 30% intrinsic 
efficacy in our hands. This may have to do with lower levels of receptor expression in our 
preparation, as we explicitly selected clones for physiological rather than high expression 
levels.
Future perspectives and conclusion
With the expanded ligand repertoire reported in this study other functional assays with 
the pyrazolopyrimidines can be performed, including ERK 1/2 phosphorylation assays. 
Activation of ERK 1/2 induced by HCA2 agonists in vitro has been suggested to be predictive 
of the skin flushing side effect in vivo [19]. Furthermore, cooperativity with probes 
(orthosteric ligands) that are not structurally related to nicotinic acid should be examined. 
In the future, mutagenesis studies will hopefully shed light on the binding mode of the 
allosteric modulators and on how these ligands trigger the changes in receptor activation. 
In conclusion, we presented several pyrazolopyrimidine derivatives that do not displace 
[3H]-nicotinic acid from HCA2, but are capable of activating this receptor, which indicates 
an allosteric binding mode. Next to their agonistic effects these compounds potentiate the 
action of nicotinic acid and the endogenous ligand 3-hydroxybutyrate. Therapeutically, 
such positive allosteric modulators may represent an interesting alternative in the search 
for HCA2 receptor ligands. 
Experimental section
Chemistry
1H and 13C NMR spectra were recorded on a Bruker AV 400 (1H NMR, 400 MHz; 13C NMR, 
100 MHz) spectrometer. Chemical shifts (δ) are reported in ppm relatively to Me4Si. Purity 
was confirmed ≥95% by HPLC  performed on a Gilson 306 system (detection at 254 nm) 
equipped with an analytical C18 column in combination with a gradient of mixture A: 
1 MeCN/9 H2O, B: 9 MeCN/1 H2O. High resolution mass spectra were recorded on a 
mass spectrometer (Thermo Finnigan LTQ Orbitrap) with an electro spray ion source in 
positive mode resolution R = 60000 at m/z 400 (mass range m/z = 150-2000). Reactions 
were routinely monitored on TLC using Merck silica gel F254 plates. Microwave reactions 
were performed in an Emrys Optimizer (Biotage AB). Yields were not optimized. The final 
products were purified by column chromatography and/or by recrystallization. 
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General procedure for the synthesis of pyrazolo[1,5-a]pyrimidine 
carboxamides (20-31) 
To a solution of the appropriate pyrazolo[1,5-a]pyrimidine-6-carboxylic acid (15-19, see 
Supporting Information) (1.0 eq.) and the substituted amine (1.2 eq) in DCM (20 mL per 
mmol) was added EDC*HCl (1.2 eq.) at room temperature. After 4 h the reaction mixture 
was concentrated and purified by column chromatography. 
3-(4-Isopropylphenyl)7-methyl-N-(2-phenoxyethyl)pyrazolo[1,5-a]
pyrimidine-6-carboxamide (24). 
Started from acid 15 (0.33 mmol) and 2-phenoxy-ethylamine to give 90 mg (64%) as a 
yellow solid. 1H NMR (CDCl3): δ 8.48 (s, 1H), 8.14 (s, 1H), 7.88 (d, J = 8.4 Hz, 2H), 7.29 (d, J 
= 11.2 Hz, 2H), 7.25 (d, J = 8.0 Hz, 2H), 6.95 (t, J = 7.6 Hz, 1H), 6.87 (d, J = 8.0 Hz, 2H), 6.76 (t, 
J = 5.6 Hz, 1H), 4.22 (t, J = 5.2 Hz, 2H), 3.82 (q, J = 5.2 Hz, 2H), 2.94 (m, 1H), 2.89 (s, 3H), 1.28 
(d, J = 6.8 Hz, 6H). HRMS calcd. for [C25H26N4O2+H]+ 415.21285, found 415.21274.
General procedure for the preparation of 3-(aryl)-7-methyl-N-(2-phenoxyethyl)
pyrazolo[1,5-a]-pyrimidine-6-carboxamides via Suzuki-coupling (32-43)
According to a modified procedure of Berger [16]. A mixture of 31 (1.0 eq.), the 
substituted-phenylboronic acid (2.0 eq.), tetrakis(triphenyl-phosphine)palladium(0) (0.03 
eq.) and sodium carbonate (3.0 eq.) in toluene (3.0 mL) and H2O (0.5 mL) was heated in the 
microwave for 2 h at 150 °C. Water was added and the organics were extracted with DCM. 
The organic layer was dried, concentrated and purified by column (1% MeOH/DCM). 
Final products were obtained by recrystallization from MeOH.
3-(4-Chlorophenyl)-7-methyl-N-(2-phenoxyethyl)pyrazolo[1,5-a]
pyrimidine-6-carboxamide (40)
Started from 31 (0.33 mmol), and (4-chlorophenyl)boronic acid (0.66 mmol), yield 82 mg 
(62%). 1H NMR (CDCl3): δ 8.62 (s, 1H), 8.50 (s, 1H), 7.89 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 
8.4 Hz, 2H), 7.31 (t, J = 8.0 Hz, 2H), 7.00 (t, J = 7.6 Hz, 1H), 6.92 (d, J = 8.4 Hz, 2H), 6.42 
(s, 1H, NH), 4.21 (t, J = 5.2 Hz, 2H), 3.94 (q, J = 5.6 Hz, 2H), 3.03 (s, 3H). HRMS calcd. for 
[C22H19ClN4O2+H]+ 407.12693, found 407.12679.
Biology 
[35S]-GTPyS binding assay
This assay was performed in 96-well format in 50 mM Tris-HCl, 1 mM EDTA, 5 mM MgCl2, 
150 mM NaCl, pH 7.4 at 25 °C with 1 mM DTT, 0.5% BSA and 50 µg/mL saponin freshly 
added. HEK-HCA2 membranes (5 µg protein per well in 25 µL) were pre-incubated with 
25 µL of 40 µM GDP, in absence or presence of test compound, and 25 µL increasing 
concentrations of the orthosteric ligand, for 30 min at room temperature. Then, 25 µL 
[35S]-GTPγS was added (final concentration 0.3 nM) and the mixture was incubated 90 
min at 25 °C with constant shaking. The incubation was terminated by filtration over 
GF/B filterplates on a FilterMate harvester (PerkinElmer). The filters were dried and 25 
µL Microscint 20 (PerkinElmer) was added to each filter. After ≥3 h extraction the bound 
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radioactivity was determined in a Wallac microbeta Trilux 1450 counter.
Data analysis
Analysis of the results was performed using Prism 5.0 software (GraphPad Software Inc., 
La Jolla, USA). Nonlinear regression was used to determine IC50 values from competition 
binding curves. The Cheng-Prusoff equation [20] was then applied to calculate Ki values. 
[35S]-GTPγS curves were analysed by nonlinear regression to obtain EC50 values.
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% [3H]-nicotinic acid binding (±SEM) 
119 (4.5) 103 (1.7)
96 (5.3) 101 (2.6)
101 (4.4) 102 (5.3)
108 (0.6) 96 (2.6)
106 (3.5) 100 (2.0)
143 (6.7) 162 (8.2)
126 (6.4) 144 (14.3)
142 (12.0) 147 (11.5)
147 (4.4) 148 (23.4)
111 (4.2) 113 (9.1)
117 (9.0) 145 (11.3)
114 (12.1) 130 (2.4)
148 (9.0) 136 (3.8)
143 (3.2) 152 (1.4)
102 (3.4) 108 (18.7)
107 (7.6) 115 (8.1)
69 (4.0) 118 (15.7)
109 (5.9) 92 (6.2)
149 (6.1) 133 (2.3)
101 (6.8) 112 (9.6)
111 (5.0) 99 (7.7)
108 (10.5) 114 (10.9)
96 (7.8) 91 (5.9)
a) the percentage of [3H]-nicotinic acid specifically bound to HEK293-HCA2 membranes at equilibrium in the 
presence of 10 µM of the test compound (100% is without test compound). 
b) the percentage of [3H]-nicotinic acid still bound to HEK293-HCA2 membranes after 30 minutes of dissociation 
at 15 °C induced by 10 µM of nicotinic acid in the presence of 10 µM of the test compound (100% is without test 
compound - values above 100% indicate a slower dissociation rate in the presence of the test compound). Values are 
means (± SEM) of 3 independent experiments performed in duplicate.
Table S1. Effects on [3H]-nicotinic acid binding of a series of 3-(aryl)-7-methyl-N-(substituted)pyrazolo[1,5-a]
pyrimidine-6-carboxamides (measured at 10 µM). 
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Modulation of [3H]-nicotinic acid binding
In Figure S1-A the effect of 10 µM 24 on the full dissociation curve of the radioligand is 
shown. The data indicate that in the presence of 24 the dissociation rate is unchanged 
(t1/2 = 30 min for both curves) but that a plateau is reached at 40% specific binding in the 
presence of the modulator. The control curve reached a plateau at 10%. 
For the compounds that markedly increased the binding of [3H]-nicotinic acid in 
equilibrium assays (Table S1) we attempted to determine an EC50 of this effect. However, at 
10 µM none of the curves had reached a plateau, and the solubility of the compounds did 
not permit an increase above this concentration. The curves for three selected compounds, 
24, 29 and 38, are shown in Figure S1-B.
Correlation between potentiation of nicotinic acid and 
allosteric agonism
To investigate any correlation between the agonistic and modulating effects of the 
pyrazolopyrimidines, the [35S]-GTPγS binding activation and the potency shift of nicotinic 
acid, both at 10 µM, were plotted against each other (Figure S2), yielding a nonlinear 
correlation. The plot suggests that the ability of the pyrazolopyrimidine agonists to 
stabilize active receptor conformations contributes to, or even determines, the modulator 
strength of the compounds. 


























































Figure S1. A. Dissociation curves with and 
without 10 µM 24 at 15 °C. After 3 hours 
association of 20 nM [3H]-nicotinic acid to HEK-
HCA2 membranes, dissociation was started 
by addition of 10 µM nicotinic acid. The data 
points are means ± SEM for 3 independent 
experiments performed in duplicate. B. Binding 
curves (equilibrium) of compounds 24, 29 
and 38. The assays were performed using 20 
nM [3H]-nicotinic acid and 50 µg HEK-HCA2 
membranes per assay point, and incubation 
was 1h at 25 °C. The data points are means ± 
SEM of 3 independent experiments performed 
in duplicate.  
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The compounds at the bottom right of the curve are the most potent modulators and also 
the most active agonists. More to the left are compounds that are not potent or efficacious 
agonists, but still fairly active as modulators. However, it appears that a 3-fold or greater 
shift in nicotinic acid potency is always coupled to some agonist activity in this series. 
Closest to the origin of the graph is a cluster of compounds, 41, 33, 37 and 26. Replacing 
the 4-isopropyl by a 3-methyl (33), 3-chloro (41) or 4-methoxy (37) appears to decrease the 
agonist action significantly while preserving appreciable modulator strength. Removal 
of the phenyl from the 6-position substituent (R3) followed by methylation (26) seems to 
have a similar effect.
Modulation of the intrinsic efficacy of nicotinic acid
As described above, many of the active pyrazolopyrimidines are allosteric agonists for 
HCA2. In the concentration-effect curves of nicotinic acid with the modulator, this was 
observed as an increase in the basal receptor activation level. At the same time, many 
of the same compounds also increased the maximal [35S]-GTPγS binding. In most cases, 
nicotinic acid still caused an increase in [35S]-GTPγS binding of 100%, identical to the 
range of the curve in absence of a modulator and typical of a full agonist. However, there 
were a few cases where the allosteric modulator changed the intrinsic efficacy of nicotinic 
acid. Thus, in the presence of compounds 24, 32, 36, and, to a lesser extent, 26 and 29, 
nicotinic acid appeared to be a partial agonist (Table 1). For 36 and 29 this may be due to 
their high agonist activity and the apparent maximum in Emax at approximately 150%, but 
for the other derivatives this postulated Emax ceiling was not reached. For example, in the 
presence of 10 µM 24, the basal receptor activation was on average 71% and the Emax was 
109%, which means nicotinic acid only caused a 38% increase in [35S]-GTPγS binding (see 
Table 1 and Figure 2).  At 3 µM 24, nicotinic acid still behaved as a partial agonist with the 
concentration-effect curve ranging from 51% to 107%, on average. 
The lowest concentration of 1 µM 24 had a negligible effect on the intrinsic efficacy of 







































Figure S2. Correlation between potency enhancement of nicotinic acid and agonistic activity of the 
pyrazolopyrimidines on HCA2
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nicotinic acid: here, the basal [35S]-GTPγS binding was 30% and the maximum was 120%.
Compounds 20 and 23 had the opposite effect and made nicotinic acid behave as a 
superagonist. The effect was highly similar for the two allosteric ligands: in the presence 
of 10 µM modulator, the basal [35S]-GTPγS binding was unchanged, whereas the Emax was 
increased to approximately 130% (see Table 1 and 2). Thus, the modulators increased 
the intrinsic efficacy of nicotinic acid by 30%. These enhancers were not tested at lower 
concentrations. 
Pyrazolopyrimidines as allosteric agonists
Further characterization of the most active allosteric agonists in concentration-effect 
curves (in absence of nicotinic acid) revealed that 24, 35 and 36 have a similar potency to 
nicotinic acid on HCA2 (Table S2). The other compounds all seem to have a 2- to 3-fold 
lower potency, although the difference is not significant. All pyrazolopyrimidines are 
partial agonists; the most efficacious derivative, 24, has an intrinsic efficacy close to 90%. 
None of the pyrazolopyrimidines increased [35S]-GTPγS binding in non-transfected HEK 
cells (data not shown). 






nicotinic acid 4.7 (0.5) 100
24 3.0 (0.6) 87 (8)
29 9.0 (6.8) 75 (3)
30 9.2 (6.7) 70 (2)
32 9.7 (6.5) 65 (6)
35 3.8 (1.3 ) 72 (5)
36 3.0 (0.6) 70 (9)
38 9.9 (6.4) 64 (6)
Table S2. Agonism of the pyrazolopyrimidines in [35S]-GTPγS assays on HEK-HCA2 membranes. The values are 
means (SEM) of 3 independent experiments performed in duplicate.
3-OHB alone 3.82 (2.04) 29 (3)
3-OHB+24 0.54 (0.14) 39 (6)
3-OHB+27 0.62 (0.05) 46 (4)
3-OHB+29 0.51 (0.15) 36 (6)
3-OHB+38 0.55 (0.16) 51 (8)





Table S3. Potency and intrinsic efficacy (basal activation by modulator minus E max) of 3-hydroxybutyrate (3-OHB) 
in the presence and absence of 10 µM pyrazolopyrimidine. The data is from [35S]-GTPγS binding assays performed 




Experimental Section – Pharmacology
[3H]-Nicotinic acid (60 Ci/mmol) was purchased from BioTrend (Koeln, Germany). [35S]-
GTPγS (1250 Ci/mmol) was purchased from Perkin Elmer (Waltham, MA).
Cell culture and membrane preparation
Human embryonic kidney (HEK) 293T cells stably expressing human HCA2 were cultured 
in DMEM supplemented with 10% newborn bovine serum, 0.4 mg/mL G418, 50 IU/mL 
penicillin and 50 µg/mL streptomycin. The cells were harvested by scraping in cold 
PBS, centrifuged at 1000g for 10 min and resuspended in cold 50 mM Tris-HCl buffer, 
pH 7.4. Then a DIAX 900 electrical homogenizer (Heidolph, Schwabach, Germany) was 
used for 15 sec to obtain cell lysis. The suspension was centrifuged at 100 000g for 20 
min at 4 °C and the supernatant was discarded. The pellet was resuspended in Tris-HCl, 
and the homogenization and centrifugation steps were repeated. The membranes were 
resuspended in cold assay buffer (50 mM Tris HCl, 1 mM MgCl2, pH 7.4) and the protein 
content was determined using a BCA assay (Thermo Scientific, Waltham, USA). During 
membrane preparation the suspension was kept on ice at all times. Membrane aliquots 
were stored at -80 °C until the day of the assay.
[3H]-nicotinic acid binding assays
Competition assays
Membranes of the HEK293T-HCA2 cell line (50 µg protein per tube) were incubated 1 
hour at 25 °C with 20 nM [3H]-nicotinic acid and increasing concentrations of the test 
compound in assay buffer (50 mM Tris HCl, 1 mM MgCl2, pH 7.4). The total assay volume 
was 100 µL. To assess the total binding a control without test compound was included. The 
non-specific binding was determined in the presence of 10 µM unlabeled nicotinic acid. 
Final DMSO concentration in all samples was ≤ 0.25%. The incubation was terminated by 
filtering over GF/B filters using a 24-sample harvester (Brandel, Gaithersburg, USA). The 
filters were washed 3 times with 2 mL cold buffer (50 mM Tris HCl, pH 7.4). Filters were 
transferred to counting vials and counted in a Perkin Elmer LSA Tri-Carb 2900TR counter 
after  2 h extraction in 3.5 ml Emulsifier Safe liquid scintillation cocktail (Perkin Elmer, 
Waltham, USA). 
Dissociation assays
HEK-HCA2 membranes (50 µg protein per tube) were incubated 3 h at 15 °C with 20 
nM [3H]-nicotinic acid in 50 mM Tris HCl, 1 mM MgCl2, pH 7.4, in a total volume of 100 
µL. Then, 5 µL nicotinic acid (final concentration 10 µM), in absence or presence of test 
compound (final concentration 10 µM) was added. In the single point screen dissociation 
was terminated after 30 min at 15 °C, and for full curves dissociation was measured at 
different time points. Non-specific binding was determined in the presence of 10 µM 
nicotinic acid, added prior to the membranes. Otherwise the assay was performed as the 
competition assay.
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Putative role of the adenosine A
3
 receptor in the 
anti-proliferative action of N6-(2-isopentenyl)adenosine
This chapter is based on: Blad CC, von Frijtag Drabbe Künzel JK, de Vries H, Mulder-




We tested a panel of naturally occurring nucleosides for their affinity towards adenos-
ine receptors. Both N6-(2-isopentenyl)adenosine (IPA) and racemic zeatin riboside were 
shown to be selective human adenosine A3 receptor (hA3R) ligands with affinities in the 
high nanomolar range (Ki values of 159 and 649 nM, respectively). These values were 
comparable to the observed Ki value of adenosine on hA3R, which was 847 nM in the same 
radioligand binding assay. IPA also bound with micromolar affinity to the rat A3R. In a 
functional assay in CHO cells transfected with hA3R, IPA and zeatin riboside inhibited 
forskolin-induced cAMP formation at micromolar potencies. The effect of IPA could be 
blocked by the A3R antagonist VUF5574.
Both IPA and reference A3R agonist 2-chloro-N6-(3-iodobenzyl)adenosine-5′-N-
methylcarboxamide (Cl-IB-MECA) have known antitumor effects. We demonstrated 
strong and highly similar antiproliferative effects of IPA and Cl-IB-MECA on human 
and rat tumor cell lines LNCaP and N1S1. Importantly, the antiproliferative effect of 
low concentrations of IPA on LNCaP cells could be fully blocked by the selective A3R 
antagonist MRS1523. At higher concentrations, IPA appeared to inhibit cell growth by an 
A3R-independent mechanism, as was previously reported for other A3R agonists. We used 
HPLC to investigate the presence of endogenous IPA in rat muscle tissue, but we could 
not detect the compound. 
In conclusion, the antiproliferative effects of the naturally occurring nucleoside IPA are at 
least in part mediated by the A3R. 
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Introduction
Four adenosine receptors have been cloned and pharmacologically characterized: A1, 
A2A, A2B and A3. Of these subtypes, the A3R has been identified last [1]. The hA3R has a 
wide distribution in the body. High expression is observed in liver, lungs and immune 
cells, whereas the brain, testes, placenta and heart display moderate expression levels 
[2-3]. Furthermore, a very high expression level is observed in tumor cell lines and cancer 
tissues, making the A3R an interesting target for the treatment of cancer (for a review, see 
[4]). A recent study even showed that the 3-fold A3R upregulation in human colorectal 
cancer was reflected, via an unknown mechanism, in peripheral blood cells [5]. This could 
make the A3R a promising biomarker for this and possibly other types of cancer.  We 
and others have previously shown that A3R agonists have antiproliferative effects on 
tumor cells in vitro and in vivo, characterized by induction of G0/G1 cell cycle arrest and 
apoptosis [4]. It has been shown that, in most cases, a deregulation of the NF-κB and 
Wnt signaling pathways is at the basis of these effects [4]. However, other mechanisms 
may be more important in specific cell types. For example, in A375 human melanoma 
cells, A3R stimulation activated phosphatidylinositol 3-kinase (PI3K) which induced Akt 
phosphorylation, finally resulting in reduced levels of phosphorylated extracellular signal-
regulated kinase 1/2 (ERK1/2) [6].  Another recent study suggested that A3R upregulation 
may precede asbestos-induced malignant mesothelioma formation [7]. The A3R agonist 
2-chloro-N6-(3-iodobenzyl)adenosine-5′-N-methylcarboxamide (Cl-IB-MECA) prevented 
TNF-α-mediated cell survival after asbestos exposure in vitro by acting on the de-regulated 
Akt/NF-κB pathways, showing that A3R is a possible target for cancer prevention as well 
as treatment. Interestingly, A3R agonists do not inhibit the growth of normal cells [7-9]. 
Moreover, these ligands can act as cytoprotective agents, for example by preventing the 
myelotoxic effects of chemotherapy [10]. In view of the promising preclinical data, the 
safety profile of the A3R agonist IB-MECA has been evaluated in phase I clinical studies 
[11]. This agonist was tolerated very well. Related A3R agonist Cl-IB-MECA is currently 
in phase I/II clinical trials for hepatocellular carcinoma ([12] and trial ID: NCT00790218).
On the basis of these studies and observations we hypothesized that endogenous A3R 
agonists might also contribute to the body’s natural defense mechanism against tumors. 
In particular, such compounds may be excreted by striated muscle cells, protecting the 
tissue from metastases [13]. We have shown that extracts from muscle cells inhibited tumor 
proliferation while protecting bone marrow cells in vivo. These effects were dependent on 
A3R activation. However, they could not be attributed to adenosine, as the effect was not 
sensitive to ADA and could not be reproduced by administration of adenosine alone [13]. 
Thus, we set out to identify other endogenous agonists for the A3R.
In the current work we report the affinity of a panel of naturally occurring nucleosides 
for the human adenosine receptors, while focusing on the hA3R. Then, we assessed the 
potency of the two higher affinity compounds, the nucleosides IPA and racemic zeatin 
riboside, in cAMP generation assays. The effect of IPA and the reference A3R agonist Cl-
IB-MECA on tumor cell line proliferation was also determined. We provide evidence that 
the antiproliferative effects of IPA are indeed linked to the A3R as they can be partially 
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blocked by a selective antagonist for that receptor. We also present a HPLC method to 
investigate the IPA content of muscle tissue. However, endogenous IPA could not be 
detected in our analysis.
Materials & Methods
Materials
[3H]-DPCPX and [125I]-AB-MECA were purchased from Amersham Biosciences 
(Roosendaal, the Netherlands). [3H]-ZM241385 and [3H]-MRS1754 were obtained from 
Tocris Cookson, Ltd. (Bristol, UK). All nucleosides listed in table 1 were supplied by 
Sigma-Aldrich (Zwijndrecht, the Netherlands). Ammonium acetate and EDTA for analysis 
of muscle tissue were obtained from Fluka (Zwijndrecht, the Netherlands), whereas 
methanol for the HPLC analysis was from Biosolve (Valkenswaard, the Netherlands).
Chinese hamster ovary (CHO) cells expressing the human adenosine A1 receptor were 
kindly provided by Dr. A. Townsend-Nicholson (University College of London, UK). 
Human embryonic kidney (HEK) 293 cells stably expressing the human adenosine 
A2A receptor were a gift from Dr. E. Wang (Biogen/IDEC, San Diego, CA, USA). CHO 
cells expressing the human adenosine A2B receptor were donated by Dr. S. Rees (GSK, 
Stevenage, UK) and both CHO and HEK293 cells expressing the hA3R were kindly 
provided by Dr. K.-N. Klotz (University of Wuerzburg, Germany). RBL-2H3 cells were 
a kind gift of Dr. Frank Redegeld (Utrecht University, the Netherlands). LNCaP (human 
prostate carcinoma) and N1S1 (rat hepatocellular carcinoma) cells were purchased from 
the American Type Culture Collection (Manassas, Virginia, USA).
Fresh Wistar rat cadavers from an untreated control group of another study were kindly 
provided by the animal facility of the Leiden/Amsterdam Center for Drug Research 
(Leiden, the Netherlands).
Radioligand binding studies
Cell culture and membrane preparation 
CHO cells expressing the human A1 receptor were cultured in a 1:1 mixture of Dulbecco’s 
modified Eagle’s medium (DMEM) and Ham’s F12 medium containing 10% newborn calf 
serum, streptomycin (50 μg/ml), penicillin (50 IU/ml) and G418 (0.2 mg/ml) at 37 °C and 
5% CO2. HEK 293 cells stably expressing either the human A2A adenosine receptor or the 
hA3R were grown in DMEM containing 10% newborn calf serum, streptomycin (50 μg/
ml), penicillin (50 units/ml) and G418 (0.5 mg/ml) at 37 °C and 7% CO2. Membranes were 
prepared as previously described [14]. ADA was added in the final preparations at 0.8 IU/




Affinity for the human A1 receptor was determined on membranes from CHO cells 
expressing the human receptors, using [3H]-DPCPX as the radioligand. Membranes 
containing 10 μg of protein were incubated in a total volume of 200 μl of 50 mM Tris/HCl 
(pH 7.4) and [3H]-DPCPX (final concentration 1.6 nM) for 1 h at 25 °C in a shaking water 
bath. Nonspecific binding was determined in the presence of 10 μM CPA. The incubation 
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was terminated by filtration over Whatman GF/B filters under reduced pressure with a 
Brandell harvester. Filters were washed three times with ice-cold buffer and placed in 
scintillation vials. Packard Emulsifier Safe (3.5 ml) was added, and after 2 h radioactivity 




Affinity for the human A2A receptor was determined on membranes from HEK293 cells 
stably expressing this receptor, using [3H]-ZM241385 as the radioligand. Membranes 
containing 30 μg of protein were incubated in a total volume of 200 μl of 50 mM Tris/HCl 
(pH 7.4) and [3H]-ZM241385 (final concentration 1.7 nM) for 2 h at 25 °C in a shaking water 
bath. Nonspecific binding was determined in the presence of 10 μM CGS21680. Filtration 




At the human A2B receptor radioligand displacement was determined on membranes from 
CHO cells stably transfected with this receptor, using [3H]-MRS1754 as the radioligand. 
Membranes containing 20 μg of protein were incubated in a total volume of 100 μl of 
50 mM Tris/HCl (pH 7.4), 10 mM MgCl2, 1 mM EDTA, 0.01 w/v % CHAPS (pH 8.26 at 
5 °C), and [3H]-MRS1754 (final concentration 1.2 nM) for 1 h at 25 °C in a shaking water 
bath. Nonspecific binding was determined in the presence of 1 mM NECA. Filtration and 




The affinity at the hA3R was measured on membranes from HEK293 cells stably expressing 
this receptor, using [125I]-AB-MECA as the radioligand. Membranes containing 35 μg of 
protein were incubated in a total volume of 100 μl of 50 mM Tris/ HCl, 10 mM MgCl2, 1 
mM EDTA, 0.01% w/v CHAPS (pH 8.26 at 5 °C ), and [125I]-AB-MECA (final concentration 
0.10 nM) for 1 h at 37 °C in a shaking water bath. Nonspecific binding was determined in 
the presence of 100 μM R-PIA. The incubation was terminated by filtration over Whatman 
GF/B filters under reduced pressure with a Brandell harvester. Filters were washed three 
times with ice-cold buffer and placed in counting tubes. Radioactivity was counted in a 




The affinity at the rat A3R was measured on membranes from RBL-2H3 (rat basophilic 
leukemia) cells endogenously expressing this receptor, using [125I]-AB-MECA as the 
radioligand. Membranes of these cells were prepared as described previously [15]. 
Membranes containing 60 μg of protein were incubated in a total volume of 100 μl of 50 
mM Tris/ HCl, 10 mM MgCl2 (pH 7.7 at 22 °C ), and [125I]-AB-MECA (final concentration 
0.20 nM) for 1 h at 37 °C in a shaking water bath. Nonspecific binding was determined in 








CHO cells expressing the hA3R were grown overnight as a monolayer in 24 well tissue 
culture plates (400 μl/well; 2 x 105 cells/well) in a 1:1 mixture of Dulbecco’s modified 
Eagle’s medium (DMEM) and Ham’s F12 medium containing 10% newborn calf serum, 
streptomycin (50 μg/ml), penicillin (50 IU/ml) and G418 (0.2 mg/ml) at 37 °C and 5% CO2. 
To determine the potencies of IPA, adenosine and zeatin riboside, cAMP generation was 
performed in DMEM/N-(2-hydroxyethyl)piperazine-N’-2-ethanesulfonic acid (HEPES) 
buffer (0.60 g HEPES/50 ml DMEM pH 7.4). Each well was washed twice with HEPES/
DMEM buffer (250 μl), after which the PDE inhibitors rolipram (50 μM) and cilostamide 
(50 μM) were added to each well. This mixture was  incubated for 30 min at 37 °C followed 
by the introduction of either the compound of interest (10 μM), reference compound 
Cl-IB-MECA (10 μM) or DMEM/HEPES. After a further 10 min of incubation, forskolin 
was added (10 μM). After a subsequent 15 min, incubation was stopped by aspirating 
the assay medium and by adding 200 μl of ice-cold 0.1 M HCl. The amount of cAMP 
was determined by competition with [3H]-cAMP for protein kinase A (PKA). Briefly, the 
sample, approximately 1.8 nM [3H]-cAMP, and 100 μl of PKA solution were incubated on 
ice for at least 2.5 h. The incubations were stopped by rapid dilution with 2 ml of ice-cold 
Tris/ HCl buffer (50 mM, pH 7.4), and bound radioactive material was then recovered by 
filtration through Whatman GF/C filters. Filters were additionally rinsed with 2 x 2 ml of 
Tris/HCl buffer, Packard Emulsifier Safe (3.5 ml) was added, and after 2 h radioactivity 
was counted in a Perkin-Elmer Tri-Carb 2900 β-scintillation counter. 
In the assays evaluating the effects of ADA and VUF5574, intracellular cAMP levels were 
measured using a LANCE cAMP 384 kit (PerkinElmer, The Netherlands) as described 
previously [16]. �To each well, 5 μL of the agonist Cl-IB-MECA, adenosine or IPA (10 μM 
final concentration) in stimulation buffer (PBS with 5 mM Hepes, pH 7.4 supplemented 
with 0.1% BSA, rolipram (50 μM) and cilostamide (50 μM)) was added in the absence 
(control) or presence of ADA (0.8 IU/mL) or VUF5574 (1 μM). Then 4.5 μL hA3-CHO cell 
suspension in stimulation buffer was seeded into a 384-well plate (approximately 5000 cells/
well), which was followed by incubation for 15 min at room temperature. Subsequently, 
2.5 μL forskolin (1 μM) was added and the mixture was incubated for 30 min at room 
temperature. Then, detection mix (6 μL) and cAMP antibody solution (6 μL) were added 
and incubated for 3h. Intracellular cAMP levels were measured using a TR-FRET assay 
on a Victor spectrometer (PerkinElmer, The Netherlands) according to instructions of the 
supplier. All data reflect the average of at least three independent experiments performed 
in duplicate. 
Proliferation assays on tumor cell lines
Effect of IPA on the proliferation of tumor cell lines
Cell proliferation was studied in both N1S1, a rat hepatocellular carcinoma cell line, and 
LNCaP, a human prostate carcinoma cell line. The cells were grown in RPMI 1640 with 
penicillin (100 units/ml), streptomycin (100 μg/ml), L-glutamine (2 mM) and 10% fetal 
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bovine serum (FBS). The cells were maintained in T-75 flasks at 37 °C in a 5% CO2 incubator 
and transferred to freshly prepared medium twice weekly. For the in vitro studies with 
the LNCaP cell line serum-starved cells were used. In these experiments FBS was omitted 
from the culture medium for 18 h and the experiment was carried out on monolayers of 
cells in RPMI medium supplemented with 1% FBS. For the N1S1 cells no serum starvation 
was used and the assay was carried out in the growth medium of the cells.  
The cells (1.5 x 104/ml) were incubated in 96-well microtiter plates in the presence of 25 μM 
adenosine or various concentrations of Cl-IB-MECA and IPA (0.01, 0.1, 1, and 10 μM). A 
24 h [3H]-thymidine incorporation assay was used to evaluate cell growth, except for the 
experiments evaluating the effect of EHNA (10 μM), which lasted 48 hours. For the last 
18 h of incubation, each well was pulsed with 1 μCi [3H]-thymidine. Cells were harvested 
and the [3H]-thymidine uptake was determined in an LKB liquid scintillation counter 
(LKB, Piscataway, NJ, USA).




The effect of IPA on the proliferation of LNCaP cells in the presence of the A3R antagonist 
MRS1523 was also examined. The cells (1.5 x 104/ml) were incubated in 96-well microtiter 
plates with IPA (0.01, 0.1, 1 and 10 μM) in the absence or presence of MRS1523 (0.01, 0.1 
and 1 μM). Cell growth was evaluated in a 24-hour [3H]-thymidine incorporation assay as 
described above. 
Data analysis
All radiologand displacement curves and cAMP concentration-effect curves were analyzed 
with GraphPad Prism software (version 5.0). Statistical analysis of the results of the cAMP 
production assays was done using an unpaired Student’s t-test.
HPLC analysis of the presence of IPA in rat muscle tissue 
The presence of IPA in rat muscle tissue was investigated by HPLC analysis. Fresh rat 
muscle tissue (hind leg vastus lateralis and semimembranosus) was used. About 5 gram of 
tissue was weighed exactly and cut into small pieces of about 5x5x5 mm. The material was 
spiked with IPA and/or internal standard cyclopentyladenosine in methanol (2.5 μg). Then, 
30 ml of 5 mM ammonium acetate (pH 5.2), 50 mM EDTA was added and the material was 
treated with a Diax 900 homogenizer (Heidolph, Schwabach, Germany) equipped with 
a 1.5 cm probe, for 1.5 min at speed 1. The homogenate was subjected to 4 freeze-thaw 
cycles in liquid nitrogen and a 60 oC water bath. The sample was centrifuged at 6000 g at 
4 oC for 30 min and the supernatant was additionally centrifuged at 200000 g at 4 oC for 
45 min. After the centrifugation steps, the clear supernatant was filtered over Miracloth 
to remove fat particles and transferred to an activated C18 solid phase extraction column 
(Grace, Deerfield, USA). After passing the sample, the column was washed with 25 ml 5 
mM ammonium acetate and the material of interest was eluted with 5 ml methanol. The 
methanol was evaporated in a vacuum centrifuge and the sample was reconstituted in 0.5 
ml 5 mM ammonium acetate after which HPLC analysis was performed. 
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The system consisted of a gradient solvent delivery system (Gilson, Den Haag, the 
Netherlands), equipped with a Gilson 115 UV detector, monitoring at 270 nm. The column 
was a Discovery® RP 18 (Supelco, Zwijndrecht, the Netherlands), 125 x 4.6 mm, packed 
with 5 μM particles. As eluent a gradient between solvent A (10% methanol in 5 mM 
ammonium acetate) and solvent B (90% methanol in 5 mM ammonium acetate) was 
applied with a flow of 0.6 ml/min. The profile of the gradient was as follows; 0 min, 0% B; 
10 min, 0% B; 15 min, 37.5% B; 35 min, 37.5% B; 40 min, 100% B; 50 min, 100% B; 51 min, 0% 
B and 60 min, 0% B. For analysis, 100 μl of sample in 5 mM ammonium acetate pH 5.2 was 
injected by an autoinjector. Data were recorded and processed using ADchrom software 
(Leiden University, the Netherlands).
Results
Radioligand binding studies on human adenosine receptors
The affinities of the naturally occurring modified nucleosides 1-methyl-adenosine, 
2’-O-methyl-adenosine, IPA, trans-zeatin riboside and racemic zeatin riboside were 
determined in radioligand binding studies on all four subtypes of human adenosine 
receptors (table 1). The affinity of adenosine for the A1, A2A and A2B receptors could not be 
assessed in this experimental set-up due to the essential presence of ADA in the assays. 
Both IPA and the racemic mixture of cis- and trans-isomers of zeatin riboside showed 
affinities in the higher nanomolar range (Ki values of 159 nM and 643 nM, respectively) for 
the hA3R, in the same range as the affinity of adenosine itself. The affinities of both zeatin 
riboside and IPA at the other adenosine receptor subtypes were negligible, given the lack 
of displacement at a test concentration of 1 μM.













0 0 159±19 nM
1c trans-zeatin riboside CH2CHC(CH3)CH2OH- -OH 2 6 31%
1d racemic zeatin riboside -CH2CHC(CH3)CH2OH -OH 17 0 643±27 nM
1e 2’-O-methyladenosine -H -OH 0 8 0%

















Table 1. Chemical structures of naturally occurring modified nucleosides and their effects in radioligand binding 
studies at human adenosine A1, A2A, A2B and A3 receptors.
% displacement at 1 μM (N=2) or Ki value (N=3) is shown; data are means (±S.E.M.) of N experiments performed 
in duplicate.
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Affinity of IPA for the rat A
3
R
The affinity of IPA for the rat A3R was also determined in radioligand binding studies 
(figure 1). A Ki value of 4.69 ± 0.20 μM was found for the rat orthologue, so the affinity of 
IPA for the rat A3R was lower than for the hA3R.
Effect of IPA on the cAMP production in cells expressing the hA
3
R
The potency of adenosine, IPA and racemic zeatin riboside to modulate cAMP production 
was determined in intact CHO cells stably expressing the hA3R (table 2). Adenosine and 
IPA inhibited forskolin-stimulated cAMP accumulation with similar potencies in the low 
micromolar range and virtually identical intrinsic activities.
In a second assay the effects of ADA and the selective hA3R antagonist VUF5574 were 
investigated (figure 2). The selective A3R agonist Cl-IB-MECA was included for comparison 
next to adenosine and IPA. As expected, adenosine and IPA inhibited cAMP production 
to a similar extent when added at 10 μM, whereas Cl-IB-MECA had a more potent effect. 
Inclusion of ADA abolished the effect of adenosine, whereas IPA and Cl-IB-MECA were 
insensitive to the enzyme. Modulation of the second messenger pathway by each of the 

























Figure 1. Competition binding experiment on RBL-
2H3 cell membranes endogenously expressing the 
rat A3R. IPA displaced [125I]-AB-MECA from the rat 
A3R with a Ki value of 4.69 ± 0.20 μM (N=3). Data 
from one representative experiment is shown. 
Incubation was 1 h at 37 °C in 50 mM Tris/ HCl, 10 
mM MgCl2 (pH 7.7)
EC50 (µM)
adenosine 2.9 ± 1.1
N6-(2-isopentenyl)- 
adenosine (IPA) 2.0 ± 0.7
racemic zeatin riboside 5.8 ± 1.8
Table 2. Potency of naturally occurring nucleosides on the human adenosine A3 receptor, as inhibitors of forskolin-
stimulated cAMP production in CHO cells expressing the hA3R. 
EC50 value (N=4, except zeatin riboside N=3) is shown; 




Effect of IPA on the proliferation of tumor cell lines
In view of the reported anti-tumor effects of agonists for the A3R we investigated the effect of 
IPA on the proliferation of human prostate carcinoma cells (LNCaP) and rat hepatocellular 
carcinoma cells (N1S1). In both tumor cell lines IPA inhibited the incorporation of [3H]-
thymidine in a similar fashion as the reference A3R agonist Cl-IB-MECA (figures 3 and 4). 
At 10 μM, IPA even had a significantly greater effect than Cl-IB-MECA on both cell lines 
(P<0.01). An approximate EC50 value of 1 μM for IPA was established in the LNCaP cell 
line, whereas the potency on the N1S1 cell line seemed somewhat lower. Adenosine, at a 
concentration of 25 μM, had only a modest effect on N1S1 proliferation and no effect on the 
LNCaP cell line. Addition of ADA inhibitor EHNA (10 μM) did not increase the adenosine 
effect in the LNCaP cell line (data not shown), although it significantly increased the effect 
of adenosine on the N1S1 cells, yielding almost full growth inhibition (data not shown; 
available with the published article as Online Resource 1). Addition of EHNA but not 
adenosine to N1S1 cells also revealed a 22% basal growth inhibition, probably mediated 
by adenosine excreted by the tumor cells.




In a final proliferation assay we investigated whether MRS1523, an antagonist with 
appreciable affinity for both human and rat A3R, was capable of blocking the effect of IPA 
on LNCaP cell proliferation (figure 5). The antagonist (at 0.1 and 1 μM) prevented the anti-
proliferative effect of 0.01 and 0.1 μM IPA. When IPA was added at 1 μM, the inhibition 
by MRES1523 was small but still significant at higher concentrations. At 10 μM IPA, the 
antagonist had no effect.
Determination of IPA in muscle tissue by HPLC









forskolin + + + + + + + + + +
Cl-IB-MECA - + + + - - - - - -
adenosine - - - - + + + - - -
IPA - - - - - - - + + +
ADA - - - + - - + - - +











Figure 2. Effect of ADA and A3R antagonist 
VUF5574 in cAMP accumulation assays. 
In CHO cells stably expressed with hA3R, 
forskolin-stimulated cAMP production was 
inhibited by adenosine, IPA and Cl-IB-MECA, 
all at 10 μM. The effects of the concomitant 
presence of either the enzyme ADA (0.8 IU/
ml) or the antagonist VUF5574 (10 μM) were 
also assessed. The cells were incubated for 15 
min at room temperature with the ligand(s) 
of interest ±ADA. Then forskolin was added 
to the reaction mixture for a further 30 min. 
Data are means (± S.E.M.) of four experiments 
performed in triplicate. Statistical evaluation 
was done using an unpaired Student’s t-test. 
* P<0.05; *** P<0.001
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tissue. We therefore analyzed extracts from Wistar rat muscle. The spectra of spiked and 
unspiked tissue extracts are shown in figures 6A and 6B, respectively. From the spiked 
tissue, 23% of the added IPA was recovered in the extract. In the unspiked spectrum no 

































































































Figure 3. IPA and Cl-IB-MECA have similar antiproliferative effects on LNCaP tumor cells. IPA and Cl-IB-MECA 
(0.01-10 μM) both inhibited proliferation of the human prostate carcinoma cell line LNCaP. Adenosine (A) (25 μM) 
had virtually no effect. IPA and Cl-IB-MECA had significantly larger antiproliferative effects than adenosine at all 
concentrations (P<0.01). The effect of IPA increased significantly at 1 μM compared to the lower concentrations 
(P<0.01), and the effect increased further at 10 μM. The effect of Cl-IB-MECA showed a significant decrease from 0.01 
μM to 1 μM (P<0.01), and then significantly increased again at 10 μM (P<0.001). At 10 μM, IPA had a significantly 
larger effect than Cl-IB-MECA (P<0.001). Proliferation was evaluated by incubating a monolayer of serum-starved 
cells for 24h with the compound of interest. For the last 18 h, 1 μCi of [3H]-thymidine was included in the buffer. 
Data are means (± S.E.M.) of three experiments performed in triplicate. Statistical evaluation was done using an 
unpaired Student’s t-test. ** P<0.01; *** P<0.001. Stars without brackets indicate the significance of the difference to 
adenosine treatment.
Figure 4. IPA and Cl-IB-MECA have similar antiproliferative effects on N1S1 tumor cells. IPA and Cl-IB-MECA 
(0.01-10 μM) both inhibited proliferation of the rat hepatocellular carcinoma cell line N1S1. Adenosine (A) (25 μM) 
had only a modest effect. IPA and Cl-IB-MECA had significantly larger antiproliferative effects than adenosine 
(P<0.01), with the exception of 0.01 μM IPA and 1 μM Cl-IB-MECA. The effect of IPA increased significantly at 10 
μM compared to the other concentrations (P<0.001). The effect of Cl-IB-MECA showed a significant decrease from 
0.01 μM to 1 μM, and then significantly increased again at 10 μM (both P<0.001). At 10 μM, IPA had a significantly 
larger effect than Cl-IB-MECA (P<0.01). Proliferation was evaluated by incubating a monolayer of serum-starved 
cells for 24h with the compound of interest. For the last 18 h, 1 μCi of [3H]-thymidine was included in the buffer. 
Data are means (± S.E.M.) of three experiments performed in triplicate. Statistical evaluation was done using an 




In vitro evaluation of IPA activity
We have shown that zeatin riboside and particularly IPA are ligands for the A3R. These 
naturally occurring modified nucleosides bind with submicromolar affinity to the hA3R. 
Moreover, the affinity of IPA for A3R is not restricted to the human orthologue, but extends 
to the rat A3R. In line with previous findings on N6-substituted adenosine derivatives with 
small alkyl substituents, IPA discriminates between the two A3R homologues and has 
a 30-fold higher affinity for the human A3R [17].  Our next step was the evaluation of 
receptor activation by IPA, zeatin riboside and adenosine in cAMP generation assays. The 
compounds had similar potencies in the low micromolar range, with zeatin riboside 2- or 
3-fold less potent than IPA and adenosine.
The potency of adenosine towards the A3R was classically considered to be in the 







































Figure 5. The antiproliferative effect of IPA is partly 
blocked by A3R antagonist MRS1523. The selective A3R 
antagonist MRS1523 (0.01-1 μM) blocked the effect 
of low concentrations (0.01-0.1 μM) of IPA on human 
prostate carcinoma (LNCaP) cells. MRS1523 did not 
inhibit the effect of high concentrations of IPA (1-10 μM). 
Proliferation was evaluated by incubating a monolayer 
of serum-starved cells for 24h with the compound of 
interest. For the last 18 h, 1 μCi of [3H]-thymidine was 
included in the buffer. Data are means (± S.E.M.) of 
three experiments performed in triplicate. Statistical 
evaluation was done using an unpaired Student’s t-test. 



































Figure 6. HPLC analysis of rat 
muscle extract detects no IPA. 
Comparison of rat muscle 
tissue spiked with IPA (B) 
and unspiked muscle extract 
(A) tissue shows that IPA, 
which is eluted at 34.2 min in 
the spiked tissue, cannot be 
detected in the blank tissue.
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micromolar range and rather lower than the potency towards the adenosine A1 and A2A 
receptors [18]. In contrast, several more recent publications report similar potencies of 
adenosine towards the A1, A2B and A3 subtypes, in the submicromolar range [19-21]. The 
affinity and potency that we observed for A3R activation by adenosine are clearly in better 
agreement with the more recent reports.  Some care should be taken in the interpretation 
of cAMP assay results, however, as receptor expression levels may have a strong impact 
on the EC50 values of tested agonists.  
Anti-proliferative effects of IPA
Interestingly, IPA has antitumor activity both in vitro and in vivo [22-23]. In 1975 this 
compound has been tested in a pilot clinical trial for leukemia, where it caused remission 
in three patients out of twenty [24]. Currently, there is a renewed interest in the compound; 
in a recent review IPA was defined as an emerging anticancer drug [25]. The molecular 
mechanism of the anti-tumor activity of IPA has not been elucidated so far.
In view of the well-known role of the A3R in cancer, we decided to investigate whether the 
antiproliferative effects of IPA are mediated by this receptor. IPA inhibits the proliferation 
of human prostate cancer cells (LNCaP) and rat hepatocellular cancer cells (N1S1) to a 
similar extent as the A3R reference agonist Cl-IB-MECA, which has nanomolar affinity 
at the receptor. These effects may be mediated by the A3R which is highly expressed in 
N1S1 cells and probably also in LNCaP cells [12, 26]. The potency of IPA in this assay 
seems somewhat lower in the rat cell line than in the human cell line; this would be in 
line with the difference in affinity of IPA towards the rat and human A3R. At 10 μM, IPA is 
significantly more active than Cl-IB-MECA in both cell lines. 
The A3R antagonist MRS1523 was able to completely inhibit the effect of low concentrations 
of IPA (10 and 100 nM) but not higher concentrations (1 and 10 μM). The affinity of 
MRS1523 for the hA3R is approximately 6-fold higher compared to IPA [27]. Therefore, it 
may be that the antiproliferative effect of higher concentrations of IPA is not mediated by 
the A3R, but by a different mechanism. A3R-independent antiproliferative effects of high 
concentrations of A3R agonists, including Cl-IB-MECA and IB-MECA, have previously 
been observed [28-30]. For example, 30 μM Cl-IB-MECA inhibited growth of leukemia 
cell lines HL-60 and MOLT-4 in the presence of antagonists MRS1523 (10 μM) or MRS1220 
(5 μM) [28]. Furthermore, Cl-IB-MECA and IB-MECA, but also adenosine, 2-chloro-
adenosine and 3’-deoxyadenosine had antiproliferative effects on breast cancer cell lines 
lacking A3R mRNA [29]. Involvement of other adenosine receptor subtypes was excluded. 
Suggested pathways for these effects include downregulation of the estrogen receptor α 
[29], upregulation of death receptor Fas [28] and downregulation of cyclins D1 and E2 
together with dephosphorylation of ERK1/2 [30].  It should be noted that the concentrations 
used in these reports are between 10 and 100 μM (even 500 μM for adenosine). The A3R-
independent effect of IPA seems to occur even at 1 μM, so it may be a significantly more 
potent anti-cancer agent than the other agonists that have been assessed. At 10 and 100 nM 
IPA, the antiproliferative effect was entirely blocked by antagonist MRS1523, so at these 
low IPA concentrations the effect seems entirely A3R-dependent. Plasma concentrations of 
IPA were not reported in the pilot clinical trial on leukemia patients [24, 31]. However, they 
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are expected to be very low since IPA is metabolized very fast [31]. After IPA enters the 
circulation, more than 50% is excreted in urine in the first 4 hours, mostly in metabolized 
form. Metabolites include N6-(3-methyl-hydroxybutylamino)purine, hypoxanthine, 
adenine and several N6-alkylated adenines and N-alkylated xanthines [31].
Origin and levels of endogenously occurring IPA
IPA and zeatin riboside are widely studied plant cytokinins controlling various processes 
in plant growth and development [32-33]. The nucleosides are also components of 
tRNA, but only IPA has been found in mammalian tRNA [33-34]. Free IPA is probably 
present in the mammalian cytoplasm, since its precursor N6-(2-isopentenyl)adenosine-3-
monophosphate has been identified in several cell lines [35]. Unchanged IPA has been 
detected in human urine at an  average amount of 50 μg per day [36]. Although levels of 
IPA and zeatin riboside in grains, vegetables and fruits at the moment of consumption 
could not readily be extracted from the literature, these foods might be exogenous sources 
of these compounds. Tuberous roots, such as (sweet) potatoes, seem especially likely 
sources [37-38]. Furthermore, ingested or residential bacteria in the gut may provide 
additional cytokinins [33]. In plants, free zeatin riboside is in the trans conformation, but 
tRNA is a source of cis-zeatin riboside. Most likely, the cis-isomer has the higher affinity 
for the A3R, since the trans-isomer is less active than the racemate (table 1). However, cis-
zeatin riboside is not commercially available and was therefore not tested in our study. 
Colocalization and thus interaction of the proposed nucleoside ligands and the A3R may 
occur at the cellular membrane or, keeping in mind that A3R has a nuclear localization 
signal, in or at the nucleus [39]. A3R localized in colon could interact with IPA and zeatin 
riboside from exogenous sources [40]. 
Detection of endogenous IPA
We have previously reported that an unknown A3R agonist with anti-tumor properties is 
excreted by muscle cells [13]. Since IPA activates A3R and has anti-proliferative properties, 
the compound might qualify as this unknown factor. We used HPLC to investigate its 
presence in commercial cow, pork and chicken meat, but detected no IPA. Since the 
freshness and storage conditions of commercial meat may not be ideal, we then switched 
to fresh rat muscle tissue. Again, IPA could not be detected, nor did we detect peaks of 
IPA metabolites. It is therefore unlikely that IPA is the muscle-derived A3R agonist we 
observed previously [13]. 
Conclusion
In conclusion, we have shown that both IPA and zeatin riboside bind selectively to the 
A3R. Moreover, we provide evidence that the antiproliferative effect of low concentrations 
of IPA is mediated by the A3R. Higher concentrations of the compound seem to have a 
potent A3R- independent antitumor effect. It is however unlikely that IPA is the previously 
reported muscle-derived antiproliferative A3R agonist, since it could not be detected in rat 
muscle. More research is needed to elucidate the putative physiological roles of IPA and 
the importance of the A3R for the antitumor action of IPA.
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Compound screen on orphan 
G protein-coupled receptor GPR88
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GPR88 is a G protein-coupled receptor without known endogenous or synthetic ligands. 
However, multiple genetic and expression studies suggest that GPR88 may be implicated 
in psychiatric disorders such as schizophrenia, depression and bipolar disorder. We 
performed a ligand identification screen testing over 4000 small molecules and peptides. 
This was done in a 384-well format, using changes in intracellular calcium levels detected 
with a Fluorescent Imaging Plate Reader (FLIPR) as the readout. Since the G protein 
coupling specificity of GPR88 is unknown, HEK293s cell lines stably co-expressing the 
receptor with Gα16 or Gαqi5 were used, as well as a native HEK-GPR88 cell line. In the 
calcium screen 46 hits were identified, with responses occurring in different GPR88-
expressing cell lines giving no clue as to the G protein coupling specificity. In validation 
assays, dose-response curves could be obtained for papaverine, an opium alkaloid. 
However, this compound also provoked calcium responses in HEK cells that were not 
transfected with GPR88. Thus, identification of a ligand, either endogenous or synthetic, 
for GPR88 remains an unmet challenge.
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Introduction
Since approximately 30% of all drugs currently on the market target rhodopsin-like G 
protein-coupled receptors (GPCRs), this protein family is of great interest for drug 
research. However, from a total of 284 human non-olfactory class A receptors, only about 
50 are currently targets of marketed drugs. Even more strikingly, 63 class A GPCRs 
have no known endogenous ligand or function (see also Chapter 1). Unlocking the full 
therapeutic potential of all these receptors could bring highly significant advances to the 
treatment of a variety of diseases. A first step towards this goal can be the identification of 
(endogenous) ligands for orphan receptors. 
This study focused on the orphan receptor GPR88, which was initially identified 
as a striatum-specific receptor [1-2]. We have also reported it as a gene with enriched 
expression in the central extended amygdala [3]. GPR88 is of special interest, since it 
may be implicated in several psychiatric and neurological disorders. Mice lacking this 
receptor, which is predominantly expressed in the brain, show a schizophrenia-like 
phenotype with impaired prepulse inhibition of startle (PPI), increased apomorphine-
induced climbing and stereotypy, and increased amphetamine-stimulated locomotor 
hyperactivity [4]. These phenotypes were sensitive to treatment with antipsychotics. 
Lack of GPR88 modulated the striatal dopaminergic system by increasing the functional 
sensitivity of dopamine D2 receptors and increasing DARPP-32 Thr-34 phosphorylation. 
Other hints regarding the role of GPR88 come from gene expression studies. We and 
others have reported regulation of the rodent GPR88 gene in several brain regions after 
treatment regimens with addictive drugs, antidepressants and mood regulators [5-10]. For 
example, a 13-fold upregulation was seen in nucleus accumbens dopaminergic neurons 
after chronic treatment of mice with the tricyclic antidepressant amitriptyline [6]. Other 
antidepressant treatments, including fluoxetine, sleep deprivation and electro-convulsive 
therapy, were shown to cause changes in GPR88 expression in the hypothalamus [8]. In 
our laboratory, GPR88 upregulation was seen in mouse central extended amygdala after 
chronic morphine treatment [5]. Changes in GPR88 expression levels were also observed 
in lactating rats [11], in rodent models of depression [12] and Parkinson’s disease [13], and 
in human Huntington’s disease brains [14]. 
GPR88 is most closely related to the biogenic amine receptors, especially the β1 and β3 
adrenergic receptors, and the 5-HT1D receptor. However, even to these receptors the 
sequence homology is relatively low (up to 27% amino acid identity) and it lacks the 
aspartic acid in the third transmembrane (TM) domain that is the hallmark of biogenic 
amine receptors. A phylogenetic analysis using only 30 residues predicted to line the TM 
binding cavity of GPCRs detected similarities between the class A receptor GPR88 and the 
class C receptors GABAB, taste and metabotropic glutamate receptors [15]. In this analysis 
GPR88 was the only receptor clustering to a different receptor class. Possibly, GPR88 and 
certain class C receptors bind structurally related ligands in their TM binding pockets 
(which is the allosteric pocket for class C receptors).
In our ligand identification campaign, we screened over 4000 compounds, including 
naturally occurring and synthetic small molecules and peptides, for activation of human 
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GPR88. Elevation of intracellular calcium concentrations was the functional readout 
in our screen. The G protein coupling specificity of GPR88 is unknown, so to obtain 
calcium responses we co-expressed the receptor with the chimeric G protein Gαqi5 or the 
promiscuous Gαq-family protein Gα16, thus forcing GPR88 to couple to the Gq pathway, 
regardless of the native coupling preference [16-18].
Materials and Methods 
Generation and characterization of HEK293s-hGPR88 cell lines
Construction of a hGPR88 - N-Flag - signal-sequence plasmid
Human GPR88 cDNA cloned in pcDNA 3.1+ (Neomycin) was bought from the cDNA 
Resource Center from the University of Missouri-Rolla. A modified influenza hemaglutinin 
signal sequence [19] and a Flag tag were inserted upstream of the receptor sequence. The 
~240 N-terminal bases of the GPR88 gene were amplified by PCR using a Signal sequence-
Flag tag sense primer and Expand High Fidelity polymerase (Roche). The sequences of the 
primers were: Sense: GCGAATTCCACCATGAAGACGATCATCGCCCTGAGCTACATCTTCTGC
CTGGTATTCGCCGACTACAAGGACGATGATGACGCCACCAACTCCTCCTCCACATCCACC; 
Reverse: GGACGACACGAGATAGATGACCATGCCGTT. In total 50 ng of matrix was used 
with 100 pmol of each primer in a total volume of 100 µl. An initial denaturation step of 
3 min at 94 °C was followed by 20 amplification cycles (30s 94 °C; 30s 55 °C; 20s 72 °C). A 
phenol-chloroform precipitation was carried out after which the product was taken up in 
10 mM Tris pH 7.4 / 1 mM EDTA. Then, 2 µg was digested with 20 IU of EcoRI and AgeI 
and the resulting product was inserted into the pcDNA3.1+ plasmid bearing the cDNA 
of GPR88 that was pre-digested with the same enzymes. The ligation was carried out 
with 50 ng linearized plasmid and 2 ng fragment in 10 µl of commercial buffer with 3 IU 
ligase (Biolabs) for 4h at 4 °C. The product was used to transform competent Escherichia 
Coli XLM Blue cells and the plasmid was isolated from an ampicillin-resistant colony. 
Sequencing confirmed that the plasmid contained the tagged human GPR88 sequence.
Generation of stable cell lines expressing hGPR88- Flag-signal sequence
Transfection of HEK293s cells
The day before transfection 2.5-4.106 human embryonic kidney (HEK) 293s cells were 
seeded in a 10 cm diameter cell culture plate. For transfection, 16 µl JetPEI transfection 
reagent (Polyplus transfection) in 500 µl NaCl 150 mM was added to a solution of 8 µg 
pcDNA3+/GPR88 in 500 µl NaCl 150 mM, and incubated for 15-30 min at RT. The empty 
vector pcDNA3 was used as a negative control. Fresh cell culture medium was added to 
the cells and 1 ml of the transfection mixture was added to each plate. To obtain a stable 
cell line, Geneticin 418 was added to the medium on day 4.
Cell lines and cell culture conditions
Three HEK293s cell lines from AstraZeneca R&D Montréal were used: HEK293s 
nontransfected cells, HEK293s stably expressing chimeric Gαqi5 and HEK293s stably 
expressing Gα16. Plasmids used for construction of these cell lines were pCEP-Gαqi5-HA 
from Molecular Devices and pcDNA3.1-Gα16 from AstraZeneca Montréal.
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Cells were grown at 37 °C and 5% CO2, in Dulbecco’s modified Eagle medium (DMEM), 
supplemented with 10% fetal calf serum (FCS), 1000 units/ml penicillin G and 1 mg/ml 
streptomycin. The HEK-Gαqi5 cells were grown in the presence of 300 µg/ml Hygromycin 
B and HEK-Gα16 cells were grown in the presence of 350 µg/ml Zeocin. Geneticin 418 
sulfate was used at a concentration of 500 µg/ml for selection of the cells stably expressing 
GPR88.
Enrichment of hGPR88-Flag expressing cells by fluorescent automated cell sorting 
(FACS)
Cells were detached using 10 mM EDTA and washed two times in PBS, followed by 30 min 
incubation on ice with the monoclonal antibody anti-Flag M2 (Sigma Aldrich) (1:20000 
in PBS 1% BSA, filter sterilized). Cells were washed two times with PBS 1% BSA and 
incubated 30 min on ice with the secondary antibody goat F(ab’)2 fragment antimouse 
IgG (H+L)-FITC (Beckman Coulter) (1:200 in PBS 1% BSA, filter sterilized). After two final 
washes in PBS the cells were diluted at 5.105 cells/ml in culture medium. Cell clumps were 
removed with a sterile 50 µm Filcon filter (Consul T.S.). Cells were sorted on a Becton 
Dickinson FACS DiVa using a 100 µm gauge. FITC-positive cells with fluorescence ≥ 1000 
units were deflected into tubes containing 0.5 ml culture medium.
Assessment of GPR88-Flag expression in HEK293s cell lines
Flow cytometric analysis
Preparation of the cells for flow cytometric analysis was performed as described for 
FACS, but not under sterile conditions. The amount of fixed FITC was analyzed on a 
Becton Dickinson FACS DiVa as described, or on a Becton Dickinson FACSCalibur using 
essentially the same settings. A total of 3.104 single cells were included in each analysis.
Immunocytochemistry
Cells were seeded in 6-well plates containing glass coverslips coated in poly-L-ornithine 
or poly-D-lysine at 2.105 cells per well. After 1-2 days cells were washed three times in 
PBS and fixed for 15-60 min with 4% PFA in PBS at room temperature. Cells were washed 
three times with PBS and incubated overnight at 4 °C with the monoclonal anti-Flag M2 
antibody (Sigma Aldrich) (1:20000 in PBS 1% BSA 0.1% Tween20). Cells were washed 
three times with PBS 0.1% Tween20. The glass slides were covered with the secondary 
antibody goat F(ab’)2 fragment antimouse IgG (H+L)-FITC (Beckman Coulter) (1:200 in 
PBS 1% BSA 0.1% Tween20). Alternatively, the secondary antibody goat anti mouse Alexa 
fluor 488 (1:800 in PBS 1% BSA 0.1% Tween20) was used. After two washes in PBS the cells 
were DAPI stained (1:10000 in PBS 5 min at RT). After final washing (3xPBS, 1xH2O) the 
glass slides were air dried and mounted on microscope slides using Mowiol. Alternatively 




Compound library screening for activation of GPR88
Calcium mobilization experiments using Fluorescent Imaging Plate Reader 
(FLIPR)
Cells were detached with Accutase (Innovative Cell Technologies) and resuspended in 
10 ml complete medium without selection agents. Cells were seeded in 384-well black, 
clear-bottom poly-D-lysine coated plates (Becton Dickinson BioCoat) at approximately 104 
cells/well in 50 µl, titrated to obtain a confluence of 80% the following day. Then, Fluo-4 
AM (Invitrogen) (8 µM) and Pluronic F-127 (Molecular Probes) (0.08%), both from DMSO 
stocks, were dissolved in the assay buffer (HBSS containing calcium and magnesium 
and 5 mM glucose (Wisent) with 0.1% BSA and 20 mM Hepes added fresh, pH 7.4). The 
final concentration of DMSO in the loading solution was 0.8%. Before loading, part of 
the medium was removed with an Embla 384 cell washer (Molecular Devices) so that 25 
µl residual medium was left in each well. Then, 25 µl loading buffer was added to each 
well using a Multidrop 384 (Thermo Scientific). The plates were incubated 1 h at 37 °C 
with 5% CO2. After the incubation period the cells were washed four times in assay buffer 
using the Embla cell washer, leaving 25 µl buffer per well after the wash protocol. Then 
the cells were allowed to rest at least 5 min at room temperature in the dark. The plates 
were read in a FLIPR384 system (Molecular Devices) using the following settings: pipettor 
height: 30 µl; dispense speed: 15 µl/s; fluid volume: 12.5 µl; exposure length: 0.4 s; filter #1 
(510-570 nm). The baseline was read for 10 seconds, and then 12.5 µl of the ligands (final 
concentration 1 µM) was automatically added to the cell plate. The DMSO concentration 
at the cells never exceeded 2%. The total reading time was 3 min. The data was analysed 
using the SoftMax Pro software (Molecular Devices).
Calcium mobilization experiments using Flexstation 3
The experiments were carried out essentially as for FLIPR with the following exceptions.
Cells were plated in 96-well black, clear-bottom poly-D-lysine coated plates (Becton 
Dickinson BioCoat) at about 5.104 cells/well in 200 µl. The assay buffer composition 
was HBSS (Sigma) with 0.1% BSA and 20 mM Hepes added fresh. The loading solution 
contained 4 µM Fluo-4 AM (Invitrogen) and 0.04% Pluronic F-127 (Molecular Probes) in 
a mixture of 50% assay buffer and 50% of the usual culture medium without selection 
antibiotics. Before loading, the medium was removed by decanting. Then, 100 µL loading 
buffer was added to each well using a multichannel pipette. After the incubation period the 
cells were washed three times in assay buffer (200 µl/well), and then 40 µl assay buffer was 
added per well. The plates were analyzed in a Flexstation 3 system (Molecular Devices). 
Fluo-4 was excited at 488 nm and the emission at 520 nm was detected. The ‘Flex’ reading 
mode was used and the detection sensitivity was set to ‘high’. The baseline was read 
during 25 s and then 20 µl of the ligands was automatically added to the selected wells of 
the cell plate (pipetting speed 1; pipette height 50 µl). For compounds cherry-picked from 
the compound plates this resulted in a final compound concentration of 1 µM.
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Compound collection
The compounds tested in the ligand identification campaign were stored at 3 µM in 
aqueous solution at -80 °C, in 96-well compound plates. Prior to the experiments four 
96 well plates were combined into one 384 well plate using a Biomek FX robot (Beckman 
Coulter). The compound libraries tested were the Sigma-RBI LOPAC640 TM ligand 
collection (640 compounds), the Prestwick Chemical Library (880 compounds), a library 
of endogenous and predicted peptides (1611 compounds) and the Jerini (JPT) RF-amide 
collection (1000 compounds), yielding a total of 4131 compounds.
Results
Generation and characterization of HEK293s-hGPR88 cell lines
Construction of a hGPR88 - N-Flag - signal-sequence plasmid
In order to facilitate immunostaining and membrane expression of GPR88 in HEK293s 
cell lines we inserted a Flag-tag and a modified influenza hemaglutinin signal sequence 
[19] upstream of the receptor sequence. The full GPR88 sequence was resistant to PCR 
amplification, so a cloning strategy was developed where only the 240 N-terminal bases 
of the GPR88 genes were amplified by PCR to insert the Flag-tag and signal sequence. 
Cloning of the product into pcDNA3.1+ bearing the cDNA of GPR88 yielded the correct 
plasmid as verified by digestion and sequencing.
Subcellular localization of transiently expressed GPR88
We verified by immunocytochemistry that hGPR88 with Flag tag and signal sequence was 
expressed on the plasma membrane in transiently transfected HEK293s cells. We used 
transient transfection with a Flag-tagged human delta opioid receptor (DOR-Flag) as a 
positive control. Cells transfected with GPR88-Signal-Flag and DOR-Flag showed both 
intracellular and membrane staining in about 50% of the cells 48 h after transfection (data 
not shown).
Generation of stable cell lines expressing hGPR88- Flag-signal sequence
Since the G protein coupling specificity of GPR88 is unknown, co-transfection with 
promiscuous Gα16 or with chimeric Gαqi5 was employed to facilitate coupling to the 


















GPR88 GPR88 G16 GPR88 Gqi5
Figure 1. Expression of GPR88-Flag in the three 
stable cell lines estimated by flow cytometric 
analysis of 30000 cells (N=2). Timepoint 0 
represents the values before FACS sorting. All 




calcium pathway. Native HEK293s cells and HEK293s cell lines stably expressing either 
Gα16 or Gαqi5 were transfected with the pcDNA3+/hGPR88/Flag/signal sequence plasmid. 
Control cell lines were generated by transfection with empty pcDNA3 vector. Four 
days after transfection the appropriate selection agents were added. Per cell line, twelve 
resistant colonies were isolated and stored, whereas all other resistant colonies (>100 per 
cell line) were pooled. Six weeks after transfection the expression level of GPR88-Flag in 
the resistant cell pools was determined by labeling with a primary anti-Flag antibody 
and a secondary antibody labeled with FITC, followed by flow cytometry. At the first 
analysis the transfected HEK293s and HEK293s Gαqi5 cell lines had approximately 5% 
FITC-positive cells, whereas the transfected HEK293s Gα16 cell line had 25% FITC-positive 
cells.
Enrichment of GPR88-Flag expressing cells by fluorescent automated cell sorting 
In order to obtain higher GPR88 expression, FITC positive cells were selected by fluorescent 
automated cell sorting (FACS). HEK cells transfected with the empty vector showed 
fluorescence below 800 units, so cells with fluorescence above 1000 units were considered 
FITC-positive. The negative control cell lines HEK293s, HEK293s-Gα16 and HEK293s-Gαqi5 
Figure 2. Immunocytochemical staining 
with an anti-Flag antibody in order to 
demonstrate expression of GPR88-Flag at 
the cell membrane of HEK293 cells. The 
same staining was performed on control 




Gqi5 pcDNA3 Gqi5 hGPR88-NFlag
G16 hGPR88-NFlag
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transfected with pcDNA3 were also passed through FACS as a mock-sorting.
The enriched HEK-Gαqi5-GPR88 cells lost expression of GPR88 in the first week after 
sorting. We therefore analyzed the 12 clones isolated after the Geneticin selection, of which 
two had a moderate percentage of GPR88 expressing cells (14 and 17% FITC positives) 
and one a low percentage (0.5%). The three positive colonies were pooled and the positive 
cells were isolated by FACS sorting.
The stability of the GPR88-Flag expression over time was monitored by flow cytometric 
analysis (figure 1). The expression of GPR88 was fairly stable, although the percentage of 
expressing cells diminished in the Gαqi5 GPR88 cell lines.
Monitoring of GPR88-Flag expression by immunocytochemistry
The expression of GPR88-Flag over time was also assessed by immunocytochemistry 
using a primary anti-Flag antibody and a fluorescent secondary antibody. Three weeks 
after FACS enrichment, the percentage of positive cells was estimated at 45%, 50% and 
40% for the HEK cells containing GPR88 alone, GPR88-G16, and GPR88-Gqi5, respectively. 
Prior to the start of experiments on a new batch of cells the expression level of GPR88-Flag 
was checked by immunocytochemistry, an example of which is shown in figure 2. The 
expression levels were checked again at the end of each series of experiments. Typically, 
membrane staining was observed in approximately 50% of the cells stably transfected 
with GPR88-Flag. In some cases, especially in the cells transfected with Gαqi5, a strong 
signal was observed around the nucleus.
Compound library screening for activation of GPR88
We performed a ligand identification campaign for GPR88. The compounds we tested in 
the screen were stored in ready-for-use compound plates at -80°C. In total, 4131 compounds 
were tested at least in duplicate at a final concentration of 1 µM. The compound libraries 
we tested were the Sigma-RBI LOPAC640 TM ligand collection, the Prestwick Chemical 
Library, an in-house library of endogenous and predicted peptides and the Jerini (JPT) 
RF-amide collection.
Calcium mobilization primary screen using FLIPR
The collection of 4131 compounds was tested for the capability of provoking a calcium 
response through activation of GPR88 in native HEK cells or cells co-expressing Gα16 
or Gαqi5. Corresponding cell lines transfected with empty vector pcDNA3 were used as 
negative controls. The experiments were conducted on attached cells in 384 well plates, 
using a FLIPR system (Molecular Devices) for detection of the fluorescent signal of the 
calcium indicator Fluo-4, and for robotic addition of the test compounds. The DMSO 
concentration never exceeded 2% and controls showed that this amount did not change the 
fluorescence signal. The fluorescence maxima and the shape of the curves were examined 
by eye to conclude whether GPCR activation took place. A maximum fluorescence 
below 1000 fluorescence counts was considered background. On each compound plate 
positive and negative (buffer only) controls were included. As positive controls, the 
agonists endothelin-1, vasoactive intestinal protein (VIP) and pituitary adenylate cyclase-
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activating peptide (PACAP), capable of activating endogenous HEK293s GPCRs, were 
used. All compounds were tested in two independent single-point experiments at a final 
concentration of 1 µM.
The calcium responses obtained from potential hits were low to moderate. Out of 71 
calcium responses to the most promising compounds only 5 responses were above 3000 
fluorescence counts, and 47 reached their maximum below 2000 fluorescence counts. Some 
compounds provoked calcium responses in the cell line HEK293s-Gαqi5-GPR88, some in 
the cell line HEK293s-Gα16-GPR88 and yet others in the cell line HEK293s-GPR88, whereas 
several compounds stimulated more than one cell line. Only the hits peptide beta-12, 




































GPR88 Gqi5GPR88 G16GPR88 GPR88 Gqi5
Figure 4. A. Calcium mobilization responses to papaverine in HEK cells expressing GPR88-Flag. This experiment 
was performed with compound solution cherry-picked from the screening plates (final concentration 1 µM). The 
arrow indicates the time of compound addition. B. Dose-response curves of papaverine from calcium mobilization 
assays. Mean data from two independent experiments is shown. The compounds were also tested on nontransfected 




















































































































































































































































































































































































































































































Figure 3. Maximum fluorescence responses in a calcium mobilization assay for 46 hits from the primary screen. The 
compound solutions were cherry-picked from the screening plates (final concentration 1 µM). Average values (± 
SEM) (N≥2) are shown. The arrows indicate compounds yielding a robust response in this assay.
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chelidonine monohydrate (+), chloroquine diphosphate, clidinium bromide and PWGRF 
could be confirmed in two independent experiments. When the average responses over 
the two experiments were taken into account, 26 compounds qualified as hits. Several 
other compounds that provoked a robust calcium response, but only in one of the two 
experiments were also selected for further study, bringing the total to 46 hits.
Hit validation assays
The compounds that were selected from the screen performed on FLIPR were entered 
in a secondary screening round that was performed in a similar manner but using a 
Flexstation 3 (Molecular Devices). First, the ideal conditions for the calcium experiments 
at the Flexstation 3 were determined. In order to keep the compound use as low as possible 
a working volume of 60 µl was selected instead of the recommended 150 µl, which did not 
affect the reproducibility and the signal-to-noise ratio.
In total, 46 promising compounds were tested twice at the Flexstation 3 on the three cell lines 
expressing GPR88. Figure 3 shows the maximum responses that were observed in these 
experiments. Most compounds did not provoke a calcium response. Small responses were 
seen in one experiment for papaverine (Figure 4A) and mometasone furoate and moderate 
responses were seen for peptide beta-12 and the peptide ASDFRTVCNNVIPKSIPDI. The 
responses to peptide beta-12 administration could not be reproduced in two further 
experiments using this compound from the same and a different compound plate. Fresh 
solutions were prepared for testing mometasone furoate, papaverine hydrochloride and 
the peptide ASDFRTVCNNVIPKSIPDI at higher concentrations. Mometasone furoate and 
papaverine were tested at ten concentrations ranging between 15 nM and 200 µM, and the 
peptide was tested at 1 and 10 µM (N=2). No responses were seen to either concentration 
of ASDFRTVCNNVIPKSIPDI. For mometasone furoate small responses were observed 
in all GPR88 expressing cell lines at the highest compound concentration (200 µM), but 
the responses were also observed in the HEK293s pcDNA3 cells and no dose-response 
curve could be obtained. For papaverine, a dose-response curve was observed in the cell 
lines containing Gαqi5 (figure 4B) and Gα16 (not shown), but the small responses observed 
were similar in the pcDNA3-transfected cells. Therefore we must conclude that no GPR88-
mediated responses could be demonstrated.
GABA
B
 allosteric modulators as putative GPR88 ligands
As described in the introduction, phylogenetic analysis suggests that ligands for GPR88 
might bear a certain resemblance to allosteric modulators of the GABAB receptor. 
Therefore, we tested three commercially available compounds that are known to modulate 
GABAB (CGP7930, CGP13501 and GS39783) on the GPR88 expressing cell lines, using the 
Flexstation 3. The compounds did not provoke a calcium response, even at a concentration 
of 10 µM (data not shown).
Discussion
Despite a decade of academic and private research efforts, GPR88 remains an orphan 
receptor with no known synthetic or endogenous ligands. The only hint at compounds 
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activating GPR88 was found in the patent literature, where ligands for GPR84 were 
described with limited selectivity towards this receptor over GPR88 [20]. The ligand 
identification screen we performed yielded 46 hits out of 4131 compounds tested, but 
none of the hits could be confirmed as a GPR88 agonist.
Our failure to identify an agonist for GPR88 may be due to the limited number of 
compounds we tested. Compound collections of tens to hundreds of thousands in size 
are no exception [21], and Johnson and coworkers even screened over a million molecules 
[22]. Major GPCR ligand classes were represented in our compound collection but 
GPR88 may display specific binding to a ligand or ligand class that was not included. It 
is possible that this receptor, which does not show high sequence similarity to any GPCR 
subfamily [23-25], binds to an unusual or unknown signaling molecule. Testing at a higher 
concentration could also increase the chances of identifying a ligand. Even a low potency 
agonist could give valuable clues regarding downstream signaling, and at the same time 
serve as a starting point in the search for a more potent ligand. Furthermore, some GPCRs 
may not bind with a high affinity to their endogenous ligands, as seems to be the case 
for the recently deorphanized hydroxy-carboxylic acid receptor family [26]. Despite the 
added cost, screening at a higher concentration may be worth it.
A major difficulty in deorphanization screens is the inherent absence of real positive control 
conditions to test the detection of receptor activation by an agonist. Accessory proteins 
potentially required for GPR88 function could be absent in HEK293s cells. Although we 
confirmed that the receptor was expressed at the membrane and that the signals from 
endogenous GPCRs on HEK cells were detected correctly, it is also conceivable that our 
screening methods were not ideal for the detection of GPR88 activation. We cast our net 
wider by performing a second screen, where the read-out was a membrane depolarization 
instead of a change in intracellular calcium concentration. This screen, which is not 
further described here, yielded 77 hits of which none could be confirmed in validation 
experiments.
GPR88 so far resisted attempts at deorphanization, not only by us but by several other 
groups as well, judging from personal communications and the website of the Michael J. 
Fox Foundation, which awarded a grant for exploring GPR88 as a target for the treatment 
of Parkinson’s disease in 2008, which did not yield any ligands (http://www.michaeljfox.
org/research_MJFFfundingPortfolio_searchableAwardedGrants_3.cfm?ID=432). It could 
be that GPR88 is one of the ‘real’ orphans that do not have an endogenous ligand, nor 
need one to function. The physiological relevance of such a GPCR could be as a chaperone 
for another receptor, similar to GABAB2 [27] or as a constitutively signaling protein, like 
GPR3 (GPR12), a Gs-coupled orphan receptor with an apparently ligand-independent role 
in the female reproductive system [28-29]. 
Another example of an orphan receptor functioning independently from a ligand is 
GPR50 dimerizing with the MT1 and MT2 melatonin receptors, which prevents melatonin 
signaling in the case of MT1 [30]. In fact, unpublished data from R. Massart, P. Sokoloff 
et al. (briefly summarized in this editorial: http://scielo.isciii.es/pdf/ejpen/v24n1/editorial.
pdf) suggest an unusual and possibly ligand-independent function for GPR88: the 
receptor may have a role as an intranuclear, chromatin-associated protein modulating 
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developmental nuclear transportation in differentiating cortical neurons. However, the 
same group also reported localization of GPR88 outside of the nucleus in mature striatal 
medium spiny neurons, preferentially in post-synaptic domains [13].
A first step towards future deorphanization of GPR88 could be the elucidation of its 
downstream signaling. Receptor overexpression or mutagenesis could be used to trigger 
enhanced basal or constitutive signaling. Further screening could then be limited to one 
GPR88-expressing cell line and one assay only, while we screened on three cell lines in two 
assays. Screening in a striatal, neuronal cell line [see for example 31, 32] expressing GPR88 
naturally would further increase the chances of success, since all necessary machinery for 
receptor signaling is presumably expressed in these cells.
In GPCR deorphanization, the identification of the first ligand is an enormous hurdle. 
When this is overcome, further ligands can be identified with relative ease, and the role 
of the receptor in (patho-)physiology can be explored in more detail. In my opinion, new 
ligands for orphan GPCRs, even if they have a low potency, should be made public as 
soon as possible after discovery. This would be in the interest of the scientific community 
as a whole, and the pharmaceutical industry in particular.
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For the preparation of this thesis a ligand-based approach was used to investigate three 
different G protein-coupled receptors from class A, that are all (potentially) important 
drug targets. The most well characterized is the adenosine A3 receptor, which was 
discovered by homology cloning in 1992 and readily recognized as an adenosine receptor 
[1]. The adenosine A3 receptor has received attention as a potential target for anti-cancer 
medication. Approximately a decade later, the second receptor of interest, GPR109A, 
was deorphanized by pairing to endogenous ligand 3-hydroxybutyrate, prompting 
re-naming as the hydroxy carboxylic acid receptor 2 (HCA2). This receptor is a target 
for anti-atherosclerotic drugs. The focus of the last research chapter is on the orphan 
receptor GPR88, which is still a mystery in many aspects, but it may play a role in the 
pathophysiology of the brain.
The hydroxy-carboxylic acid receptor 2 (HCA
2
)
In chapter 2, an overview is presented of the literature on the 3-hydroxybuyrate receptor 
HCA2 and the two other members of the subfamily, namely HCA1 (for lactate) and 
HCA3 (for β-oxydation intermediates). As the target of nicotinic acid, HCA2 has been 
most widely studied, although HCA1 and HCA3 may present interesting future drug 
targets, for instance for the treatment of obesity and dyslipidemia, respectively. After 
their deorphanization, the physiological roles of the HCA receptors on adipocytes are 
now coming into focus: HCA1 boosts the antilipolytic effect of insulin, and HCA2 and 
HCA3 inhibit excessive lipolysis during starvation. Especially for HCA2, but also HCA3, 
many synthetic agonists have been developed, with the aim of introducing a new and 
improved successor for nicotinic acid in the clinic. Hopes were high for MK-0354, a biased 
HCA2 agonists with very low ERK1/2 activation in vitro and almost no flushing in vivo, 
but in phase II clinical trials the lipid modification targets were not reached [2]. Another 
HCA2 agonist, MK-1903, followed a similar path. However, new findings concerning the 
mechanism of action of nicotinic acid beg the question whether other clinical endpoints 
are needed for clinical trials of HCA2 agonists. A significant part of the anti-atherosclerotic 
effect of nicotinic acid appears to be mediated by activation of HCA2 on immune cells, 
decreasing endothelial dysfunction and vascular inflammation, and increasing cholesterol 
efflux from plaque macrophages [3]. Therefore, instead of a complete focus on lipid 
modification, more attention should be paid to the anti-inflammatory effects of new HCA2 
agonists in (pre)clinical drug testing.
The skin flushing side-effect of nicotinic acid was recently shown to be partly mediated by 
HCA2 on keratinocytes (through COX-2 and PGE2), next to the well-known involvement 
of Langerhans cells [4]. Better understanding of flushing could lead to better prevention 
in the future, although advances have already been made. The use of extended-release 
formulations of nicotinic acid [5] and combination with the DP1 prostaglandin receptor 
antagonist laropiprant [6] have significantly reduced the occurrence and severity of 
nicotinic acid-induced flushing.
In chapter 3, the in vitro and in vivo effects of two partial agonists for HCA2, both pyrazole 
compounds, are presented. We have shown that these ligands have lower relative potency 
for ERK1/2 phosphorylation compared to nicotinic acid, a property that has been linked 
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to decreased skin flushing [7]. In mice, we confirmed that the pyrazoles did not increase 
cutaneous temperature. Although less precise than laser doppler velocimetry, we believe 
surface temperature recording is a good alternative for measuring blood flow in the skin, 
and thus flushing. The absence of a skin flushing response may be due to the moderate 
shift in the relative potencies on the G protein pathway and the ERK phosphorylation 
pathway, to the reduced intrinsic efficacy of these ligands, or to a combination of these 
two factors. Nicotinic acid and both partial agonists significantly reduced plasma VLDL 
concentrations. In the case of nicotinic acid, a 2-fold reduction of hormone-sensitive 
lipase (HSL) and adipose triglyceride lipase (ATGL) in the adipose tissue seemed mainly 
responsible for this effect. Interestingly, the two pyrazole compounds did not affect gene 
expression in the adipose tissue. Instead, these compounds triggered a >40% reduction of 
apolipoprotein B (ApoB) in the liver, which indicates decreased hepatic VLDL production. 
The reduced ApoB expression could be downstream from suppressed hepatic PGC-1β 
expression, which has been previously reported as an effect of nicotinic acid [8]. No effect 
was seen on HDL, but this is expected in wildtype mice that naturally lack a homolog to 
the human cholesterylester transfer protein (CETP), responsible for transfer of cholesterol 
from HDL to less dense particles [9].
Chapters 4 and 5 describe medicinal chemistry programs in which potential new ligands 
for HCA2 were devised, synthetized and characterized in our laboratory. In chapter 4 a 
series of propenoic acid derivatives and their affinity for HCA2 is presented. Two agonists 
of this compound class, monomethyl- and monoethyl-fumarate (MMF and MEF), are used 
in the clinic as anti-psoriatic drugs [10]. We confirmed binding of these compounds and 
of cinnamic acid to HCA2, and describe synthesis and affinity testing of a series of fumaric 
acid esters and amides, as well as cinnamic acid derivatives. The binding pocket for these 
ligands seems very restricted: in a series of 55 related compounds, only 15 had a Ki of ≤10 
μM, and none could be identified with higher affinity than MMF and MEF. On the basis 
of molecular modeling and analysis of the structure-activity relationships, we propose a 
pharmacophore featuring a planar trans-propenoic acid with a maximum length of 8 Å, 
with larger substituents oriented out-of-plane.
Chapter 5 revolves around a very different type of ligands, the pyrazolopyrimidines, which 
are much larger and bind at an allosteric site on the HCA2 receptor protein. Starting from 
a previously published ligand series [11], we prepared a number of novel compounds and 
characterized them in radioligand binding and functional assays. Several compounds were 
potent and efficacious agonists on HCA2 when tested alone, even matching nicotinic acid’s 
potency, while at the same time enhancing the potency (up to 20-fold) and/or efficacy (up 
to +50%) of nicotinic acid when simultaneously present in the assay. We observed that the 
agonistic and potency-enhancing properties of the pyrazolopyrimidines were correlated, 
suggesting that the ability to stabilize an active receptor conformation contributed to 
the modulating properties of these ligands. Of special interest is our finding that some 
derivatives markedly enhance the efficacy and potency of the endogenous HCA2 ligand 









In chapter 6, we report that the naturally occurring nucleosides N6-(2-isopentenyl)-
adenosine (IPA) and racemic zeatin riboside are selective human A3R ligands with affinities 
in the high nanomolar range, which is comparable with the affinity of adenosine. IPA also 
bound to the rat A3R which good affinity. Both ligands could inhibit forskolin-induced 
cAMP formation with micromolar potency, and in the case of IPA we showed that an A3R 
antagonist could block this effect. IPA was previously reported to inhibit tumor growth, 
but the A3R was not implicated in this effect until now. We observed strong and similar 
anti-proliferative effects of IPA and reference A3R agonist Cl-IB-MECA in two tumor 
cell lines. At low concentrations, the effect of IPA could be blocked by a selective A3R 
antagonist, but at higher concentrations this was not the case. The anti-proliferative effect 
at higher concentrations of IPA seems to be independent of A3R, which was previously 
observed for high concentrations of other A3R agonists, for example for Cl-IB-MECA [12].
The existence of an additional endogenous ligand for A3R, next to adenosine, with 
protective anti-cancer properties, was previously predicted [13]. Although IPA could fit 
this profile, we were unable to detect the ligand in fresh rat muscle using HPLC analysis. 
Thus, no definite proof could be found for a role of IPA as an endogenous agonist for A3R.
Orphan receptor GPR88
Chapter 7 focuses on GPR88, which is one of the dozens of G protein-coupled receptors 
for which no ligand or function is known to date. Analysis of its expression pattern 
and changes in expression levels, as well as the phenotype of a mouse model lacking 
the receptor, suggest that GPR88 may be implicated in several diseases including 
schizophrenia, depression and bipolar disorder. We attempted to identify a ligand for this 
receptor by testing a library of 4131 small molecules and naturally occurring peptides, 
using changes in intracellular calcium levels as the readout. In native HEK293 cells, 
GPR88 may stimulate the calcium pathway via Gαq, but since the coupling preference of 
the receptor is unknown, cell lines co-expressing chimeric Gαqi5 or Gα16 were also used 
(in case of natural Gi or Gs coupling, respectively). Our primary screen, performed using 
the Fluorescent Imaging Platereader (FLIPR) in 384-well format, yielded 46 hits, with 
responses in all three cell lines but with poor reproducibility. In validation assays, dose-
response curves could only be obtained for papaverine, but these seemed independent 
of GPR88, since calcium mobilization was also observed in control cell lines lacking the 
receptor. Thus, our efforts mainly served to confirm the challenging nature of receptor 
deorphanization programs.
Future perspectives
G protein-coupled receptors have become an important field of study within the life 
sciences. We now know that they make up the largest gene family in our genome, and are 
prominently involved in most major physiological processes in the body [14]. Since their 
discovery, new concepts have regularly emerged that refined our understanding of this 
fascinating protein family in general, or of specific receptors. Recent advances include, 
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but are not limited to, structural data on a number of receptors (reviewed by [15]), the 
realization that GPCRs function not only as receptors for transmitters, taste and odorants, 
but also as sensors for nutrients and intermediates of metabolism [16-18], and receptor-
ligand pairing of a number of orphan receptors, including the three hydroxy-carboxylic 
acid receptors (reviewed by [19]). However, many unresolved questions remain in 
GPCR research. The current thesis focuses on three receptors: the hydroxy-carboxylic 
acid receptor 2 (HCA2) (chapters 2-5), the adenosine A3 receptor (chapter 6), and orphan 
receptor GPR88 (chapter 7). In this section I will discuss the open questions regarding 
these 3 receptors and possible routes towards their resolution. Some general remarks 
regarding the future of GPCR research will also be made. 
Hydroxy-carboxylic acid receptors
All three hydroxy-carboxylic acid receptors have been deorphanized in the last few years 
[20-23]. It has been proposed that their roles in physiology are the conservation of fat stores 
during periods of starvation (HCA2 and HCA3), and under influence of insulin (HCA1). In 
the case of HCA2, the negative feedback loop which is formed when 3-hydroxy butyrate 
counteracts its own production by activating HCA2, thus reducing lipolysis, may also be 
important as a break on the levels of acidifying ketone bodies in the blood. In primates 
HCA3 may also play a role here, since it also forms a negative feedback loop on lipolysis 
with its ligands produced by β-oxydation of free fatty acid [20]. As yet, the feedback 
mechanism I propose has not been verified. It is well known that insulin keeps the plasma 
levels of ketone bodies in check, and even if the HCA2 loop has a role here as well, it 
is apparently, in certain cases, not sufficient to prevent diabetic ketoacidosis when the 
insulin loop is non-functional. However, 3-hydroxy butyrate may not be a full agonist for 
HCA2 (chapter 5), and thus have a limited effect even at high concentrations. Full agonists 
or allosteric enhancers of HCA2 or HCA3 may have therapeutic potential in acidosis. Acute 
nicotinic acid administration also diminishes gluconeogenesis in the liver [24], which 
would be of further benefit to counteract the hyperglycaemia in diabetic ketoacidosis. In 
addition, a recent publication suggests that elevation of 3-hydroxy butyrate in diabetic 
patients, with concomitant upregulation of HCA2 expression, is a mechanism to protect 
the tissues from the damaging effects of the inflammation associated with the disease 
[25]. Even in absence of ketoacidosis, HCA2 agonists may thus be valuable drugs in the 
treatment of diabetes. However, it has also been reported that nicotinic acid may decrease 
insulin sensitivity [26] and promote the onset of diabetes [27] so more research is needed 
into the role of HCA2 and its ligands in this disease.
In intestine and skin, HCA2 appears to prevent excessive inflammation and tumor 
formation [28-29]. In the intestine, the major ligand is likely not 3-hydroxy butyrate, but 
non-hydroxylated butyrate produced by bacterial fermentation. By comparing potency 
[23] and local concentration from the literature [30], it seems that pentanoate and 
hexanoate are also likely to activate HCA2 in the intestine, but no published experimental 
work proves this. Although ligands derived from nutrition and bacterial fermentation in 
the intestine are not produced by the body itself, they could still be regarded endogenous 
ligands of GPCRs in the intestinal wall. Functionally they could be compared to the 
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receptors involved in taste, smell and vision, which also detect compounds and signals 
from the outside world. Several other GPCRs, for example the sweet taste receptor T1R2/
T1R3, have already been implicated in nutrient sensing in the bowel [31]. 
In certain inflammatory diseases, like psoriasis and multiple sclerosis, HCA2 has also 
been implicated. Psoriasis is already treated with topical application of HCA2 agonist 
monomethylfumarate (MMF) [32], and a phase III trial has recently been favourably 
concluded with oral dimethylfumarate (BG-12) for multiple sclerosis (MS) [33-34]. In vivo, 
dimethylfumarate is rapidly metabolized to HCA2 agonist MMF, and the side effect profile 
of BG-12, featuring mainly flushing and gastrointestinal complaints, is typical for a HCA2 
agonist. Inhibition of nuclear translocation of NF-κB has been reported as the mechanism 
of action, and this is a known downstream effect of HCA2 activation [29]. However, it 
has not been clearly demonstrated if HCA2 is a key player in the therapeutic action of 
fumarates, so experimental confirmation in an animal model lacking HCA2 would be 
valuable. Nicotinic acid itself has also been proposed as a potential anti-inflammatory 
therapy for MS [35], as well as sepsis [36], chronic renal failure [37] and arthritis [38]. 
For such acutely life-threatening or debilitating indications, the harmless side effect of 
skin flushing is less likely to affect patient compliance, and the side effect may be more 
acceptable if more efficacious or safer treatments are not available.
Adenosine A
3
 receptor and isopentenyl adenosine
We identified N6-isopentenyl-adenosine (IPA) as a ligand for the adenosine A3 receptor 
(A3R). We also investigated whether IPA is an endogenous ligand for the A3R. No evidence 
could be found for significant concentrations of IPA in muscle tissue, but it is still a 
possibility that IPA binds to the A3R in certain (patho-) physiological conditions. The idea 
that one receptor can have more than one orthosteric ligand is well-known, especially 
when synthetic ligands are considered. In recent deorphanization efforts, receptors have 
regularly been found to have multiple endogenous ligands, that may or may not be 
chemically related (for example GPR17 with uracil nucleotides and cysteinyl-leukotrienes 
[39], and several receptors binding a range of free fatty acids (for a review see [40]). In some 
cases this could be a sign of erroneous receptor-ligand pairing (for example for GPR65/
TDAG8, a proton sensor but not lysophosphatidylcholine receptor [41]), but in other cases 
the double or multiple pairing may be correct. It would be interesting to subject receptors 
that have known ligands (discovered by classical pharmacology or early screens) to a 
state-of-the-art receptor deorphanization screen. The possibility of additional endogenous 
ligands should also be kept in mind when investigating unexplained receptor activation or 
transmitter effects. Examples of GPCRs that were ‘partial orphans’ are the P2Y1 receptor 
which binds not only ADP but also ADP ribose [42] and β-NAD [43], and the CXCR2 
receptor that binds 3 chemokines but was later shown to bind macrophage-derived lectin 
MNCF as well [44]. For adenosine receptors it was observed that endogenous adenosine 
concentrations could not always account for the activation levels [45-46], thus raising the 
question of alternative endogenous ligands. In the case of the A3R, it has already been 
shown that it binds to inosine next to adenosine [47].
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GPR88 and other orphan GPCRs
Since no endogenous ligand is known for GPR88, it is possible that this receptor functions 
independently from a ligand. Even if this is the case, the receptor remains a potential 
therapeutic target. Drugs targeting a ligand-less receptor could aim at changing its 
expression level, at blocking its interaction with other proteins in the cell, or synthetic 
ligands could be devised just as for a liganded receptor, even in absence of an endogenous 
ligand. For example, if a lower expression level or loss-of-function of GPR88 could be 
demonstrated in patients with schizophrenia, in parallel to the ‘schizophrenic’ GPR88 
knock-out mice [48], treatment with synthetic GPR88 agonists or GPR88 up-regulating 
drugs could be effective. 
The reported similarity of the GPR88 binding pocket to the class C glutamate and 
GABAB receptor binding pockets [49] can be a starting point for the identification of a 
synthetic GPR88 ligand. An in silico prediction of GPR88 ligands (thesis J.K. Bray 2010 
[50]) identified the lipids FFA, LPA and S1P as potential ligands. Functional or binding 
assays either confirming or refuting this prediction have not been reported. In the patent 
literature, ligands for medium-chain fatty acid receptor GPR84 were described with limited 
selectivity towards this receptor over GPR88 (see table 1) [51]. From the text it could be 
deduced that these ligands have a potency on GPR88 between 10 and 100 μM (compounds 
2 and 3), or between 100 μM and 1 mM (compound 1), although this is not clearly stated. 
The reported potencies on GPR84 are in the nanomolar range, so these ligands are clearly 
not selective GPR88 ligands, but if their action on GPR88 were confirmed, they could be a 
starting point for further ligand optimization.
Ligand pairing of GPR88 and the other remaining orphan receptors will be a challenging 
task. A promising technique that may increase the chances of success is the use of a label-
free biosensor [52]. When this is used as the screening assay, no knowledge is needed 
of the downstream coupling of the orphan receptor, because any change in the cells is 















Table 1. Ligands with (high) micromolar potency at GPR88, next to nanomolar potency at GPR84. Adapted from (WO2007027661).
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for constitutively active orphans, because binding of an agonist may activate a completely 
different pathway. Another advantage of label-free assays is the high sensitivity, which 
facilitates the use of a cell line endogenously expressing the GPCR of interest [54], instead 
of using heterologous receptor expression, ensuring that all components necessary for 
receptor function are present, next to the native receptor. 
Final note
The work presented in this thesis revolves around the identification and characterization 
of novel ligands for G protein-coupled receptors: small molecule (partial) agonists and 
ago-allosteric modulators for HCA2, naturally occurring nucleosides for A3R, and a wide 
medium-throughput screen at GPR88. The model of lock and key, one receptor plus 
one ligand, opening the door to the same pathway every time, is too simple for GPCR 
reality. The receptor could be seen as a magical door, with multiple locks (orthosteric 
and allosteric sites), where different keys (ligands) in the same lock can open the door to 
different pathways, and where simultaneously inserting keys in multiple locks gives even 
more possible outcomes. In the body, a plethora of compounds is present at the receptor, 
and if there is sufficient affinity between receptor and ligand, binding will occur, possibly 
followed by an effect. The expectation that the physiological role of a GPCR is mainly 
determined by its interaction with a single ligand, may thus be somewhat simplistic. Even 
for receptors that are not orphans anymore, additional endogenous ligands may still be 
found. The interest in receptor deorphanization has prompted the development of highly 
sophisticated screening methods, and it could be profitable to use them on non-orphan 
receptors as well. Even though GPCRs can be considered established drug targets, novel 
concepts, such as those presented in this thesis, are needed to unravel their function in 
physiology, and to optimise their exploitation in medicine.
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In this thesis, several orthosteric and allosteric agonists are presented for the newly dis-
covered hydroxy-carboxylic acid (HCA) receptor 2, and their in vivo activity or in vitro 
structure-activity relationships are described. The literature on HCA receptors was also 
thoroughly reviewed, providing some insight into the future of this receptor family as 
drug targets. The anti-cancer drug N6-(2-isopentenyl)adenosine (IPA) was shown to be a 
specific ligand for the adenosine A3 receptor, and its antiproliferative effect seems to be 
mediated by this receptor at low concentrations. A ligand discovery screen for orphan 
receptor GPR88 was performed, in which over 4000 compounds were tested. 
Most G protein-coupled receptors (GPCRs) can function only in concord with their (en-
dogenous) ligand(s). When the ligand concentrations are disturbed, or when the recep-
tor has a defect that precludes ligand-dependent activation or signaling, correct receptor 
function becomes impossible, and often this causes a disease. Knowing which endogenous 
ligand binds to a GPCR in the body is therefore considered essential for understanding 
its function. On the other hand, synthetic ligands for GPCRs can be highly effective drugs 
for correcting a pathophysiological imbalance. This thesis is about three receptors, the 
hydroxy-carboxylic acid receptor 2 (HCA2), the adenosine A3 receptor, and GPR88, and 
the quest for ligands that may influence these proteins in the body, either naturally or as 
drugs.
In chapter 1, GPCRs are introduced, and special attention is given to ‘orphan’ GPCRs, and 
the research focusing on the identification of their endogenous ligands. GPR88 is still an 
orphan receptor today, whereas the HCA receptors were deorphanized recently.
Chapter 2 is a review of our current knowledge on HCA receptors 1, 2 and 3, with spe-
cial attention for HCA2 as the receptor activated by the anti-atherosclerosis drug nicotinic 
acid. These three receptors were deorphanized in recent years as the receptors for lactate, 
3-hydroxybutyrate and β-oxidation intermediates like 3-hydroxyoctanoate. Their physi-
ological roles are most likely the fine-tuning of free fatty acid release from the adipose 
tissue (lipolysis) in conditions of food shortage (HCA2 and HCA3) or abundance (HCA1). 
The importance of HCA2 receptor activation for the therapeutic effects of nicotinic acid 
is still under discussion. Anti-inflammatory effects of HCA2 agonists have been found in 
multiple studies, and may be of relevance to other diseases like multiple sclerosis. 
In chapter 3, in vitro and in vivo studies into the pharmacological effects of two partial 
agonists for HCA2, compared to nicotinic acid, are described. These partial agonists of the 
pyrazole class, LUF6281 and LUF6283, were shown to have affinities of 3 µM and 0.55 
µM for HCA2. In [35S]-GTPγS functional studies, the rank order of potency was nicotinic 
acid>LUF6283>LUF6281, and the efficacies of the partial agonists were ~75% for LUF6283 
and 50% for LUF6281. The partial agonists, like nicotinic acid, were more potent in an ERK 
1/2-phosphorylation assay, but the EC50 ratio [35S]-GTPγS/pERK was 2-3x higher for nico-
tinic acid. In mice, the pyrazoles reduced VLDL levels to a similar extent as nicotinic acid, 
but these compounds did not elicit a flushing response as measured by skin temperature 
increase. Whereas nicotinic acid halved the expression of pro-lipolytic enzymes HSL and 
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ATGL in the adipose tissue, LUF6281 and LUF6283 did not affect their expression levels. 
On the other hand, the pyrazoles increased the expression of ApoB in the liver by ~40%. 
These findings show that LUF6281 and LUF6283, although activating the same receptor as 
nicotinic acid, have different in vivo effects, retaining the lipid-lowering properties, while 
the flushing effect was not detected.
In chapters 4 and 5, the identification and in vitro characterization of new ligands for 
HCA2 is described. Chapter 4 focuses on derivatives of trans-propenoic acid, which are 
related to the anti-psoriasis drug monomethylfumarate. In a series of cinnamic acid de-
rivatives and fumaric acid esters and amides, ligands with affinities in the high nanomolar 
to high micromolar range were indentified. The binding pocket seemed rather restricted, 
and trans-cinnamic acid was the longest planar ligand. Taking into account the structure-
activity relationships (SAR) of this compound series, molecular modeling suggests a pla-
nar trans-propenoic acid pharmacophore of 8 Å in length, where any larger substituents 
may only be oriented out-of-plane.
In chapter 5 ligands for the allosteric binding site of HCA2 are explored using both func-
tional and radioligand binding assays. Several compounds were found to be positive 
allosteric enhancers of HCA2 activation by nicotinic acid, and in addition most of the 
modulators were (allosteric) agonists when tested alone. Several different parameters for 
ago-allosteric action were used to reveal the ligand texture and the multi-dimensional 
SAR. Since allosteric modulation is dependent on the orthosteric ligand that is used, we 
also investigated the enhancing properties of several compounds with regard to the en-
dogenous HCA2 ligand 3-hydroxybutyrate. Interestingly, several pyrazolopyrimidine lig-
ands were found to increase the efficacy of 3-hydroxybutyrate and enhance its potency up 
to 10-fold.
Chapter 6 describes the discovery that the naturally occurring nucleosides N6-(2-isopente-
nyl)adenosine (IPA) and zeatin riboside are selective ligands for the human adenosine A3 
receptor (A3R), with affinities of 159 and 649 nM, respectively. IPA also bound with micro-
molar affinity to the rat A3R. In a cAMP accumulation assay in CHO cells stably expressing 
hA3R, IPA and zeatin riboside exhibited potencies in the micromolar range. The effect of 
IPA could be blocked by the selective A3R antagonist VUF5574. Like the reference A3R ag-
onist 2-chloro-N6-(3-iodobenzyl)adenosine-5’-N-methylcarboxamide (Cl-IB-MECA), IPA 
has known activity against tumor growth. In vitro antiproliferative effects on human and 
rat tumor cell lines LNCaP and N1S1 were highly similar for IPA and Cl-IB-MECA, and at 
low concentrations the effect could be blocked by the selective A3R antagonist MRS1523. 
Higher concentrations of IPA seemed to inhibit tumor cell growth by an A3R-independent 
mechanism. A similar phenomenon has previously been observed for other A3R agonists. 
Since it is a natural compound, we hypothesized that IPA might activate the A3R in vivo 
under physiological conditions. However, IPA could not be detected in fresh rat striated 
muscle preparation using HPLC.
In chapter 7, a ligand discovery screen on the human orphan receptor GPR88, which may 
be implicated in several psychiatric disorders, is described. Over 4000 compounds, includ-
ing small molecules and peptides, were tested in a medium-throughput, 384-well format 
Fluorescent Imaging Platereader (FLIPR) screen using increases in Ca2+ concentrations as 
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the readout. Next to a native HEK cell line stably expressing GPR88, stable co-transfection 
of Gα16 and Gαqi5 was also done, since the natural coupling preference of GPR88 is un-
known. In the primary screen, a total of 47 hits was identified, and in validation assays, 
dose-response curves could be obtained for papaverine, an opioid alkaloid. However, the 
effects of papaverine seemed independent of GPR88, since similar responses were seen in 
non-transfected cells. This research was finalized in 2009, and even today no ligand has 
been published for GPR88.
Chapter 8 provides a general discussion of the work presented in this thesis, and future 
perspectives in this area of research are discussed. The relevance of HCA2, the A3 ad-
enosine receptor and GPR88 as targets for drugs is still to be confirmed. In the case of 
HCA2, the identification of an antagonist, especially one that can be used in humans, could 
clarify the role of the receptor in the action of nicotinic acid. Anti-inflammatory effects of 
HCA2 agonists should be more thoroughly explored in drug discovery programs, since 
this could yield therapies for diseases like psoriasis and multiple sclerosis. A3 ligand IPA 
could become a valuable anticancer drug, either alone or as add-on to other drugs, espe-
cially since it may protect against common side effects on bone marrow cells. GPR88 is still 
an orphan receptor, but sensitive techniques to monitor the activation of endogenously 
expressed receptors, for example through impedance measurement, could be of value for 





In dit proefschrift worden verschillende orthostere en allostere agonisten voor de recent 
ontdekte hydroxy-carbonzuur (HCA) receptor 2 gepresenteerd, en hun in vivo activiteit of 
in vitro structuur-activiteits relaties worden beschreven. De literatuur met betrekking tot 
de HCA receptoren wordt ook uitgebreid besproken, en geeft inzicht op de toekomst van 
deze receptorfamilie als aangrijpingspunten voor medicijnen. Het wordt aangetoond dat 
het anti-kanker medicijn N6-(2-isopentenyl)adenosine (IPA) een specifiek ligand is voor 
de adenosine A3 receptor, en aannemelijk gemaakt dat het celgroei-remmende effect van 
deze stof, bij lage concentraties, afhankelijk is van deze receptor. Tevens is er een ligand-
identificatiescreen voor de wees-receptor GPR88 uitgevoerd, waarin meer dan 4000 stof-
fen werden getest.    
De meeste G eiwit-gekoppelde receptoren (GPCRs) kunnen alleen functioneren in sa-
menspel met hun (endogene) ligand(en). Als de ligandconcentraties verstoord zijn, of 
als de receptor, of de intracellulaire signaaltransductie, niet geactiveerd kunnen worden 
onder invloed van het ligand, dan kan de receptor niet functioneren, en vaak leidt dit tot 
ziekte. De identificatie van het endogene ligand is dus essentieel om de functie van een 
receptor te begrijpen. Tegelijkertijd kunnen synthetische liganden voor GPCRs zeer effec-
tieve medicijnen zijn, omdat ze kunnen worden ingezet om pathofysiologische verstorin-
gen te corrigeren. In dit proefschrift staan drie receptoren centraal, namelijk de hydroxy-
carbonzuur receptor 2 (HCA2), de adenosine A3 receptor, en GPR88, en in het bijzonder de 
zoektocht naar liganden die deze eiwitten kunnen beïnvloeden in het lichaam, op natu-
urlijke wijze of als medicijn.
Hoofdstuk 1 is een inleidend hoofdstuk, waarin GPCRs worden geïntroduceerd, met spe-
ciale aandacht voor zogenaamde wees-GPCRs, en het onderzoek dat de identificatie van 
hun endogene liganden tot doel heeft. GPR88 is nog steeds een wees-receptor, en de natu-
urlijke liganden van de HCA receptoren zijn recent ontdekt.
Hoofdstuk 2 geeft een overzicht van de huidige kennis over de HCA receptoren HCA1, 
HCA2 en HCA3, waarbij de nadruk ligt op HCA2, de receptor voor het atherosclerose-
medicijn nicotinezuur. De natuurlijke liganden voor deze drie receptoren zijn in het laat-
ste decennium geïdentificeerd, en dit zijn respectievelijk lactaat, 3-hydroxybutyraat en 
tussenproducten van β-oxidatie, zoals 3-hydroxyoctanoaat. De rol van de HCA recep-
toren in het lichaam is waarschijnlijk het reguleren van het vrijkomen van vetzuren uit het 
vetweefsel (lipolyse) wanneer er gebrek is aan voeding (HCA2 en HCA3), of juist in tijden 
van overvloed (HCA1). Het belang van HCA2 activatie voor de atherosclerose-remmende 
werking van nicotinezuur staat nog ter discussie. Ontstekingsremmende effecten van 
HCA2 agonisten zijn gevonden in een aantal studies, en dit zou gebruikt kunnen worden 
in de strijd tegen andere ziektes als multiple sclerosis.
Hoofdstuk 3 beschrijft in vitro en in vivo onderzoek naar de farmacologische effecten 
van twee partiële agonisten voor HCA2, in vergelijking met nicotinezuur. Deze partiële 
agonisten, LUF6281 en LUF6283, hebben structuren gebaseerd op de pyrazol-ring, en hun 
affiniteit voor HCA2 was repectievelijk 3 µM en 0.55 µM. In [35S]-GTPγS experimenten 
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was de rangorde van activiteit (potency) nicotinezuur > LUF6283 > LUF6281, en het maxi-
male effect van de partiele agonisten was ~75% voor LUF6283 en ~50% voor LUF6281. De 
partiële agonisten waren, net als nicotinezuur, actiever in een ERK 1/2 fosforylatie experi-
ment, maar de EC50 ratio [35S]-GTPγS / pERK was 2-3x hoger voor nicotinezuur. In mui-
zen verlaagden de pyrazolen het VLDL-gehalte in vergelijkbare mate als nicotinezuur, 
maar deze stoffen gaven geen ‘flushing’ (bloedvatverwijding in de huid), aangezien de 
huidtemperatuur niet toenam. Nicotinezuur verlaagde de expressie van de pro-lipolyse 
enzymen HSL en ATGL met de helft, terwijl LUF6281 en LUF6283 geen effect hadden op 
hun expressie. Aan de andere kant verhoogden de pyrazolen de expressie van ApoB in de 
lever met 40%. Dit suggereert dat LUF6281 en LUF6283, hoewel ze dezelfde receptor activ-
eren als nicotinezuur, andere in vivo effecten hebben, waarbij de cholesterol-verlagende 
werking behouden blijft, terwijl het flush-effect niet werd waargenomen.   
In hoofdstuk 4 en 5 wordt de identificatie en in vitro karakterisatie van nieuwe HCA2-
liganden beschreven. In hoofdstuk 4 staan derivaten van trans-propeenzuur centraal. 
Deze stoffen zijn chemisch verwant aan het psoriasis medicijn monomethylfumaraat. Uit 
een serie kaneelzuurderivaten en fumaarzuuresters en –amides konden liganden worden 
geïdentificeerd met een affiniteit in het hoge nanomolaire tot hoge micromolaire bereik. 
De bindingsplek leek vrij beperkt, en trans-kaneelzuur was het langste vlakke ligand. Een 
moleculair computermodel op basis van de structuur-activiteits relatie van deze serie stof-
fen, suggereert een vlakke trans-propeenzuur farmacofoor van 8 Å lang, waarin grotere 
substituenten alleen buiten het vlak kunnen worden aangebracht.
In hoofdstuk 5 zijn liganden voor de allostere bindingsplek van HCA2 onderzocht met 
behulp van functionele en radioligand-binding analyses. Verschillende stoffen bleken 
positieve allostere modulatoren te zijn voor de activatie van HCA2 door nicotinezuur, en 
bovendien waren de meeste modulatoren ook (allostere) agonisten wanneer ze afzonder-
lijk getest werden. Verschillende parameters werden bepaald om de details van de ago-al-
lostere werking in kaart te brengen, en de multi-dimensionale structuur-activiteits relaties 
te kunnen beschrijven. Omdat allostere modulatie afhankelijk is van het gebruikte orthos-
tere ligand, hebben we van een aantal stoffen ook de versterkende werking op de HCA2 
activatie door het endogene ligand 3-hydroxybutyraat getest. Verschillende pyrazolopy-
rimidines bleken in staat om het maximale effect van 3-hydroxybutyraat te versterken, en 
de EC50 tot tien maal te verlagen.
In hoofdstuk 6 is beschreven hoe de natuurlijke nucleosiden N6-(2-isopentenyl)adenosine 
(IPA) en zeatine riboside geïdentificeerd worden als selectieve liganden voor de humane 
adenosine A3 receptor (A3R), met affiniteiten van respectievelijk 159 en 649 nM. IPA bond 
ook met micromolaire affiniteit aan de rat A3R. In een cAMP accumulatie experiment in 
CHO cellen met stabiele expressie van de hA3R, hadden IPA en zeatine riboside een ac-
tiviteit (EC50) in het micromolaire bereik. Het effect van IPA kon worden geblokkeerd 
door de selectieve A3R antagonist VUF5574. Het is bekend dat IPA effectief tumorgroei 
kan tegengaan, net als de referentie A3R agonist 2-chloro-N6-(3-iodobenzyl)adenosine-
5’-N-methylcarboxamide (Cl-IB-MECA). De groeiremmende eigenschappen van IPA en 
Cl-IB-MECA op de kanker cellijnen LNCaP en N1S1 waren zeer vergelijkbaar, en bij lage 
concentraties kon de A3R antagonist MRS1523 dit effect blokkeren. Hogere concentraties 
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IPA leken de celgroei tegen te gaan via een mechanisme dat onafhankelijk was van de 
A3R. Vergelijkbare observaties zijn in  het verleden ook gedaan voor andere A3R agonisten. 
Aangezien IPA in de natuur voorkomt, zou deze stof, in theorie, de A3R in vivo kunnen 
activeren onder fysiologische condities. IPA kon echter niet worden gedetecteerd door 
middel van HPLC in vers dwarsgestreept spierweefsel van de rat. 
Hoofdstuk 7 behandelt een ligand-identificatiescreen met de wees-receptor GPR88, die 
mogelijk een rol speelt bij verschillende psychiatrische aandoeningen. Meer dan 4000 stof-
fen, waaronder kleine moleculen en peptiden, werden getest in een medium-throughput 
screen in 384-well platen, met verhoging van Ca2+ concentratie gemeten door middel van 
een Fluorescent Imaging Plate Reader (FLIPR). Naast de constructie van een ongemodifi-
ceerde HEK cellijn die GPR88 stabiel tot expressie bracht, werden de Gα16 en Gαqi5 eiwit-
ten ook samen met GPR88 getransfecteerd, omdat de natuurlijke G eiwitkoppeling van 
GPR88 onbekend is. In een primaire screen werden 47 hits gevonden, en in bevestigings-
experimenten konden dosis-effect curves worden gemeten voor papaverine, een opium-
alkaloide. Het effect van papaverine leek echter onafhankelijk te zijn van GPR88, want 
vergelijkbare uitkomsten werden gemeten in niet-getransfecteerde cellen. Dit deel van het 
onderzoek werd in 2009 afgerond, en er is in de literatuur ook nu nog geen ligand voor 
GPR88 gepubliceerd.
In hoofdstuk 8 wordt een algemene discussie van het hier beschreven onderzoek gep-
resenteerd, en ook worden de toekomstperspectieven besproken. Het belang van HCA2, 
de adenosine A3 receptor en GPR88 als aangrijpingspunten voor medicijnen moet nog 
worden bevestigd. In het geval van HCA2 zou de identificatie van een antagonist, vooral 
één die aan mensen kan worden toegediend, de rol van de receptor in de werking van 
nicotinezuur kunnen verhelderen. Ontstekingsremmende effecten van HCA2 agonisten 
zouden nog verder kunnen worden onderzocht in het kader van de geneesmiddel-on-
twikkeling, want dit zou therapieën kunnen opleveren voor ziektes as psoriasis en mul-
tiple sclerosis. A3 ligand IPA zou een waardevol antikanker middel kunnen worden, als 
monotherapie of in combinatie met andere cytostatica, vooral aangezien het zou kunnen 
beschermen tegen de gangbare bijwerkingen op beenmerg cellen. GPR88 is nog steeds een 
wees-receptor, maar gevoelige technieken om de activatie van endogeen aanwezige recep-
toren te meten, bij voorbeeld door middel van impedantie-bepalingen, zouden waardevol 




Samenvatting voor algemeen publiek
Anno 2012 begrijpen we tamelijk veel van het menselijk lichaam: we hebben het erfelijk 
materiaal in kaart gebracht, we kunnen met geavanceerde instrumenten de levende or-
ganen in beeld brengen, en we hebben een heel scala aan medicijnen, die in veel gevallen 
ook helpen tegen de aandoening in kwestie. We weten nu ook dat ongeveer een derde van 
deze medicijnen werken via een bepaald soort ontvanger-eiwitten, die G-eiwit-gekoppel-
de receptoren (GPCR) genoemd worden.
G-eiwit-gekoppelde receptoren
De mens heeft zo’n 800 verschillende GPCRs, die betrokken zijn bij vrijwel alle lichaams-
functies. Medicijnen maken gebruik van deze receptoren, maar hun originele functie is 
communicatie tussen verschillende cellen van het lichaam. Hierbij maken de verzendende 
cellen een stof aan, en vangen andere cellen het signaal op via receptoren. Bekende stoffen 
die via receptoren werken zijn bijvoorbeeld endorfinen, smaakstoffen, dopamine, adrena-
line, THC (de werkzame stof in marihuana) en cafeïne. Nicotinezuur is ook een stof die op 
een GPCR inwerkt, en dit is belangrijk voor dit proefschrift.
De ontdekking van nicotinezuur
In de jaren ’50 van de twinstigste eeuw waren receptor-eiwitten al bekend, maar er was 
nog niet zo veel kennis van de individuele receptoren die specifieke signaalstoffen opvan-
gen. Meer dan nu berustte het ontdekken van nieuwe medicijnen toen op trial and error. 
Het medicijn nicotinezuur, dat aderverkalking (atherosclerose) kan voorkomen of vertra-
gen, werd bij toeval ontdekt in de vijftiger jaren door de Canadese psychiater dr. Hoffer. 
Hij zag namelijk dat de schizofrene patienten die hij ermee behandelde, lagere cholester-
olwaarden kregen. Daarna zette zijn vroegere professor, dr. Altschul, het onderzoek voort, 
en hij wordt nu meestal genoemd als de ontdekker van nicotinezuur als medicijn. Behan-
deling van hoog cholesterol met nicotinezuur verkleint de kans op een hartinfarct of een 
beroerte. Waarschijnlijk werkt dit medicijn zo goed omdat het een drievoudige werking 














Figuur 1: G-eiwit-gekoppelde receptor (GPCR). Deze receptoren gaan zeven keer door de celmembraan (nummers 
1-7). Het ligand komt van de buitenkant van de cel, en het G-eiwit neemt het signaal over aan de binnenkant.
 
156
en 3) remming van ontstekingsreacties in de bloedvaten. Een minpunt is dat nicotinezuur 
een huidreactie veroorzaakt, die lijkt op verbranding door de zon.
De nicotinezuur-receptor
Pas veel later, begin twinstigste eeuw, werd ontdekt dat nicotinezuur een GPCR activeert, 
die daarna ook meteen bekend werd als de nicotinezuur-receptor. Intussen zijn er meer 
cholesterolverlagende middelen op de markt, maar nicotinezuur is nog steeds het beste 
middel om het goede (HDL) cholesterol te verhogen. Helaas is de bijwerking op de huid, 
ook wel flushing genoemd, zo vervelend dat veel patienten al snel hun pillen niet meer in-
nemen. Een mogelijke oplossing zou kunnen zijn, om een nieuw medicijn te ontwikkelen 
dat de nicotinezuur-receptor ook activeert, maar geen huidreactie geeft.
Op zoek naar de klik
Het grootste gedeelte van mijn proefschrift gaat over de zoektocht naar nieuwe activators, 
ook wel liganden of agonisten genoemd, voor de nicotinezuur-receptor. Hiervoor maken 
we gebruik van menselijke cellen die onder laboratoriumcondities kunnen groeien in een 
petrischaal, als producenten en ‘huisvesting’ voor de receptor-eiwitten. We hebben het 
gen voor de nicotinezuur-receptor in flinke hoeveelheden in deze cellen gestopt, waar-
door ze veel receptor-eiwitten aanmaken. Vervolgens kunnen we de cellen blootstellen 
aan stoffen, die bij ons in het laboratorium zijn gemaakt (of, in sommige gevallen, kant en 
klaar gekocht). We kunnen daarbij meten of de nicotinezuur receptor wordt geactiveerd 
door deze stoffen, en zo ja, hoe sterk ze op de receptor inwerken.
Halfzachte liganden
Twee van deze stoffen, zogenaamde partiële agonisten, hadden een minder sterke werk-
ing op de receptor in vergelijking met nicotinezuur, maar verlaagden wel het slechte cho-
lesterol in muizen. Daarnaast hebben we gekeken naar een verandering in de huidtemper-
atuur, wat een maat is voor flushing. Als nicotinezuur werd toegediend aan muizen ging 
de huidtemperatuur ongeveer drie graden omhoog, terwijl de partiële agonisten geen 
effect hadden. Er zijn twee mogelijke verklaringen voor het verbeterde werkingsprofiel 
van de partiële agonisten. Het zou kunnen dat er minder activatie van de receptor nodig 
is om cholesterolverlaging te krijgen, en relatief meer om de bijwerking op de huid in 
gang te zetten. Hierdoor zouden partiële agonisten minder flushing veroorzaken door hun 
subtielere werking op de receptor. De tweede mogelijkheid is dat de partiële agonisten de 
receptor in een andere ‘stand’ zetten, waardoor het uiteindelijke effect op de (huid)cellen 
anders is. De balans tussen de activatie van twee andere eiwitten in de cel, namelijk het G-
eiwit en ERK, zou daarbij betrokken kunnen zijn. We hebben laten zien dat nicotinezuur 
via de receptor twintig keer krachtiger inwerkt op ERK dan op het G-eiwit, terwijl dit 
verschil veel kleiner is voor de partiële agonisten (vijf tot tien keer). Of dit de reden is voor 
de verminderde flushing-reactie is echter op dit moment nog niet duidelijk.
Samenwerken
Ik beschrijf ook een serie stoffen die de nicotinezuur-receptor zelfstandig kunnen activ-
Samenvatting
157
eren, maar daarnaast kunnen samenwerken met andere agonisten, en hun werking ver-
sterken. Deze ‘allostere’ agonisten binden op een andere plek aan het receptor-eiwit, en 
daardoor blijft de plek voor nicotinezuur en andere ‘orthostere’ agonisten vrij en kunnen 
ze tegelijk aankoppelen aan de receptor. Als dit soort allostere agonisten geschikt gemaakt 
kunnen worden voor gebruik bij mensen, dan zouden ze gecombineerd kunnen worden 
met nicotinezuur. De dosis nicotinezuur zou dan tien keer lager kunnen zijn, omdat de 
werking op de receptor zo veel sterker is. Nog veel interessanter is het idee, dat allostere 
agonisten de werking van lichaamseigen liganden voor de nicotinezuur-receptor zouden 
kunnen versterken. We hebben als eerste laten zien dat het lichaamseigen ligand beta-hy-
droxy-butyraat sterker werkt, en bij lagere concentraties, als een allostere agonist tegelijk-
ertijd aanwezig is. Zo zou toediening van een allostere agonist als medicijn ervoor kunnen 
zorgen dat er geen nicotinezuur meer hoeft te worden toegediend, omdat de stoffen die 
het lichaam zelf produceert sterker gaan werken.
Andere receptoren
Aan het eind van mijn proefschrift beschrijf ik nog onderzoek naar twee andere GPCRs: 
de adenosine A3 receptor en GPR88. Ik heb laten zien dat het experimentele anti-kanker 
medicijn isopentenyl adenosine zijn effect gedeeltelijk te danken heeft aan de activatie van 
de adenosine A3 receptor. We hebben ook gekeken naar de aanwezigheid van dit ligand 
in spierweefsel, omdat het misschien een lichaamseigen ligand zou kunnen zijn, maar dit 
is waarschijnlijk niet het geval. GPR88 is een zogenaamde wees-receptor: het is nog niet 
bekend door welke stof(fen) dit eiwit wordt geactiveerd. Ik heb geprobeerd een agonist te 
vinden voor GPR88 door ruim 4000 stoffen te testen, maar helaas is het niet gelukt daar-
tussen een ligand te ontdekken.
Toekomst
Er is vandaag de dag zeer veel informatie beschikbaar over de werking van het menselijk 
lichaam, en elke dag komt er meer bij. Maar er valt nog veel te ontdekken. Op het gebied 
van de nicotinezuur-receptor is het nog steeds niet helemaal duidelijk of het medicijn 
nicotinezuur met name via deze receptor werkt, of dat het effect van nicotinezuur op 
andere lichaamsprocessen belangrijker is voor de werking als geneesmiddel. Het zou kun-
nen dat activatie van de nicotinezuur-receptor een positief effect heeft op ontstekingsziek-
ten als MS en psoriasis, maar bewijs ontbreekt nog. Naast agonisten, is het ook belangrijk 





Figuur 2: Orthostere en allostere liganden. Het orthostere ligand (O) kan zelfstandig de receptor activeren, en dat 




receptor. Die zijn namelijk nog niet bekend. De A3 receptor agonist isopentenyl adenosine 
zou een goed anti-kanker medicijn kunnen worden, vooral omdat het geen negatief effect 
heeft op gezonde lichaamscellen (zoals veel bestaande anti-kanker middelen wel hebben). 
Het word nu nog niet gebruikt bij mensen. GPR88 is nog steeds een wees-receptor, maar 
nieuwe technieken zouden kunnen helpen eindelijk een ligand te vinden. Als men het gen 
voor deze receptor uitschakelt bij muizen, krijgen ze een soort schizofrene trekjes. Daarom 
denken we dat agonisten voor deze receptor interessant zouden kunnen zijn voor de be-




Het onderzoek voor dit proefschrift heeft zich op drie verschillende plekken afgespeeld. 
Om te beginnen met de ‚Leidse tijd‘: Ik wil Jaco en Ad graag als eersten noemen, die 
beiden een grote bijdrage hebben geleverd aan dit onderzoek. Jaco, jouw synthese-vaar-
digheden en chemisch inzicht hebben veel mooie stofjes opgeleverd, en vooral de allostere 
modulatoren zullen in de literatuur voortleven. Al onze discussies over HCA2 hebben ook 
geweldig geholpen. Ad, je bent al sinds mijn derde BFW-jaar een mentor voor mij, en hebt 
me op wetenschappelijk en persoonlijk vlak geadviseerd, gemotiveerd, en uitgedaagd. 
Onze gedeelde belangstelling voor klassieke muziek heeft ook mooie momenten opgelev-
erd. Hartelijk dank voor alle steun en vertrouwen. Mijn kantoorgenoten, Miriam, Henk, 
Elisabeth, Annelien en Ann, jullie zorgden voor een gezellige sfeer, leuke discussies, en 
stonden altijd klaar om te helpen. Miriam, onze (soms lange) gesprekken over alle aspect-
en van het AIO-schap waren naar mijn idee zeker geen verloren tijd! Met jou als paranimf 
kan ik tijdens de verdediging met een gerust hart flauwvallen. Henk, aan jouw analytische 
vermogens heeft het niet gelegen dat we geen endogeen IPA hebben gevonden! Mijn stu-
denten, Margot, Maha, Laurens, Lucienne en Maarten, jullie hebben allemaal je bijdrage 
geleverd aan het bestuderen van HCA2. Het was erg leuk om met jullie samen te werken 
en ik hoop dat het net zo leerzaam was voor jullie als voor mij. De studenten die met 
Jaco liganden hebben gesynthetiseerd voor het HCA2 project moeten hier natuurlijk ook 
genoemd worden, net als Marysa die HCA2 in silico heeft bestudeerd. Rob, thank you 
for giving me a ‚jumpstart‘ at the beginning of the project, and for your help and sugges-
tions. Munikumar en Gerard hebben onder andere in silico teststofjes geselecteerd en de 
(allostere) bindingsplek van HCA2 voorspeld. Eigenlijk jammer dat we uiteindelijk niet 
meer bio/chem-informatics hebben kunnen koppelen aan dit project, dat zou interessant 
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